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Abstract 
 
Chronic obstructive pulmonary disease (COPD) is defined by irreversible airflow 
limitation, usually caused by exposure to noxious particles or gases.  COPD patients 
suffer from chronic daily symptoms, and may occasionally suffer acute 
exacerbations – episodes in which there is a worsening of symptoms above day-to-
day levels.  Exacerbation aetiology is variable and controversial, although infection 
and air pollution are believed to play a part.  Certain bacterial pathogens, known as 
typical airway bacteria, are found with high prevalence in individuals at 
exacerbation.  The burden of other airway bacteria is currently ill-defined. 
 
This study initially compared microbiological culture with quantitative PCR for 
detection of three commonly identified airway bacteria in COPD, Haemophilus 
influenzae, Streptococcus pneumoniae, Moraxella catarrhalis (typical airway 
bacteria).  Quantitative PCR was utilised to establish prevalence and load of these 
species at stable, exacerbation and exacerbation recovery states.  Typical airway 
bacterial prevalence and load was assessed against a range of clinical factors in 
COPD.  Additional quantitative PCRs examined the prevalence and load of atypical 
airway bacteria (Chlamydophila pneumoniae, Legionella pneumophila, Mycoplasma 
pneumoniae) and the entire bacterial microflora of the lungs. 
 
My original contribution to knowledge is that higher load of typical airway bacteria 
is associated with higher levels of systemic inflammation and airflow limitation in 
both stable and exacerbated COPD.  For the first time it has also been 
demonstrated that airway microbiome load is not associated with airflow limitation 
or systemic inflammation changes, providing evidence that typical airway bacteria 
in particular are contributing to disease severity.  Atypical airway bacteria 
prevalence in COPD was negligible.   
 
The investigations in this thesis highlight the need for rapid antibiotic therapy in 
exacerbations where typical airway bacteria presence is suspected or confirmed.  
Furthermore, prophylactic antibiotic therapy should be considered for stable COPD 
patients with confirmed typical airway bacterial presence, as a means of reducing 
inflammation and airflow limitation.  
3 
 
Acknowledgments 
 
I am very thankful for the support provided by my primary supervisor, Professor 
Wisia Wedzicha, with her frequent pearls of wisdom setting me on the right path 
whenever I was unsure of myself.  I also wish to thank my secondary supervisor, 
Professor Timothy McHugh, for his honest, thoughtful advice and encouragement. 
 
I would also like to thank the clinicians and nurses of the London COPD Cohort, for 
all of their hard work in looking after such a large group of patients with COPD. 
Without their collection of clinical sputum samples and data this thesis would never 
have gotten off the ground.  For his hard work in processing the sputum each day 
with a smile on his face, I thank Ray Sapsford.  Particular mention must also be 
reserved for Dr. Anant Patel and Dr. Alex Mackay, for patiently allowing me to get 
clinical advice and let off some steam over a Peroni.  For his support in statistical 
analysis I thank Dr. Gavin Donaldson - I always know I can get an honest view from 
him!  I am also very appreciative of the London COPD Cohort patients, who 
dedicate their time and energy into helping others combat this debilitating disease. 
 
In the Centre for Clinical Microbiology I thank all the members of the Research 
team for their expertise on all things ‘Micro’.  In particular , Dr. Gemma Vanstone 
for her support with the ‘Atypical PCR’, Sarah Thurston and Dr. Clare Ling for their 
help with the ‘Typical PCR’ and Laura Wright for her assistance with the ‘16S PCR’. 
 
I also want to thank my office colleagues and dear friends, Ayedh Al Ahmari and 
Sîobhán Nicole George – you made these last few years more enjoyable than they 
ought to have been! 
 
Finally, I dedicate this thesis to mum and dad, without whose love and support I 
would not be in this position. 
4 
 
Table of Contents 
 
Declaration…………………………………………………………………………………………….………..….1 
Abstract…………………………………………………………………………………………………………...….2 
Acknowledgments……………………………………………………………………………….….………..…3 
Table of Contents………………………………………………………………………………….……………..4 
List of Tables…………………………………………………………………………………………………......12 
List of Figures..………………………………………………………………………………………………..….14 
Abbreviations ………..………………………………………..…………………………………….……..…..18 
Publications arising from this thesis.….………………….………………………………….…..…..20 
 
CHAPTER 1. Introduction .................................................................................... 22 
1.1 Chronic Obstructive Pulmonary Disease ................................................... 23 
1.1.1. COPD: A historical perspective ....................................................... 25 
1.1.2. Aetiology of COPD .......................................................................... 26 
1.1.3. History of COPD identification ....................................................... 26 
1.1.4. Cigarette smoke, genetics and COPD ............................................. 27 
1.1.5. Genetics and COPD ......................................................................... 30 
1.1.6. Inflammation .................................................................................. 32 
1.1.7. Differences between healthy smokers and COPD patients ........... 37 
1.1.8. Pathology ........................................................................................ 37 
1.1.9. Treatment of stable COPD .............................................................. 40 
 1.1.10. Lower airway bronchial colonisation ............................................. 43 
1.2 Acute Exacerbations of COPD .................................................................... 45 
 AE-COPD: Triggers and associations ............................................... 45 1.2.1.
1.3 Micro-organisms in COPD......................................................................... 53 
1.3.1. London COPD cohort ...................................................................... 54 
    1.3.2.         COPD and micro-organisms ............................................................ 55 
5 
 
 1.3.3. H. influenzae virulence mechanisms .............................................. 55 
1.3.4. S. pneumoniae virulence mechanisms .......................................... 57 
1.3.5. M. catarrhalis virulence mechanisms ............................................ 58 
   1.3.6. Atypical airway bacteria ................................................................. 59 
   1.3.7. Bacterial load and strain-switching hypotheses ............................ 60 
   1.3.8. Airway microbiome ........................................................................ 60 
   1.3.9. Detection of bacterial infection ..................................................... 61 
          1.3.10. Viral infection ................................................................................. 62 
  1.3.11. Bacterial and viral coinfection ....................................................... 62 
          1.3.12. Comorbidities ................................................................................. 63 
          1.3.13. Bacterial infection in other airway infections ................................ 63 
1.4. Questions to be answered in bacteriology of COPD ................................. 65 
1.5. Aims and objectives ................................................................................... 66 
 
 CHAPTER 2. Materials and Methods .................................................................. 69 
2.1 London COPD cohort – funding and ethics ............................................... 70 
2.2 Recruitment ............................................................................................... 71 
2.3 Subjects ..................................................................................................... 72 
  2.3.1 Patient visits ................................................................................... 72 
   2.3.2     Community-based data acquisition with daily diary cards............. 72 
2.4 Sputum sampling ....................................................................................... 73 
   2.4.1      Sputum processing ......................................................................... 73 
2.5 DNA extraction from sputum samples ...................................................... 75 
2.6 PCR for detection and quantification of bacteria ...................................... 77 
    2.6.1 Correlation of colony-forming units with DNA concentration .......... 79 
      2.6.1.1 Quantification of colony forming units .......................................... 79 
6 
 
    2.6.2     Standard curve preparation to quantify PCR amplimers ............... 80 
2.7 Quantitative PCR for typical airway bacteria ............................................ 82 
       2.7.1 Typical airway bacteria PCR protocol ............................................. 85 
2.8 Quantitative PCR for atypical airway bacteria .......................................... 87 
       2.8.1 Atypical airway bacteria PCR protocol ........................................... 89 
2.9 Quantitative PCR for 16S ribosomal DNA .................................................. 90 
       2.9.1 16S quantitative PCR optimisation ................................................. 90 
        2.9.1.1 DNA extraction and 16S PCR .......................................................... 94 
   2.10   Statistical analysis......................................................................................97 
 
 Comparison of Quantitative PCR and Routine Microbiological CHAPTER 3.
Culture as Techniques to Detect Typical Airway Bacteria Presence in COPD ......... 98 
 Introduction ............................................................................................. 100 3.1
3.1.1 Background of typical airway bacteria in respiratory disease ..... 103       
        3.1.2 Prevention of typical airway bacterial infection .......................... 104 
        3.1.3 Typical airway bacteria in COPD ................................................... 105 
3.2 Subjects ................................................................................................... 109 
        3.2.1 Patient characteristics for culture & PCR comparison ................. 109 
3.3 Results ..................................................................................................... 111 
        3.3.1 Prevalence of typical airway bacteria using qPCR and routine 
microbiological culture .................................................................................. 111 
        3.3.2 Cases detected by PCR and culture .............................................. 112 
        3.3.3 Rate of detection of multiple bacterial species in samples by culture 
and qPCR... ..................................................................................................... 112 
        3.3.4 Prevalence of typical airway bacteria using a composite model 
compared with qPCR alone ............................................................................ 114 
        3.3.5 Bacterial load in patients dependent on detection outcome ...... 114 
7 
 
3.4 Discussion ................................................................................................ 117 
3.5 Conclusion ............................................................................................... 123 
 
 CHAPTER 4. Prevalence and load of typical airway bacteria in COPD patients at 
both stable and exacerbated states of disease ..................................................... 124 
 Introduction ............................................................................................. 125 4.1
 Analysis of typical airway bacteriology in sputum from patients at either 4.2
stable or exacerbation states ............................................................................. 128 
         4.2.1.    Clinical assessment .................................................................... 129 
4.3. Results ..................................................................................................... 130 
         4.3.1.    Sample acquisition ..................................................................... 130 
         4.3.2.    Characteristics of patients with paired state data ..................... 130 
         4.3.3.    Typical airway bacterial prevalence ........................................... 132 
         4.3.4.    Typical airway bacterial load ..................................................... 133 
4.4. Paired sub-analysis examining changes in bacterial prevalence and load 
between stable and exacerbation states ........................................................... 136 
         4.4.1.  Typical airway bacteria prevalence in paired patients ................ 136 
         4.4.2.  Typical airway bacterial load in paired patients ......................... 138 
         4.4.3.   Effect of antibiotic therapy ......................................................... 139 
         4.4.4.  Changes in lung function between states ................................... 140 
4.5. Systemic inflammation at stable state and at exacerbation ................... 141 
         4.5.1.   Exacerbation symptoms and typical airway bacteria ................. 145 
4.6. Discussion ................................................................................................ 147 
 
CHAPTER 5. The relationship between typical airway bacterial load and clinical 
outcomes in stable COPD patients ......................................................................... 153 
5.1 Introduction ............................................................................................. 154 
8 
 
5.2 Patient characteristics ............................................................................. 157 
5.3 Results ..................................................................................................... 158 
          5.3.1   Systemic inflammation in stable COPD ...................................... 158 
          5.3.2     Bacterial load and systemic inflammation ................................ 159 
          5.3.3     Systemic inflammation and airflow limitation .......................... 160 
          5.3.4     Airflow limitation and typical airway bacteria at stable state .. 161 
          5.3.5     Systemic inflammation and inhaled corticosteroid therapy ..... 164 
5.4 Inhaled corticosteroid therapy during the stable state .......................... 167 
          5.4.1     Inhaled corticosteroids and airflow limitation .......................... 170 
5.5 Discussion ................................................................................................ 173 
 
CHAPTER 6. Changes in Airway Bacteria Prevalence and Load at Exacerbation 
and during Exacerbation Recovery ........................................................................ 177 
6.1 Introduction ............................................................................................. 178 
6.2 Patient characteristics ............................................................................. 182 
6.3 Results ..................................................................................................... 184 
          6.3.1      Antibiotic treatment type and duration ................................... 184 
          6.3.2      Prevalence and load of typical airway bacteria during 
exacerbation recovery ................................................................................... 185 
           6.3.3    Prevalence and load of airway microbiome during exacerbation 
recovery..... .................................................................................................... 188 
           6.3.4    Typical airway bacterial load relationship to total microbiome 
load.................... ............................................................................................ 189 
            6.3.5   Systemic inflammation during exacerbation and 
recovery.............................. ........................................................................... 191 
            6.3.6   Presence of typical airway bacteria during exacerbation recovery 
does not suggest increased risk of recurrent exacerbation .......................... 195 
9 
 
            6.3.7    Lung function during exacerbation recovery.......................... 195 
                 6.3.8    Systemic corticosteroid prescription ...................................... 199 
6.4 Discussion ................................................................................................ 203 
                6.4.1    Typical airway bacteria load falls following antibiotic 
therapy.................. ......................................................................................... 203 
                6.4.2    Typical airway bacteria load is related to the load of the airway 
microbiome .................................................................................................... 204 
                6.4.3    Typical airway bacteria dominate the load of the airway 
microbiome when present ............................................................................. 204 
                6.4.4    Microbiome load falls following antibiotic therapy but it is not 
eradicated. ..................................................................................................... 205 
                6.4.5    Systemic inflammation biomarkers fall following 
commencement of systemic corticosteroids ................................................. 206 
6.4.6   Typical airway bacteria presence is associated with systemic   
inflammatory biomarker levels....................................................................206 
6.4.7    Airway microbiome load is not associated with systemic 
inflammatory biomarker levels....................................................................207 
6.4.8 Typical airway bacterial prevalence falls following antibiotic 
therapy.......................................................................................................208 
6.4.9 Typical airway bacterial load is not associated with dosage 
levels of systemic corticosteroid.................................................................210 
       6.5      Conclusion..........................................................................................211 
 
CHAPTER 7. Changes in the airway microbiome between stable COPD and 
exacerbation..... ..................................................................................................... 212 
 Introduction ............................................................................................. 213 7.1
 Patient characteristics ............................................................................. 217 7.2
 Results ..................................................................................................... 218 7.3
10 
 
      Airway microbiome load in stable and exacerbated               7.3.1
COPD............. ................................................................................................. 218 
     Airway microbiome load and airflow limitation at             7.3.2
exacerbation................ .................................................................................. 220 
Airway microbiome load and sputum            7.3.3    
volume/purulence..................... .................................................................... 222 
Relationship of airway microbiome load at stable and            7.3.4   
exacerbation state with biomarkers of systemic inflammation .................... 223 
 Discussion ................................................................................................ 225 7.4
 
CHAPTER 8. Prevalence and Load of Atypical Airway Bacteria at Stable and 
Exacerbation States of COPD ................................................................................. 228 
8.1 Introduction ................................................................................................. 229 
           8.1.1  Pathogenesis .............................................................................. 230 
           8.1.2  Atypical bacteria in COPD: Current 
knowledge......................................... ............................................................. 232 
8.2 Atypical respiratory PCR methodology ........................................................ 235 
           8.2.1  Analysis of patient samples for atypical respiratory bacteria at 
various time-points of disease severity ......................................................... 235 
8.3 Results .......................................................................................................... 237 
           8.3.1 ...   Atypical airway bacterial prevalence and load.......................237 
8.4 Discussion ..................................................................................................... 239 
 
CHAPTER 9. Summary and Future Work .......................................................... 244 
9.1 Main Findings ............................................................................................... 247 
9.2 Additional findings ....................................................................................... 253 
9.3 Clinical implications of findings .................................................................... 255 
11 
 
9.4 Conclusion .................................................................................................... 259 
9.5 Future Work ................................................................................................. 260 
 
References.............................................................................................................262 
 
Appendix................................................................................................................308 
London COPD Cohort diary card............................................................................309 
Papers & abstracts.................................................................................................311 
 
  
 
 
 
 
 
 
 
 
 
12 
 
List of Tables 
 
Table 1.1  NICE COPD severity classification based on spirometry FEV1 
measurement........................................................................................................... . 24 
 
Table 2.1.  List of primers and probes used for typical airway bacterial PCRs.. ........ 78 
Table 2.2.  Mastermix for conventional 16S PCR amplification. ................................ 81 
Table 2.3.   Target genes for typical airway bacteria PCR. ......................................... 82 
Table 2.4 Reagents used to make up mastermix for multiplex typical airway bacteria 
qPCR.......................................................................................................................... 84 
Table 2.5.   Target genes for typical airway bacteria PCR. ......................................... 87 
Table 2.6. Reagents used to make up mastermix for multiplex atypical airway 
bacteria qPCR  ............................................................................................................ 88 
Table 2.7.   List of primers and probes used for atypical airway bacterial PCR. ........ 89 
Table 2.8. List of primers and probes used for 16S airway bacterial PCR.. ............... 91 
Table 2.9. Species tested to establish efficacy of 16S quantitative PCR .................... 92 
Table 2.10. Colony counts for bacterial species used as test organisms to verify 
efficacy of 16S bacterial PCR ...................................................................................... 94 
Table 2.11. Reagents used to make up mastermix for 16S bacterial qPCR.. ............. 95 
 
Table 3.1.  Description of nucleic acid amplification techniques. ........................... 101 
Table 3.2. Description of stable and exacerbation state definitions in the literature 
of bacterial presence in COPD. ................................................................................ 106 
Table 3.3. ATCC strains of the three typical airway bacteria were cultured in 
duplicate and DNA was extracted.  .......................................................................... 108 
Table 3.4. Quantification limit for typical bacteria. ................................................. 108 
Table 3.5. Baseline physiological characteristics of the 202 patients. .................... 109 
Table 3.6. Stable-state clinical characteristics of 143 COPD patients examined in this 
analysis. .................................................................................................................... 110 
 
Table 4.1. Characteristics of 61 patients of the London COPD Cohort who 
participated in a longitudinal study of typical airway bacterial presence in COPD. 131 
13 
 
Table 4.2.  Sputum samples obtained at exacerbation. .......................................... 142 
 
Table 5.1.  Parameters available in the London COPD Cohort database................. 155 
Table 5.2. Characteristics of 90 patients of the London COPD Cohort, who 
participated in a longitudinal study of typical airway bacterial presence in stable 
COPD and in whom CRP data was also available from the stable state sample. .... 157 
Table 5.3.  Median CRP of stable state patients exhibiting presence of at least one 
typical bacterial species. .......................................................................................... 158 
Table 5.4.  Inhaled corticosteroid usage in sampled patients from the London COPD 
Cohort....................................................................................................................... 164 
Table 5.5. Median ICS dose prescribed for each ICS type........................................ 165 
 
Table 6.1. Baseline characteristics of 94 patients of the London COPD Cohort, who 
participated in a study of typical airway bacterial presence during acute 
exacerbations of COPD. ........................................................................................... 183 
Table 6.2. Median levels of C-reactive protein at different phases of exacerbation 
recovery in an unpaired analysis. ............................................................................. 194 
 
Table 7.1  Commensal microbiomes of the human body ........................................ 215 
Table 7.2. Characteristics of 47 patients of the London COPD Cohort, who 
participated in a study of the airway microbiome at stable and exacerbation states..
 .................................................................................................................................. 217 
 
Table 8.1. Mean characteristics of patients whose samples were analysed for 
atypical bacteria ....................................................................................................... 236 
 
 
 
 
14 
 
List of Figures 
 
Figure 1.1 Cellular mechanism for activation of NF-κB ............................................. 35 
Figure 1.2 The vicious circle hypothesis of inflammation in COPD............................ 39 
Figure 1.3.  Antibiotic targets in a bacterial cell ........................................................ 51 
 
Figure 2.1. Standard curve generation for absolute quantification of bacterial load..
 .................................................................................................................................... 86 
Figure 2.2.  Test run examining detection of the 16S rRNA gene in bacterial species.  
Negative controls were not detected. ....................................................................... 96 
 
Figure 3.1. Comparison of culture and qPCR for the detection of three typical airway 
bacteria in sputa from 439 COPD patients. ............................................................. 112 
Figure 3.2.  Detection rates of a single species or multiple species of typical airway 
bacteria, by PCR and by culture. .............................................................................. 113 
Figure 3.3.  Bacterial load detected by qPCR segregated according to detection by 
culture ...................................................................................................................... 116 
 
Figure 4.1. Comparison of typical airway bacteria prevalence at different phases of 
COPD. ....................................................................................................................... 132 
Figure 4.2.  Prevalence of the three typical airway bacteria examined, at both stable 
and exacerbation states. .......................................................................................... 133 
Figure 4.3. Mean (SEM) typical airway bacterial load in patients at stable and 
exacerbation states. ................................................................................................. 134 
Figure 4.4.  Mean airway bacterial load of the three bacterial organisms studied, at 
both stable and exacerbation states ........................................................................ 135 
Figure 4.5.  Prevalence of typical airway bacteria in 61 patients at both stable and 
exacerbation states. ................................................................................................. 136 
Figure 4.6. Prevalence of the three typical airway bacterial species in paired stable 
and exacerbation data ............................................................................................. 138 
15 
 
Figure 4.7. Mean typical airway bacterial load in ten patients who had typical airway 
bacteria both at stable and exacerbation states ..................................................... 139 
Figure 4.8.  Median (IQR) levels of C-reactive protein at stable and exacerbation 
states of COPD .......................................................................................................... 141 
Figure 4.9.  Median CRP levels of exacerbating COPD patients, separated into 
presence or absence of typical airway bacterial species ......................................... 143 
Figure 4.10.  Changes in CRP values in 12 patients with paired stable state and 
exacerbation state data ........................................................................................... 144 
Figure 4.11.  Typical airway bacteria load split by presence or absence of purulent 
sputum at exacerbation. .......................................................................................... 145 
 
Figure 5.1. Relationship of typical airway bacterial load and C-reactive protein (CRP)
 .................................................................................................................................. 159 
Figure 5.2.  Correlation of CRP levels with GOLD stage. .......................................... 161 
Figure 5.3.  Relationship between typical airway bacterial load and airflow limitation
 .................................................................................................................................. 162 
Figure 5.4.  Comparison of percentage predicted of forced expiratory volume in 1 
second (FEV1% predicted) dependent on typical airway bacteria presence. .......... 163 
Figure 5.5.  CRP levels according to ICS prescription ............................................... 166 
Figure 5.6. ICS dosage prescribed, sub-divided according to typical airway bacterial 
presence ................................................................................................................... 168 
Figure 5.7.  Relationship between ICS dosage and CRP in stable COPD patients. ... 169 
Figure 5.8.  Relationship of ICS dosage with airway bacterial load in stable COPD 
patients. ................................................................................................................... 170 
Figure 5.9.  Inhaled corticosteroid dosage for stable COPD patients at different 
GOLD stages. ............................................................................................................ 171 
Figure 5.10.  Relationship between airflow limitation and ICS dosage ................... 172 
 
Figure 6.1. Antibiotics prescribed to patients in this study ..................................... 184 
Figure 6.2. Bacterial prevalence at stable, exacerbation and recovery phases of 
COPD. ....................................................................................................................... 185 
16 
 
Figure 6.3. Typical airway bacteria load changes in paired exacerbation and 
recovery samples ..................................................................................................... 186 
Figure 6.4. Cross-sectional analysis demonstrating differences in typical airway 
bacterial load at the respective recovery time points. ............................................ 187 
Figure 6.5. Airway microbiome load changes in paired exacerbation (black bars) and 
recovery (white bars) samples. ................................................................................ 188 
Figure 6.6. Microbiome population size in presence or absence of typical airway 
bacteria. ................................................................................................................... 189 
Figure 6.7. Association of microbiome load with typical airway bacterial load during 
COPD exacerbation and recovery (n=83) ................................................................. 190 
Figure 6.8.  Relationship between typical airway bacterial load and systemic 
inflammation ............................................................................................................ 191 
Figure 6.9.  Difference in rate of systemic inflammation based on presence or 
absence of typical airway bacteria. .......................................................................... 192 
Figure 6.10.  Airway microbiome load is not related to systemic inflammation ..... 193 
Figure 6.11.  Median FEV1%predicted does not significantly differ during 
exacerbation recovery. ............................................................................................ 196 
Figure 6.12.  Airflow limitation measurements according to typical airway bacteria 
presence ................................................................................................................... 197 
Figure 6.13.  Relationship between typical airway bacterial load and airflow 
limitation, during exacerbation and recovery ......................................................... 198 
Figure 6.14.  Relationship between airflow limitation and load of the airway 
bacterial microbiome. .............................................................................................. 199 
Figure 6.15.  Serum CRP levels at exacerbation presentation sub-divided based on 
whether systemic corticosteroids were prescribed................................................. 200 
Figure 6.16.  Relationship between typical airway bacterial load and systemic 
corticosteroid dose prescription at exacerbation presentation .............................. 201 
Figure 6.17.  Relationship between airflow limitation and systemic corticosteroid 
dose prescription at exacerbation presentation ..................................................... 202 
 
Figure 7.1.  Airway microbiome load at stable (n=32) and exacerbation (n=68) states 
of COPD in an unpaired analysis. ............................................................................. 218 
17 
 
Figure 7.2. Intra-patient changes in airway microbiome load between stable and 
exacerbation states.. ................................................................................................ 219 
Figure 7.3.  Airway microbiome load in the presence or absence of typical airway 
bacteria, in the stable state. .................................................................................... 220 
Figure 7.4.  Airway microbiome load was not found to be related to FEV1 fall from 
stable state to exacerbation .................................................................................... 221 
Figure 7.5.  Airway microbiome load split by presence (n=46) or absence (n=22) of 
purulent sputum at exacerbation. ........................................................................... 223 
Figure 7.6. The relationship of airway microbiome load and CRP. .......................... 224 
 
Figure 8.1.  Prevalence of atypical airway bacteria in airways of COPD patients at 
stable (n=97) and exacerbation (n=79) states ......................................................... 236 
Figure 8.2.  Bacterial load of patients with positivity for L. pneumophila (n=5) and M. 
pneumoniae (n=1)...................................................................................................237 
 
 
 
 
 
18 
 
Abbreviations 
 
AAT = α1-antitrypsin 
AE-COPD = Acute exacerbations of chronic obstructive pulmonary disease 
BAL = Broncho-alveolar lavage 
CAP = Community-acquired pneumonia 
CF = Cystic fibrosis 
CFTR = Cystic Fibrosis Transmembrane Conductance Regulator 
CFU = Colony forming units 
ChoP = Phosphorylcholine 
COPD = Chronic obstructive pulmonary disease 
C. pneumoniae = Chlamydophila pneumoniae 
cps = Capsular polysaccharide layer 
CRP = C=reactive protein 
CXCL-10 = C-X-C motif chemokine 10 
FEV1 = Forced expiratory volume in one second 
FVC = Forced vital capacity 
GOLD = Global Initiative for Chronic Obstructive Lung Disease 
GSH = Glutathione 
HDAC2 = Histone deacetylase-2 
H. influenzae = Haemophilus influenzae 
IAC = Internal amplification control 
ICS = Inhaled corticosteroid 
IκBα = inhibitory protein κBα 
IKK = IκB-kinase 
IL-1α = Interleukin-1α 
IL-8 = Interleukin-8 
LABA = Long-acting β-2 adrenoceptor agonist 
LABC = Lower airway bronchial colonisation 
LAMA = Long-acting muscarinic antagonist 
19 
 
L. pneumophila = Legionella pneumophila 
LPS = Lipopolysaccharide 
LRT = Lower respiratory tract 
LRTI = Lower respiratory tract infection 
LTB4 = Leukotriene B4 
M. catarrhalis = Moraxella catarrhalis 
MM = Mastermix 
MMP = Matrix metallo-protease 
M. pneumoniae = Mycoplasma pneumoniae 
NAAT = Nucleic acid amplification test 
NF-κB = Nuclear factor-κB 
NICE = National Institute of Health and Clinical Excellence 
NTHi = Non-typeable Haemophilus influenzae 
PavA = Pneumococcal adhesion and virulence factor A 
PCR = Polymerase chain reaction 
PSB = Protected specimen brush 
PspA = Pneumococcal surface protein A 
qPCR = Quantitative polymerase chain reaction 
RSV = Respiratory syncytial virus 
SABA = Short-acting β-2 adrenoceptor agonist 
SAMA = Short-acting muscarinic antagonist 
SERPIN = Serine protease inhibitor 
SNP = Single nucleotide polymorphism 
S. mitis = Streptococcus mitis 
S. pseudopneumoniae = Streptococcus pseudopneumoniae 
S. pneumoniae = Streptococcus pneumoniae 
TNF-α = Tumour necrosis factor-α 
URT = Upper respiratory tract 
20 
 
Publications & Abstracts 
 
Original article: 
Garcha, D.S., Thurston, S.J., Patel, A.R., Mackay, A.J., Goldring, J.J., Donaldson, G.C., 
McHugh, T.D., Wedzicha, J.A. (2012) Changes in prevalence and load of airway 
bacteria using quantitative PCR in stable and exacerbated COPD. Thorax, 67(12), 
pp.1075–1080. 
 
Oral presentations 
 
Garcha, D.S., Patel, A.R., Mackay, A.J., Singh, R., Donaldson, G.C., McHugh, T.D., 
Wedzicha, J.A. (2012) Bacterial prevalence and load during COPD exacerbation and 
recovery. European Respiratory Journal, 40: Suppl. 56, 243s 
 
Garcha, D.S., Thurston, S.J., Patel A.R., Mackay, A.J., Goldring, J.J., Donaldson, G.C., 
McHugh, T.D., Wedzicha, J.A. (2011) A comparison of prevalence and load of airway 
bacteria in COPD patients with paired stable and exacerbation state samples. 
Thorax, 66:A11 
 
Poster presentations & discussions 
Garcha, D.S., Thurston, S.J., Patel, A.R., Mackay, A.J., Goldring, J.J., Donaldson, G.C., 
McHugh, T.D., Wedzicha, J.A. (2012) Association between airway bacterial load and 
clinical parameters in stable COPD and at exacerbation. American Journal of 
Respiratory and Critical Care Medicine, 185;2012:A3742  
 
Garcha, D.S., Thurston, S.J., Patel A.R., Goldring, J.J., Donaldson, G.C., McHugh, T.D., 
Wedzicha, J.A. (2011) Quantitative PCR-based detection of typical and atypical 
bacterial strains in COPD patients and relationship to culture. American Journal of 
Respiratory and Critical Care Medicine, 183;2011:A3024 
21 
 
Garcha, D.S., Thurston, S.J., Patel A.R., Goldring, J.J., McHugh, T.D., Donaldson, G.C., 
Wedzicha, J.A. (2011) Quantitative PCR-based detection and quantification of 
atypical bacteria at baseline and exacerbation of COPD. Thorax, 2010 65:A124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                       Chapter 1 - Introduction 
22 
 
 
CHAPTER 1. Introduction 
  
                                                                       Chapter 1 - Introduction 
23 
 
1.1 Chronic Obstructive Pulmonary Disease 
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, made 
up of a number of different syndromes which are defined as COPD through 
spirometry testing. The most widely accepted current definition for COPD is that 
outlined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), in 
which COPD is defined as “a preventable and treatable disease with some 
significant extrapulmonary effects that may contribute to the severity in individual 
patients.  Its pulmonary component is characterized by airflow limitation that is not 
fully reversible.  The airflow limitation is usually progressive and associated with an 
abnormal inflammatory response of the lung to noxious particles or gases” (Rabe et 
al. 2007).  This definition encompasses a wide variety of diseases, ranging from 
chronic bronchitis to emphysema (Polkey 2008).   
 
Chronic bronchitis is defined clinically as the presence of cough and sputum 
production for three months per year for at least two successive years (Baik et al. 
2008).  Conversely, the definition of emphysema is pathological, by enlargement of 
the airspace and concomitant destruction of alveolar septae (Horowitz et al. 2009). 
 
In accordance with National Institute of Health and Clinical Excellence (NICE) 
guidelines in the UK, diagnosis of COPD is considered in patients over the age of 35 
who have symptoms of chronic cough, regular sputum production or exertional 
breathlessness, or a history of exposure to risk factors for the disease (Bellamy 
2004).  Diagnosis is clinically confirmed via spirometry testing, and mirrors GOLD 
guidelines (www.goldcopd.org) (Table 1.1).  Spirometry testing involves the patient 
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taking a deep breath and exhaling as hard and fast as possible into a spirometer.  
The amount of air expired in the first second following expiration is recorded – this 
is known as forced expiratory volume in one second (FEV1).  Also measured is the 
forced vital capacity (FVC) – this quantifies the time taken to expire all air from the 
lungs. 
 
Stage 
Disease 
status FEV1/FVC FEV1 
I Mild <0.70 ≥80% predicted 
II Moderate <0.70 50%≤FEV1<80% predicted 
III Severe <0.70 30%≤FEV1<50% predicted 
IV Very severe <0.70 FEV1<30% predicted 
Table 1.1. NICE COPD severity classification based on spirometry FEV1 measurement.  FEV1: Forced 
Expiratory Volume in one second; FVC: Forced Vital Capacity. 
 
COPD is a major global health burden, having a significant impact in terms of both 
morbidity and mortality.  In 2010, COPD was the third biggest cause of death 
globally (Lozano et al. 2013). The major risk factor associated with development of 
COPD is tobacco smoking, particularly in high-income countries, where 73% of 
deaths from COPD are related to tobacco smoking (van Zyl Smit et al. 2010).  This 
compares to low- and middle-income countries, in which only 40% of COPD 
mortality is related to tobacco smoking, with an additional 35% mortality 
attributable to exposure to biomass fuel smoke (van Zyl Smit et al. 2010), where 
biomass fuel refers to fuel derived from living/ previously living organisms.  
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It is unclear precisely how many smokers develop COPD, although estimates range 
from 15% to 50% (Polkey 2008; Laniado-Laborín 2009). Given that not all smokers 
develop COPD - regardless of their smoking history – it would appear that an 
abnormal inflammatory response to noxious particles may play a significant role in 
the development of the disease.  In a lung health study of 4194 subjects with 
airflow obstruction, it was reported that 52.2% were smokers (Anthonisen et al. 
2002).  It should also be noted that in a small subset of COPD patients, α1-
antitrypsin (AAT) deficiency rather than exposure to noxious particles is considered 
the principal factor in disease progression (Abboud & Vimalanathan 2008). 
 
Patients with COPD usually exhibit a state which involves chronic symptoms, with 
little day-to-day variation.  This typically involves being on regular maintenance 
therapy, and is described as stable COPD (NICE 2004).  However, occasionally, 
patients suffer from an acute worsening of symptoms, often requiring additional 
therapy – this is known as an acute exacerbation of COPD (www.goldcopd.org).   
1.1.1. COPD: A historical perspective 
 
Some of the earliest known writings on COPD come from the 17th century, with a 
description from Bonet of voluminous lungs (Petty 2006).  In 1814, the British 
doctor Charles Badham was one of the first individuals to recognise and highlight 
the chronic bronchitis component associated with COPD (Badham 1814). Less than 
a generation following this description, the French physician René Laennec found 
that some patients with obstructive lung disease had hyperinflated lungs which did 
not empty well (Laennec 1829).  This finding has proven to be of extreme 
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importance in COPD diagnosis, as it is investigated in the form of lung spirometry 
testing. The spirometer was initially developed in 1846 by John Hutchinson, but it 
was only in 1947 that it was adapted to include a timed measure of FVC as we are 
now familiar with it (Hutchinson 1846; Tiffeneau & Pinelli 1947). 
1.1.2. Aetiology of COPD 
 
Tobacco smoking is widely acknowledged as the principal cause of COPD, with other 
causes including biomass fuel, air pollution and chemical fumes.  However, not all 
long-term smokers go on to develop COPD, with estimates of COPD amongst 
smokers ranging from 15-50% (Fletcher & Peto 1977; Lundback et al. 2003).  This 
indicates a genetic susceptibility towards the development of COPD.  A well-defined 
phenotype in such development is AAT deficiency.  This leads to a lack of protection 
in the lung against proteolytic enzymes, as AAT is responsible for neutralising these 
proteases, most notably neutrophil elastase (Stoller & Aboussouan 2012).  This can 
ultimately result in the emphysematous subtype of COPD, both in smokers and 
non-smokers with the deficiency. However, this is a relatively rare deficiency, and it 
is responsible for COPD in only 1-2% of patients (Chitkara & Hurst 2012; DeMeo & 
Silverman 2004). 
 
1.1.3. History of COPD identification 
 
The heterogeneic nature of COPD gave rise to difficulties in terms of defining the 
disease, and this became a particular problem several decades ago, as cases of 
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pulmonary disease were increasing.  In the 1950s and 1960s two rival hypotheses 
emerged.  One of these became known as the Dutch hypothesis. This proposed that 
airway obstruction such as that seen in asthma, emphysema and chronic bronchitis 
are different phenotypes of one disease entity, with a strong genetic component 
termed chronic non-specific lung disease (Orie & Sluiter 1961).  An alternative 
hypothesis, termed the British hypothesis, suggested that chronic bronchitis 
predisposed the lungs to subsequent infection, leading to damage to either the 
airways or alveoli, or both, triggering progressive airflow limitation (Stuart-Harris et 
al. 1953).  Given the heterogeneous nature of COPD aetiology and progression, it is 
possible that both hypotheses may be correct. 
 
Chronic bronchitis and emphysema are distinct conditions with regards to how 
pulmonary disease arises in either case, but are frequently termed together as 
COPD, and the reason for this is that that they share the phenotype of irreversible 
obstruction to bronchial airflow (Fletcher & Peto 1977). The two conditions 
therefore represent opposite poles of the COPD disease ‘spectrum’.  It is now 
recognised that the vast majority of COPD patients fall somewhere in the middle of 
the spectrum, exhibiting symptoms of both conditions (Mannino & Buist 2007). 
 
1.1.4. Cigarette smoke, genetics and COPD 
 
Chronic airway inflammation is a ubiquitous feature of COPD.  The initial stimulus 
for such inflammation is noxious gas inhalation, normally through cigarette smoke.  
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Smoking triggers oxidative stress in the lungs, which is thought to be a result of 
oxidant-antioxidant imbalance (MacNee 2000).  Furthermore, smoking also causes 
neutrophil infiltration (Baraldo et al. 2004).  These neutrophils release elastase, a 
protease which contributes to the degradation of elastin in the lungs, and this is 
thought ultimately to lead to emphysema (Houghton et al. 2006).  
 
Cigarette smoke is made up of a mixture of more than 4,700 chemicals, with more 
than 1017 molecules present in each puff (MacNee 2000).  Oxidative stress is 
triggered by smoking through two mechanisms:  cigarette smoke itself contains 
oxidants such as free radicals (1014 per puff), nitric oxide and nitrogen dioxide (300 
to 500 parts per million) (Rahman et al. 1996).  Furthermore, cigarette smoke 
induces tissue to produce oxidants (Barreiro et al. 2010), further contributing to 
high levels of oxidants in the lungs.   
 
In the body, oxidants are counteracted by antioxidants, such as glutathione (GSH), 
vitamin C and vitamin E, both intra- and extra-cellularly (MacNee 2005).  These 
antioxidants act as reducing agents, removing the danger of oxidative stress.  In 
COPD, this balance between oxidants and antioxidants is believed to be 
circumvented, resulting in an emphysematous phenotype. 
 
It is known that patients with COPD have higher levels of oxidative stress, relative 
to both healthy subjects and smokers without COPD (MacNee 2005).  It is logical 
that oxidative stress would be higher in COPD than in healthy subjects, given that 
cigarette smoke introduces so many oxidants.  However, to understand why 
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smokers without COPD have lower levels of stress than COPD patients, the impact 
of the disease must be considered.   
 
As well as cigarette smoke itself, in COPD there are a number of other mechanisms 
which contribute to oxidative stress, particularly those in relation to chronic airway 
inflammation.  This is driven by neutrophils, which are major secretors of reactive 
oxygen species, such as myeloperoxidase (Rahman & Kinnula 2012).  
 
Elastin is a key protein of skin, blood vessels and lung architecture. In the lungs, it is 
part of the elastic fibre make-up, conferring the ability for the lungs to stretch and 
undergo elastic recoil (Turino et al. 2011).  COPD patients with an emphysematous 
phenotype present disrupted elastic fibres.  This is due to the action of proteases in 
degrading elastin.  In healthy subjects, the proteolytic action of such enzymes is 
mitigated by the action of anti-proteases, including AAT.   
 
Smoking is known to induce recruitment of high numbers of neutrophils to the 
airways (Hunninghake & Crystal 1983).  During an inflammatory response, 
neutrophils secrete neutrophil elastase, which is capable of destroying both 
bacteria and elastin.  AAT is able to combat such degradation, and is also able to 
inhibit apoptosis, by preventing the action of executioner caspases.  However, 
cigarette smoke acts directly to inactivate methionine residues of AAT, causing a 
loss of anti-elastase activity (Taggart et al. 2000). 
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Matrix metallo-proteases (MMPs), secreted by alveolar macrophages, are also 
associated with degradation of lung tissue, including elastic fibres and collagen 
(Russell et al, 2002).  Various MMPs, including MMP1, MMP2, MMP9 and MMP12 
are thought to be involved, where patients with ‘unfavourable’ allele 
polymorphisms are more susceptible to the effects of smoking (Mocchegiani et al. 
2011). 
 
It has been noted that oxidative stress causes oxidative inactivation of 
antiproteases (MacNee 2000).  This indicates that the oxidant-antioxidant 
imbalance and the protease-antiprotease imbalance may be interlinked. 
 
 
1.1.5. Genetics and COPD 
 
In recent years, increasing attention has been given to the role that genetics may 
play in pre-disposing certain individuals to developing COPD.  It has previously been 
described that presence of COPD appears to aggregate familially, independent of 
gender, smoking history and presence of AAT deficiency (Tager et al. 1978).   
 
AAT is produced by hepatocytes in the liver and is normally present in the serum at 
a concentration of between 20-53 µM (Stoller & Aboussouan 2012).  The active site 
of AAT binds to elastase, thereby resulting in its permanent inactivation (DeMeo & 
Silverman 2004).  It has been found that four distinct AAT phenotypes exist in the 
general population: normal alleles; deficiency alleles; null alleles; dysfunctional 
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alleles.  Normal alleles reflect the most prominent phenotype in the population, 
found in more than 95% of the Caucasian population (DeMeo & Silverman 2004).  
Null phenotypes have no AAT presence detected in serum, and carriers of this 
phenotype are at particularly increased risk of acquiring emphysema (Luisetti & 
Seersholm 2004).   
 
As there is a familial linkage to COPD, independent of AAT deficiency, it is important 
to consider which other factors may be involved in this association.  In a study 
which investigated COPD in families with no presence of AAT deficiency, where the 
proband demonstrated severe, early-onset COPD, it was identified that first-degree 
relatives of such probands had significantly lower FEV1 and FEV1/FVC ratio 
compared with controls (Silverman et al. 1998). 
 
AAT is also known as SERPINA1 (serine protease inhibitor, Group A, Member 1) 
(Schmechel 2007).  Other SERPINs are also thought to be involved in protecting 
against proteolytic damage.  Investigations have therefore been performed to 
assess whether dysfunction in these protease inhibitors also contributes to COPD 
development and progression.  Augmentation therapy with AAT supplementation 
has previously been examined as a means of reducing bronchial inflammation in 
patients with AAT deficiency (Stockley et al. 2002).  Stockley and colleagues found 
that augmentation therapy increased levels of serum AAT above the protective 
threshold and was associated with a decrease in both elastase activity and levels of 
the chemoattractant leukotriene B4 (LTB4). 
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Single nucleotide polymorphisms (SNPs) of the metalloprotease protein encoded by 
the gene ADAM33 have been shown to be associated with COPD in long-term 
smokers, in a study involving non-COPD long-term smokers as controls 
(Sadeghnejad et al. 2009).  This protein has previously been implicated in airway 
remodelling in asthma (Nelson et al. 2003) and the study by Sadeghnejad and 
colleagues therefore suggests a genetic mechanism by which some long-term 
smokers may develop COPD.  
1.1.6. Inflammation 
 
COPD is a disease in which the inflammatory response plays a major role in the 
manifestation of disease symptoms.  This may be either directly, through airway 
inflammation, or indirectly through systemic inflammation.  In studies examining 
inflammation in COPD, biomarkers of airway or systemic inflammation are typically 
measured for quantification.  
 
As was previously described in section 1.1.4, cigarette smoking triggers airway 
inflammation.  In a randomised cross-over study, van der Vaart and colleagues 
found that smoking increased levels of sputum neutrophils and interleukin-8 (IL-8) 
release in a group of healthy intermittent smokers (van der Vaart et al. 2005).  
Interestingly, in the same study it was found that smoking suppressed the levels of 
blood eosinophils (although the level of sputum eosinophils was not affected).   
 
IL-8 is a chemokine produced in response to oxidative stress, and is involved in the 
recruitment of polymorphonuclear leukocytes, such as neutrophils (Eckmann et al. 
                                                                       Chapter 1 - Introduction 
33 
 
1993).  Neutrophils secrete elastase principally as a means to degrade bacterial cell 
membranes.  However, elastase contributes to the degradation of elastin tissue in 
the lung parenchyma as well as mucous gland hyperplasia and mucus 
hypersecretion (Hoenderdos & Condliffe 2013). Furthermore, it reduces ciliary beat 
frequency, activates complement and inactivates immunoglobulin (Hoenderdos & 
Condliffe 2013).  Interleukin-1α (IL-1α) has also been shown to be important for 
initiation of smoke-induced neutrophilic inflammation (Botelho et al. 2011). 
 
Mucus hypersecretion involves release of the mucins MUC5AC and MUC5B, 
triggered by this secreted elastase (Park et al. 2005).  Mucin is secreted by 
specialised cells of the airway epithelium and submucosa gland cells, and combines 
with other secretions including water, proteins and salt, to form mucus (Kirkham et 
al. 2008).  From a clinical viewpoint, mucus hypersecretion is a common symptom 
in COPD, particularly in patients who exhibit the chronic bronchitic phenotype of 
chronic sputum production (Kim & Criner 2013). 
 
Bafadhel and colleagues have previously demonstrated that different inflammatory 
biomarkers are found with differing clinical phenotypes, with IL-1β associated with 
bacterial exacerbations and serum CXCL-10 associated with viral exacerbations 
(Bafadhel et al. 2011). 
 
Nuclear factor-κB (NF-κB) is a transcription factor which has an essential role in 
modulating the immune response to infection (Pasparakis 2012).  It is able to 
control the expression of a wide variety of inflammatory and apoptosis-inducing 
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genes (Brown et al. 2009).  Under non-stimulated conditions, NF-κB is inactive, 
bound to inhibitory protein κBα (IκBα) in the cytoplasm (Szulakowski et al. 2006).  
Activation occurs through cell signalling pathways:  External stimuli such as 
cytokines or virulence factors trigger activation of IκB-kinase (IKK).  IKK is then able 
to phosphorylate IκBα resulting in the latter’s degradation (Karin 1999).  This allows 
the unbound NF-κB to migrate to the nucleus and initiate transcription of a variety 
of genes involved in a pro-inflammatory response (Figure 1.1).   
 
In healthy individuals, regulation of NF-κB is tightly controlled, ensuring that any 
inflammatory outcome does not have a detrimental impact to the host.  In COPD, 
however, expression of phosphorylated NF-κB is significantly upregulated 
compared to the rates seen in both asymptomatic smokers and non-smoking 
controls (Aoshiba et al. 2012).   
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Figure 1.1 Cellular mechanism for activation of NF-κB.  Abbreviations: IκB=inhibitor of kappa B; IL-6= interleukin-6; p=phosphate group; TNF-α=Tumour necrosis factor-alpha  
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Recent evidence, however, contradicts the view that cigarette smoking is a major 
driver of NF-κB-associated inflammation (Rastrick et al. 2013).  Rastrick and 
colleagues examined the NF-κB:DNA binding activity in mouse lung extracts.  They 
found no increase in NF-κB:DNA binding activity following exposure to cigarette 
smoke extract.  However, they acknowledge that the time points at which they 
measured such activity may not have captured any increase – the earliest time 
point at which activity was measured was 2 hours post-challenge, by which time an 
acute inflammatory response may have dissipated. 
 
In the present thesis, the association of inflammation and lower airway bacterial 
presence is considered in Chapters 4, 5, 6 and 7.   
 
Contrary to the inflammatory phenotype identified in asthma, in which an 
eosinophilic influx is commonly seen, neutrophil recruitment is a routine 
component of the inflammatory response triggered in COPD (Stockley 2002).  This 
contributes significantly to the emphysematous phenotype seen in many cases of 
COPD due to the excessive production of neutrophil elastase, as discussed in 
previous sections.  Understanding the basis of neutrophilic infiltration is therefore 
an important step to understanding inflammation in COPD. 
 
Neutrophils migrate towards sites of inflammation via chemotaxis, directed by 
chemokines (Bracke et al. 2007).  LTB4 is a chemoattractant known to play a major 
role in the recruitment and activation of neutrophils (Afonso et al. 2012).  Afonso 
and colleagues found that it is secreted by activated neutrophils as they migrate 
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towards the site of inflammation.  This generates a signalling-relay, amplifying 
neutrophil recruitment.  In COPD, levels of LTB4 are significantly higher than those 
in healthy controls (Profita et al. 2010). 
1.1.7. Differences between healthy smokers and COPD patients 
 
Whilst smoking is known to be the most common risk factor associated with COPD, 
not all smokers will develop the disease.  Given this discrepancy between healthy 
smokers and smokers with COPD, and in order to understand the nature of the 
disease, it is therefore of importance to examine the factors that may pre-dispose 
certain people to be more susceptible than others.   
 
Schulz and colleagues examined rates of various inflammatory modulators in COPD 
patients versus asymptomatic smokers, with eight subjects examined in each group 
(Schulz et al. 2004). They found that both IL-8 and the related chemokine GRO-α 
increased at a significantly higher rate in COPD patients than in the control group, 
following stimulation with tumour necrosis factor-α.  Additionally, COPD patients 
have higher neutrophil levels compared with non-COPD smokers (Keatings et al. 
1996). 
 
1.1.8. Pathology 
 
It is known that structural and functional changes in the small airways (<2mm 
diameter) result in airflow limitation in COPD (Sturton et al. 2008).  Chronic 
inflammation in the lungs triggers fibrosis (Wick et al. 2013).  Furthermore, loss of 
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alveolar attachments may be identified, also due to inflammation (Saetta et al. 
1985).  In healthy individuals, alveolar attachments ensure that airways do not fully 
close during expiration.  Elastin fibres in the alveolar attachments regulate this 
process.  However, in COPD elastin is degraded.  A potential consequence of this is 
that small airways without alveolar attachments may close completely, limiting 
expiration of air from the lungs, and causing air trapping.  Air trapping is associated 
with hyperinflation of the lungs, and this leads to increased levels of dyspnoea and 
reduced exercise tolerance (Gibson 1996).  
 
It has also previously been elucidated that small airways inflammation is correlated 
with disease severity (Hogg et al. 2004).  This would support the theory of a vicious 
circle involving disease severity and inflammation (Figure 1.2). 
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Figure 1.2 The vicious circle hypothesis of inflammation in COPD
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1.1.9. Treatment of stable COPD 
 
There is no known cure for COPD.  However, there are a variety of therapies 
available by which symptoms can be alleviated.  The single most effective 
treatment for COPD is smoking cessation (Anthonisen et al. 1994; Kanner et al. 
1999).  Ever since the seminal paper by Fletcher and Peto in 1977 examining the 
effect of smoking cessation in patients with COPD, it has been known that stopping 
smoking can dramatically reduce the rate of decline in FEV1, compared with those 
patients who continue to smoke (Fletcher & Peto 1977).   Nonetheless, with or 
without smoking cessation, disease progression continues to some extent and so 
therapy is usually required.   
 
During stable COPD, a common treatment is bronchodilator therapy, via inhalation.  
Such treatment is principally in the form of β-2 adrenoceptor agonists, and this may 
be short-acting (SABA), e.g. Salbutamol, or long acting (LABA), e.g. Salmeterol.  
Occasionally, long-acting and short-acting muscarinic antagonists (LAMA/SAMA) are 
used alternatively, or in combination with β-2 agonists.  SABAs have a rapid effect 
(within 5 minutes), with a total duration of between 4-6 hours (Beeh & Beier 2010)  
As such, they are often taken as reliever medication during periods of 
breathlessness.  LABAs begin to act after 20 minutes, lasting for a total of 12 hours 
(Decramer et al. 2013).  They are utilised as maintenance therapy and taken twice-
daily by COPD patients. 
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SAMAs, such as ipratropium bromide, are provided as nebuliser therapy and act 
within 15 minutes of use, for a total of 4-6 hours (Noord et al. 2000). Conversely, 
the LAMA, tiotropium, can be taken as a once-daily medication (Noord et al. 2000). 
In a recent meta-analysis comparing use of tiotropium or placebo, it was identified 
that use of tiotropium was significantly associated with improvements in lung 
function, quality of life and exacerbation risk (Karner et al. 2012). 
 
The two bronchodilator therapies have different mechanisms of action:  β-2 
agonists target the β2-adrenergic receptors present on smooth muscle, causing 
relaxation of such muscle, with resultant dilation of bronchi (Cazzola et al. 2013).  
Anti-cholinergic therapies work by inhibiting the activity of acetylcholine receptors, 
thereby preventing bronchial constriction (Cazzola et al. 2012).   
 
A recent development in COPD treatment is the discovery of ultra-long acting β-
agonists, such as carmoterol and indacaterol, paving the way for once-daily dosing 
(Beeh & Beier 2010).  In a randomised, double-blinded crossover trial comparing 
indacaterol with tiotropium (a LAMA) and a placebo, it was found that indacaterol 
provided significant bronchodilation over a 24-hour period, at least as effective as 
tiotropium (Vogelmeier et al. 2010).  This finding was supported by a recent pooled 
analysis examining the efficacy of indacaterol in a number of different clinical trials 
– this analysis agreed that indacaterol was at least as effective as tiotropium, and 
also found that it was better than both salmeterol and formoterol (Yorgancioglu 
2012).  
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Where the clinician deems necessary, inhaled corticosteroids (ICS) may also be 
prescribed to reduce airway inflammation.  ICS are frequently used in airway 
diseases in order to reduce inflammation (Confalonieri et al. 1998).  However, they 
are generally regarded as having greater potency in other airway diseases such as 
asthma, compared to their effectiveness in COPD (Barnes 2006).  Nonetheless, ICS 
are considered an integral part of COPD therapy. 
 
In a systematic review, it was demonstrated that ICS treatment reduces 
exacerbation frequency (Alsaeedi et al. 2002).  However, in the same analysis, it 
was also demonstrated that there were a number of side-effects associated with 
ICS use.  As such, the suitability of ICS use at stable state must be carefully 
considered. The ISOLDE trial investigated the efficacy of the ICS, fluticasone 
propionate, compared with a placebo.  It was found that ICS treatment reduced 
exacerbation frequency and also slowed the rate of decline in health status (Burge 
2000). In two major trials  in which the effects of ICS in COPD were evaluated 
(TORCH and ECLIPSE trials), it was found that ICS usage was associated with a higher 
rate of pneumonia in COPD patients than that seen with other treatments 
(Calverley et al. 2007; Wedzicha et al. 2008; Calverley et al. 2011).   This association 
needs further exploration on a mechanistic basis, and is examined in the present 
thesis in Chapter 5.  
 
In a study investigating the efficacy of ICS/LABA combination therapy, involving 
patients with severe COPD, it was seen that there was a 35% reduction in 
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exacerbation frequency with the combination therapy, compared to use of a LABA 
alone (Kardos et al. 2007). 
 
ICS therapy is commonly given in asthma treatment, and is considered highly 
effective at reducing inflammation in the disease.  Conversely, in COPD, patients 
occasionally demonstrate insensitivity to ICS treatment.  One potential reason for 
this discrepancy which has been mooted is the reduction in activity of histone 
deacetylase-2 (HDAC2) in COPD patients (Barnes 2004).  HDAC2 is an enzyme which 
catalyses deacetylation of histones in chromatin, resulting in prevention of 
transcription occurring.  However, in COPD, the consequence of reduced HDAC2 
activity is a higher level of acetylation occurring, and this has been associated with 
increased transcription of the cytokine IL-8, contributing to persistent 
inflammation.   
 
1.1.10. Lower airway bronchial colonisation 
 
Lower airway bronchial colonisation (LABC) is a common feature of COPD.  
Conventional microbiological culture has previously demonstrated the presence of 
typical airway bacteria including Haemophilus influenzae, Streptococcus 
pneumoniae, Moraxella catarrhalis, Pseudomonas aeruginosa and Staphylococcus 
aureus.  Serological analysis has also linked atypical bacteria such as Legionella 
pneumophila, Chlamydophila pneumoniae and Mycoplasma pneumoniae to COPD 
exacerbations (Lieberman et al. 2002a; Lieberman et al. 2001; Lieberman et al. 
2002b).   Presence of lower airway bacteria is associated with higher airway 
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inflammation at both stable and exacerbation states of COPD (White et al. 2003; 
Soler et al. 1999). 
 
It has been frequently demonstrated, using routine microbiological culture, that 
lower airway bacteria are associated with COPD, both in the stable state and at 
exacerbation - with the bacteria most commonly identified being Haemophilus 
influenzae, Streptococcus pneumoniae, Moraxella catarrhalis and Pseudomonas 
aeruginosa (Rosell et al. 2005; Miravitlles et al. 1999).  The study by Rosell and 
colleagues found prevalence of presence of H. influenzae, M. catarrhalis and S. 
pneumoniae at 30% during stable state and 44% during exacerbation state.  These 
‘typical airway bacteria’ are commonly associated with infection in COPD patients. 
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1.2 Acute Exacerbations of COPD 
 
There is no generally agreed definition of acute exacerbations of COPD (AE-COPD) 
although it is associated with a worsening of COPD symptoms compared to usual 
daily symptoms (Burge & Wedzicha 2003).  This can be measured according to a 
number of different criteria.  According to Anthonisen and colleagues, 
exacerbations can be defined based on the symptoms caused.  If a patient saw a 
deterioration in the major symptoms, dyspnoea, sputum purulence and sputum 
volume, this was described as a Type 1 exacerbation, whilst if only two of these 
symptoms were seen, it was noted as a Type 2 exacerbation.  If one of these major 
symptoms was identified, in conjunction with either cough, wheeze or respiratory 
tract infection, then a Type 3 exacerbation was declared (Anthonisen et al. 1987).  
An alternative method of recording an exacerbation is to define it according to 
health care utilisation - an event which results in a therapeutic intervention 
(Tashkin 2010). 
  AE-COPD: Triggers and associations 1.2.1.
 
There are a number of factors known to be associated with exacerbations.  A 
previous review highlighted viruses, bacteria and airway irritants (e.g. pollutants) as 
being associated with AE-COPD (Wedzicha & Seemungal 2007).   
 
Bacterial pathogens are commonly identified in the lower airways of patients 
suffering exacerbations, with Haemophilus influenzae, Streptococcus pneumoniae, 
Pseudomonas aeruginosa and Moraxella catarrhalis particularly prevalent (Rosell et 
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al. 2005; Papi et al. 2006).  However, this association is complicated by the fact that 
some COPD patients appear to be chronically colonised with lower airway bacteria, 
even during the stable state of the disease. 
 
The major viral pathogen seen during an exacerbation is rhinovirus, with other 
viruses involved including respiratory syncytial virus (RSV) and coronavirus 
(Seemungal et al. 2001).  Rhinovirus infects the airway epithelial cells lining the 
upper and lower airways.  This stimulates the secretion of various cytokines, 
including Interleukin-6 (IL-6), IL-8 and CXCL1 (Schneider et al. 2010).  IL-6 has a 
number of roles in modulating the inflammatory response.  For example, it is able 
to stimulate T-cell activation and promote recruitment of macrophages and 
neutrophils, with consequent pathogenesis (Rincon 2012).    
 
Acute exacerbations are usually treated with oral steroids and/or antibiotic 
treatment, dependent upon the symptoms presented.  For example, purulent and 
excessive sputum production is indicative of a bacterial infection, which would pre-
dispose the patient to antibiotic therapy (Anthonisen et al. 1987).   
 
There is no standardised measure of length of antibiotic treatment for COPD 
exacerbations, and a typical treatment course is 7-10 days, with a second course 
given if symptoms have not resolved.  There are a number of different types of 
antibiotics which may be prescribed.  In the London COPD cohort, β-lactam 
antibiotics are the most frequently prescribed, namely amoxicillin and co-amoxiclav 
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(a combination of amoxicillin and clavulanic acid), although fluoroquinolone, 
macrolide and tetracycline antibiotics are also occasionally prescribed.   
 
It has previously been demonstrated that antibiotic usage during COPD 
exacerbations reduces the frequency of subsequent exacerbations, and also 
reduces the risk of mortality (Roede et al. 2009). 
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β-lactam antibiotics  
β-lactam antibiotics inhibit synthesis of the peptidoglycan cell wall (Tomasz 1979).  
This means that they are effective specifically in environments where bacteria are 
actively replicating.  Clavulanic acid is often given in combination with β-lactams, as 
it is a potent inhibitor of β-lactam-degrading β-lactamase enzymes produced by 
resistant bacterial species (Reading & Cole 1977).   
 
Fluoroquinolones 
Fluoroquinolones constitute a family of synthetic, broad-spectrum antibiotics first 
identified in the 1960s. The modus operandi of the antibiotics involves prevention 
of DNA replication, specifically by inhibiting the mode of action of the bacterial 
enzymes DNA topoisomerase II (alias DNA gyrase) and DNA topoisomerase IV 
(Hooper 1999). This inhibition stops the catalysis of bacterial DNA unwinding which 
would be a necessary first step in DNA replication.   
 
Macrolides 
Macrolide antibiotics have bacteriostatic properties, meaning that they inhibit 
bacterial reproduction.  They act by binding to the bacterial 50S ribosome subunit, 
therefore inhibiting protein synthesis.  Specifically, macrolides interact with the 
peptidyltransferase ring located in the 23S rRNA subunit section, preventing 
extension of the growing peptide chain (Franceschi et al. 2004). 
 
Macrolides also possess anti-inflammatory properties, in addition to the reduction 
of inflammation imparted by bacterial elimination (Cameron et al. 2012).  The 
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benefits of macrolides as an immuno-modulatory drug were illustrated in the 
1990s, when it was shown to dramatically improve mortality rates in patients with 
diffuse pan-bronchiolitis (Kudoh et al. 1998).   
 
There are a number of mechanisms by which macrolides are thought to act to 
facilitate an anti-inflammatory outcome - It has been demonstrated that macrolides 
decrease mucus hypersecretion (Tamaoki et al. 1995) and reduce levels of pro-
inflammatory cytokines in patients with chronic airways disease (Oishi et al. 1994). 
 
Macrolides such as erythromycin, clarithromycin and azithromycin are frequently 
used to treat exacerbating COPD patients, and trials have also demonstrated 
efficacy of macrolides in reducing exacerbation frequency, when given to stable 
COPD patients (Seemungal et al. 2008; Albert et al. 2011). 
 
Tetracyclines 
 
Like macrolides, tetracycline antibiotics also inhibit protein synthesis.  However, 
tetracyclines act by inhibiting the 30S subunit of prokaryotic ribosomes (Griffin et 
al. 2010).  
 
The bacterial targets of the major antibiotic groups currently in use for COPD are 
summarised in Figure 1.3. 
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Systemic corticosteroids are also prescribed, according to GOLD COPD guidelines 
(www.goldcopd.org). A meta-analysis examining the use of systemic corticosteroids 
in the treatment of COPD exacerbations showed that treatment improves airflow 
limitation, decreases the risk of relapse and may improve symptoms and decrease 
the length of hospital stay (Schweiger & Zdanowicz 2010). 
                                                                       Chapter 1 - Introduction 
51 
 
 
Figure 1.3.  Antibiotic targets in a bacterial cell. PBP = Penicillin-binding protein
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The relationship of antibiotic usage with development of antibiotic resistance has 
been previously well-characterised (Gould 1999).  However, in the specific context 
for the treatment of COPD exacerbations, this relationship is not clearly defined.   
 
Community-acquired pneumonia (CAP) is occasionally identified in COPD, with one 
study showing that 12-20% of COPD patients were diagnosed with pneumonia over 
a 3-year period (Calverley et al. 2007).  CAP, which is distinct from AE-COPD, is also 
primarily caused by bacterial or viral infection of the lungs.  In particular, 
Streptococcus pneumoniae has been found to be the aetiological agent in 48% of 
CAP cases in the UK, making it the single most important pathogen to target with 
antibiotic therapy (Lim et al. 2001).  
 
It has been found that there is an association between use of ICS therapy and rate 
of pneumonia in COPD.  Two randomised clinical trials, TORCH and INSPIRE, which 
examined the efficacy of ICS and combination therapies to treat COPD, both 
identified significantly increased rates of pneumonia in patients who had been 
treated with fluticasone compared to those treated with placebo (Calverley et al. 
2007; Calverley et al. 2011).  The mechanistic rationale for such a finding is not well 
understood, although it has previously been illustrated that the anti-inflammatory 
nature of ICS compromises the immune response (Adcock 2004). 
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1.3 Micro-organisms in COPD 
 
The treatment of acute exacerbations of COPD with antibiotics has previously been 
considered.  However, there is a growing body of evidence indicating that providing 
prophylactic antibiotic therapy to patients during the stable state may also prove 
beneficial in reducing the rate of exacerbations.  In a Cochrane meta-analysis 
review, analysing nine trials performed before 1970, it was found that prophylactic 
antibiotic treatment in chronic bronchitis elicited a small, statistically significant 
effect in reducing days of illness caused by exacerbations (Staykova et al. 2003).   
 
In a study involving the macrolide antibiotic erythromycin, our group has previously 
demonstrated that long-term macrolide treatment to COPD patients – 250mg twice 
daily for 12 months – significantly reduced exacerbation frequency versus placebo 
(rate ratio of 0.65 when placebo=1) (Seemungal et al. 2008).  Whether this is due to 
the antibiotic or anti-inflammatory properties of macrolides (or a combination of 
both), is currently unclear.  
 
Albert and colleagues built upon this research, treating 1142 COPD patients with 
250mg daily azithromycin or placebo for 12 months (Albert et al. 2011).  Again, it 
was seen that macrolide treatment significantly reduced exacerbation frequency 
(ratio of 0.73).  They also noted a potential side effect whereby hearing decrements 
were higher in the azithromycin group (25% vs 20%). 
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The potential benefits of prophylactic antibiotic therapy have been highlighted by 
these recent studies, but work needs to be done to establish the implications of 
such treatment on the development of bacterial resistance. 
1.3.1. London COPD cohort 
 
The London COPD cohort is a prospective cohort study which has been established 
to investigate the causes and mechanisms of COPD exacerbations.  In this study, a 
modified version of Anthonisen’s criteria is utilised in which two or more symptoms 
appear or show deterioration, at least one of which must be a major symptom – 
sputum purulence, sputum volume, dyspnoea (Seemungal et al. 1998).  Minor 
symptoms are cough, wheeze, sore throat and cold symptoms.  The study involves a 
rolling cohort of patients and at any one time there are approximately 200 COPD 
patients in the study. These patients are able to record daily changes in physiology 
using a diary card based system (see Appendix).  These diary cards record a number 
of parameters each day:  Peak flow, Change in symptoms, Change in treatment, 
Hours out of the home, Number of steps. 
 
Patients are seen quarterly for baseline visits, as well as during any reported 
exacerbations (patients are able to call a dedicated COPD phone held by a physician 
24 hours a day, seven days a week).  Each year, an annual review is performed, to 
update patient data. Following notification of an exacerbation, the patient is given 
an appointment to attend clinic on either the same day or the following day.  
Exacerbating patients re-visit the clinic at days 3, 7, 14, 35 and 56 post-exacerbation 
presentation in order to monitor recovery.   
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1.3.2. COPD and micro-organisms 
 
Bacterial, viral and fungal infections cause a range of upper and lower respiratory 
tract illnesses in the general population.  In healthy individuals, such infections are 
usually swiftly resolved following diagnosis.  COPD drives an inflammatory response 
in the airways which results in an impaired immune response.  This is coupled with 
the fact that as many as 70% of COPD patients take anti-inflammatory 
corticosteroids (Zervas et al. 2013), further altering the immune profile of the lungs.  
It is with this background that the role of micro-organisms should be considered 
with relation to COPD.  
 
1.3.3. H. influenzae virulence mechanisms 
 
The species was initially identified in the late 19th century by the German scientist 
Richard Pfeiffer, and was classified as Bacillus influenzae, due to its association with 
an influenza epidemic.  It was ultimately reclassified as Haemophilus influenzae in 
the early 1900s.  This name was retained despite the identification of influenza 
virus as the cause of influenza in 1933. In 1931 Margaret Pittman made the key 
finding that there were different strains of the species, and that these were 
differentiated based upon the presence or absence of a capsule (Pittman 1931).  
Unencapsulated strains are unable to react with antisera and so cannot be typed 
according to serology.  They are therefore referred to as non-typeable Haemophilus 
influenzae (NTHi) (Murphy et al. 2009).   
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NTHi are considered to be the major group of H. influenzae associated with COPD 
exacerbations.  Oral immunisation with inactivated H. influenzae has been shown to 
reduce rates of moderate-to-severe exacerbation in frequent exacerbators by 63% 
(Tandon et al. 2010).  There are a number of factors which have been shown to 
have a role in H. influenzae virulence:  The lipopolysaccharide (LPS) of H. influenzae 
acts as an endotoxin and stimulates secretion of pro-inflammatory cytokines by 
host cells (Matsui et al. 2001).  Furthermore, in vitro studies have demonstrated 
that LPS assists in adherence of H. influenzae to human bronchial epithelial cells 
(Swords et al. 2000). Using LPS-coated polystyrene beads, Swords and colleagues 
showed that beads coated with wild-type LPS adhered significantly more to 
bronchial epithelial cells than beads coated with a truncated version of the same 
LPS. 
 
 During infection, NTHi initially adheres to epithelial cells of the upper airway (Erwin 
& Smith 2007).  There are a number of processes which NTHi may then undergo: (i) 
invasion of respiratory epithelium; (ii) transcytosis into sub-epithelial compartment; 
(iii) microcolony formation.  A number of strains of NTHi are able to express pili, 
which are threadlike appendages capable of adhering to airway epithelial cells 
(Geme 2002) and the presence of pili has been shown to increase adherence of 
NTHi to respiratory mucus (Kubiet et al. 2000). 
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1.3.4. S. pneumoniae virulence mechanisms 
 
More than 90 serotypes of S. pneumoniae have been identified.  The organism has 
been shown to be present asymptomatically in the nasopharynx of approximately 
40% of adults in developing countries (Obaro & Adegbola 2002). Pathogenesis of S. 
pneumoniae, which involves invasion and dissemination of the organism, is most 
frequently associated with 20 of these serotypes (Hammerschmidt et al. 2005). 
There are a number of factors linked to causing increased pathogenesis by S. 
pneumoniae.  These include: 
 
 A capsular polysaccharide layer 
 Phosphorylcholine adhesion 
 Pneumococcal surface protein A (PspA) 
 Pneumococcal adhesion and virulence factor A (PavA) 
 Pneumolysin 
 
The capsular polysaccharide layer (cps) defines more than 90 serotypes of S. 
pneumoniae (Cobey & Lipsitch 2012).  The virulence of the cps varies significantly 
between serotypes, with some serotypes offering better evasion for the organism 
from complement-mediated opsonisation (Winkelstein 1984). It has also been 
demonstrated that the cps prevents mucosal entrapment of S. pneumoniae (Nelson 
et al. 2007), which would otherwise prevent transit to the epithelial surface. 
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Phosphorylcholine (ChoP) is an adhesin common to a number of bacterial species, 
including H. influenzae and S. pneumoniae.  ChoP binds to the receptor for platelet-
activating factor, with this receptor being found in a variety of host tissue, including 
the nasopharyngeal epithelium (Kadioglu et al. 2008).  Via this adherence, ChoP is 
able to assist invasion of bronchial cells (Swords et al. 2000). 
 
An important branch of the innate immune system is lactoferrin, a protein which is 
involved in iron sequestration.  This prevents bacteria from acquiring iron, thereby 
restricting growth (Shaper et al. 2004).  S. pneumoniae expresses a surface protein 
called Pneumococcal surface protein A (PspA) which binds to apolactoferrin (a form 
of lactoferrin), conferring protection on the bacterium from such bactericidal 
properties (Shaper et al. 2004). It has also been demonstrated that PspA is involved 
in interfering with the host complement response, thereby inhibiting clearance of 
the bacterium (Tu et al. 1999). 
 
Animal models have demonstrated the virulence potential of the S. pneumoniae cell 
surface molecule, Pneumococcal adhesion and virulence factor A (PavA).  In a 
mouse model of sepsis infection, PavA-null mutants showed more than 100-fold 
attenuation of virulence (Holmes et al. 2001).   
 
1.3.5. M. catarrhalis virulence mechanisms 
 
Moraxella catarrhalis (previously known as Branhamella catarrhalis) is a gram-
negative diplococcus commonly isolated as a commensal in the upper respiratory 
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tract of healthy individuals (Murphy & Parameswaran 2009).  The rate of carriage is 
3-5% in healthy adults (de Vries et al. 2009). The bacterium is now established as a 
pathogen in both upper and lower respiratory tract infections, including acute 
exacerbations of COPD (Verduin et al. 2002). 
 
Pathogenesis of M. catarrhalis is thought to be dictated by a number of virulence 
factors, including its lipo-oligosaccharide surface component and various outer 
membrane molecules (de Vries et al. 2009).  These confer a variety of traits upon 
the bacterium, such as epithelium adherence and iron uptake (Plamondon et al. 
2007).  
 
1.3.6. Atypical airway bacteria 
 
Atypical airway bacteria consist primarily of Chlamydophila pneumoniae, Legionella 
pneumophila, and Mycoplasma pneumoniae.  They are known to be common 
causes of atypical pneumonia, so called as it demonstrates symptoms distinct from 
those caused in ‘typical’ pneumonia (Hindiyeh & Carroll 2000). The atypical airway 
bacteria have been seldom identified in patients with COPD through conventional 
culture techniques.  This may be due to the fact that C. pneumoniae is an obligate 
intracellular pathogen, and both L. pneumophila and M. pneumoniae have 
intracellular components to their life cycle. although serological analysis has hinted 
at a higher prevalence of infection with these species in exacerbating COPD patients 
compared with controls, as previously described in section 1.1.10.  Given the lack of 
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supporting data from other studies, it would be important to determine the 
veracity of such findings using molecular techniques. 
 
1.3.7. Bacterial load and strain-switching hypotheses 
 
It is widely accepted that typical airway bacteria trigger acute exacerbations of 
COPD.  However, what is not so clearly defined is the mechanism by which this is 
caused.  One theory suggests that bacterial load is the major driver as it is strongly 
associated with inflammatory markers (Hill et al. 2000), whilst another hypothesis 
suggests that intra-species switching of bacterial strains is the trigger for 
exacerbations (Sethi et al. 2002).  The current thesis explores changes in bacterial 
load in patients at various disease states, and their relation to clinical outcomes, in 
Chapters 4, 5 and 6. 
 
1.3.8. Airway microbiome 
 
Historically, the healthy lungs have not been thought to be associated with any 
form of microbiota, and indeed have been believed to be sterile, with any inhaled 
bacteria thought to have been rapidly phagocytosed by alveolar macrophages.  
However, recent developments in the field have proved that a bacterial flora – 
collectively referred to as a microbiome - does exist in the lungs (Hilty et al. 2010; 
Erb-Downward et al. 2011; Huang et al. 2010).   
 
The presence of an airway microbiome poses a number of questions with respect to 
the impact of bacterial infection in COPD.  In particular, what is the impact of 
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antibiotic therapy to this microbiome, and does the microbiome have a pathogenic 
effect in acute exacerbations of COPD?  
 
The respiratory tract is a continuous tract running from the buccal orifice down to 
the lung alveoli.  It is conventionally sub-divided into an upper respiratory tract 
(URT) and lower respiratory tract (LRT).  The URT consists of the nasal cavity, 
pharynx and larynx, whilst the LRT is made up of the trachea, bronchi, bronchioles 
and lung alveoli.  This sub-division is an important facet of bacterial and viral 
infection in the respiratory tract, particularly with regards to disease severity – LRT 
infection is typically associated with more severe symptoms compared with URT 
infection.  The current study investigates changes in the airway microbiome at 
different states of COPD in chapter 6 and chapter 7. 
 
1.3.9. Detection of bacterial infection 
 
Detection of bacterial infection has been conventionally performed using routine 
microbiological culture.  However with the advent of nucleic acid amplification tests 
(NAATs) such as PCR, there has been a move towards molecular protocols.  A study 
involving 30 COPD patients has previously been performed to examine the 
proficiency of PCR and routine microbiological culture in detecting typical airway 
bacteria (Curran et al. 2007).  This indicated that PCR was a more accurate 
technique for bacterial detection.  As part of the validation process of the 
techniques performed in the present thesis, this comparison is performed using a 
multiplex PCR in Chapter 3.   
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The prevalence of typical and atypical airway bacteria in COPD has hitherto been 
little studied.  The present thesis examines the prevalence and quantity (load) of 
such bacteria at various phases of COPD in Chapters 4, 5, 6 and 8.  
1.3.10. Viral infection 
 
Unlike bacteria, viruses are not thought to colonise the airways on a long-term 
basis.  However, viruses have frequently been identified in patients suffering AE-
COPD, with rhinovirus particularly prevalent.  In an experimental model, Johnston 
and colleagues found that rhinovirus infection was able to induce exacerbations in 
stable COPD patients (Mallia et al. 2011).  This provides direct evidence of 
rhinovirus as a causative factor in COPD exacerbations.  There is also evidence that 
patients with persistent RSV infection have higher airway inflammation and faster 
FEV1 decline than patients without persistent RSV infection (Wilkinson et al. 2006a). 
1.3.11. Bacterial and viral coinfection 
 
It has been demonstrated that exacerbations exhibiting simultaneous bacterial and 
viral coinfection have higher levels of inflammatory markers (Wilkinson et al. 
2006b).  Separately, it was identified that rhinoviral infection predisposed COPD 
patients to opportunistic bacterial infection in 60% of patients, post-rhinoviral 
infection (Mallia et al. 2012).  Those patients with secondary bacterial infection had 
significantly raised levels of neutrophil elastase – this was not identified in those 
patients who had no bacterial infection.  This may lead to bacterial complications of 
                                                                       Chapter 1 - Introduction 
63 
 
viral-induced exacerbations, potentially amplifying an exacerbation (Molyneaux et 
al. 2013). 
1.3.12. Comorbidities 
 
It has become apparent that COPD is associated with disease manifestations other 
than just airflow limitation (Carlin 2012). In fact there are a number of systemic 
manifestations of COPD, including cardiovascular diseases such as ischaemic heart 
disease (Patel et al. 2012), heart failure, osteoporosis, depression and anxiety 
(Barnes & Celli 2009), and gastro-oesophageal reflux disease (Casanova et al. 2004).  
As such, COPD patients with comorbidities are at increased risk of hospitalisation, 
resulting in greater healthcare costs, as well as increased mortality (Barnes & Celli 
2009).  
 
1.3.13. Bacterial infection in other airway infections 
 
Bacterial infection is associated with a number of lung diseases distinct from COPD, 
and an understanding of the impact of such infection may contribute to the 
knowledge of the role of bacteria in COPD.  Cystic fibrosis (CF) is a hereditary 
condition affecting approximately 1 in 2500 individuals in a Caucasian population 
(Raman et al. 2002).  Bacterial infection is associated with a worsening of CF. For 
example, Pseudomonas aeruginosa infection involves the formation of a biofilm 
within the lung.  This biofilm is protective against both the host immune system and 
antibiotic treatment (Bjarnsholt et al. 2009).  NTHi is known to frequently infect CF 
patients, and is also associated with the formation of biofilms on the airway 
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epithelium (Starner et al. 2006).  Non-CF bronchiectasis involves a widening of the 
bronchi following degradation of muscle and elastic tissue.  This is triggered by 
inflammatory/infectious damage, and results in chronic cough and sputum 
overproduction (O’Donnell 2008).  Bacterial infection is commonly associated with 
bronchiectasis, with the major pathogens isolated being H. influenzae, P. 
aeruginosa, S. pneumoniae, and M. catarrhalis. Patients with P. aeruginosa 
demonstrate an accelerated decline in lung function (Martínez-García et al. 2007), 
whilst conversely, patients with no pathogen detected have the mildest disease 
(King et al. 2007). 
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1.4.  Questions to be answered in bacteriology of COPD  
 
Over the last half-century, since the British and Dutch hypotheses were proposed, 
there has been a significant wealth of information concerning the progression of 
COPD, not least of which involves the role that infection plays in the development 
and duration of acute exacerbations of the disease.  We now know that typical 
airway bacteria are associated with exacerbations.  However, it is still under 
considerable debate as to how this association may be manifesting changes in 
COPD patients.  It is of importance to understand the different nature of 
bacteriology in the stable state, at exacerbation, and during exacerbation recovery, 
as this shall enhance our knowledge of the changes occurring in individual patients, 
and provide insights as to how they may be best treated. 
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1.5.  Aims and objectives 
 
The overall aim of this thesis is to investigate the role of bacterial infection in the 
natural history of chronic obstructive pulmonary disease.  This will be assessed in a 
number of different methods: 
 
 Initial comparison of conventional microbiological culture versus a real-time 
multiplex PCR methodology in order to determine which method is most 
suitable to detect presence of typical airway bacteria (Chapter 3) 
 
 Prevalence and load of typical airway bacterial species suspected of 
involvement in acute exacerbations of COPD will be measured, at various 
disease states, in patients from the London COPD Cohort, using the 
appropriately determined method (Chapter 4) 
 
 Prevalence and load of atypical airway bacterial species will be examined 
using a real-time multiplex PCR approach, at stable and exacerbation state 
(Chapter 8) 
 
 
 Overall load of the airway microbiome of London COPD Cohort patients will 
be assessed at different states of COPD using a modified version of a 
previously-validated 16S real-time PCR method (Chapter 6, 7) 
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 Determine whether changes occur in airway bacterial prevalence and load in 
the recovery period following an exacerbation (Chapter 6) 
 
 Examine whether presence of airway bacteria during stable COPD is related 
to clinical parameters such as lung function (Chapter 5) 
 
 Assess relationship between airway bacterial load with inhaled 
corticosteroid dosage in order to follow up on previous literature suggesting 
an association between ICS use and pneumonia (Chapter 5)  
 
 The rate of presence of atypical airway bacteria will be assessed in London 
COPD Cohort patients at both the stable and exacerbation phases (Chapter 
7) 
 
 Is presence of airway bacteria associated with systemic inflammation in 
COPD patients? (Chapter 4, 5, 6, and 7) 
 
This will be the first study in which the relationship between typical airway bacteria, 
atypical airway bacteria and the total lung microbiome is characterised within the 
same group of patients.  This data collection allows for a significant amount of 
follow-up analyses: 
 
 Is inflammation driven by any bacterial species in particular? (Chapter 4) 
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 Does the airway microbiome persist during and after antibiotic therapy 
following an acute exacerbation of COPD? (Chapter 6) 
 
 To what extent does typical airway bacterial prevalence and load change 
between exacerbation presentation and the recovery period? (Chapter 6) 
 
 Does persistence of typical bacteria during exacerbation recovery increase 
the risk of recurrent exacerbations? (Chapter 6) 
 
 Is the overall load of the microbiome affected by presence or absence of 
typical airway bacteria? (Chapter 6, 7) 
 
 Does airway microbiome load correlate to typical airway bacterial load? 
(Chapter 6) 
 
Ultimately, the answers to these questions will provide significant contributions to 
our understanding of the role of typical and atypical airway bacterial infection in 
exacerbations, and will also help us to understand the changes that occur to the 
commensal airway microbiome in the face of such an insult. 
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CHAPTER 2. Materials and Methods 
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2.1 London COPD cohort – funding and ethics 
 
The London COPD cohort is a rolling cohort of approximately 200 patients enrolled 
as part of a long-term study at the Centre for Respiratory Medicine, Division of 
Medicine, University College London.  This is an observational study exploring the 
relationship between patient phenotypes and exacerbations in COPD. 
 
The London COPD cohort is funded by the Medical Research Council, United 
Kingdom (Ref. G0800570).  
 
Ethical approval was granted by the Royal Free London National Health Service 
Foundation Trust (Ref. 09/H0720/8), and informed written consent was obtained 
from the patients, allowing sputum and blood samples to be collected and 
spirometry readings to be taken.  Approval was also given to allow daily diary card 
data to be obtained from patients (explained further in section 2.3.2).   
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2.2 Recruitment 
 
Patient recruitment was performed either through referral (e.g. by General 
Practitioner) or when a patient was seen by a London COPD cohort clinician, 
whereby the Cohort Study was explained to the subject, who was then able to opt 
in or out of the study (Seemungal et al. 1998).  Patients were allowed to leave the 
study at any point.  To ensure confidentiality, each subject was assigned with a 
unique study number.  Patients were included if the forced expiratory volume in 
one second (FEV1) was ≤80% predicted and FEV1/forced vital capacity (FVC) ratio 
was <0.7, in keeping with GOLD stages II-IV (Rabe et al. 2007).  A history of chronic 
symptoms (dyspnoea, sputum production, wheeze and cough) was taken, as well as 
smoking history (number of pack-years smoked, current smoking status). Patients 
with a history of any other significant respiratory diseases were excluded, as were 
those unable to complete daily diary cards. 
 
At recruitment, the following patient characteristics were collected and recorded by 
the attending clinician (a clinician of the London COPD Cohort): age, gender, height, 
smoking status, pack-year history, maintenance therapy details, and spirometry 
details (FEV1, FVC).  Spirometry measurements were obtained using a volumetric 
storage spirometer (Vitalograph 2160; Maids Moreton, Buckingham, UK). All 
recruited patients had an FEV1 <80%, predicted from age, gender and height, and 
an FEV1/FVC ratio <0.7.  Patients with significant non-COPD respiratory disease 
were excluded. 
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2.3 Subjects 
2.3.1 Patient visits 
Patients visited the clinic as outpatients in one of a number of different states.  
They were seen either at stable state, exacerbation state, or during recovery time 
points post-exacerbation (days 3, 7, 14 and 35 post-exacerbation).  An exacerbation 
was defined as new or increased respiratory symptoms for two or more consecutive 
days, with at least one major symptom (dyspnoea, sputum purulence and sputum 
volume), and another major or a minor symptom (wheeze, cold, sore throat and 
cough), the first day of which was defined as the day of onset of the exacerbation. 
Stable state was defined as no symptom-defined exacerbations for the preceding 4 
weeks and the subsequent 2 weeks post-clinic visit. At each visit, spirometry data 
was recorded, as well as any changes in maintenance therapy.  Diary card data was 
also recorded by the patients on a daily basis (see section 2.3.2 and appendix).  
Patients were also given access to a 24-hour hotline with direct access to a 
Respiratory physician, to discuss any concerns they may have had with their illness.  
2.3.2 Community-based data acquisition with daily diary cards 
Daily diary cards recorded a number of different parameters. Peak expiratory flow 
rate, which quantifies the patient’s maximal expiratory flow (in litres/minute) was 
self-measured using a volumetric storage spirometer.  The presence of or increase 
of minor/major respiratory symptoms compared with the stable state was noted.  
This allowed for the identification of exacerbations which were not reported to the 
COPD clinic – known as ‘unreported exacerbations’.  
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2.4 Sputum sampling 
 
Patients produced sputum either spontaneously, or through sputum induction.  
Sputum induction was administered by either the Respiratory physician or 
Respiratory nurse.  Nebulisation was carried out with 3% saline, using a protocol 
modified from the procedure described by Pin and colleagues (Pin et al. 1992).  This 
modified protocol has been previously described by our group (Bhowmik et al. 
1998).  Nebulisation was performed using the DeVilbiss UltraNeb2000 ultrasonic 
nebuliser (DeVilbiss healthcare, Tipton, UK).  This nebuliser produces an aerosol 
output of 2ml/minute, with a mean particle size of between 0.5-5µm in diameter.  
In brief, the process involved seven minutes of nebulisation, after which oxygen 
saturation and spirometric tests were performed, prior to sputum expectoration.  
As long as the FEV1 had not fallen by more than 20%, nebulisation continued for an 
additional seven minutes, after which further expectoration occurred. 
2.4.1 Sputum processing 
 
Sputum was processed after being obtained from the patient, and was performed 
by either the Respiratory physician or the laboratory technician (Ray Sapsford).   
 
Initially the sputum sample was weighed and diluted ten-fold with phosphate-
buffered saline (PBS) (Sigma; P-4417) e.g. if the sputum sample weighed 0.5g, it 
would be diluted in 4.5ml PBS.  If the physician required, any excess sputum was 
sent to the clinical microbiology department for microbiological culture analysis.  
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Sterile glass beads (2.5-3.5mm; 33212 4G, VWR) were then added to the sputum-
PBS suspension, and the mixture was homogenised by being vortexed (Whirlimixer, 
Fisons, Ipswich, UK) for 15 seconds, followed by shaking on an IKA VIBRAX tube 
shaker (IKA Werke GmbH & Co.KG, Germany).  The homogenised sample was then 
aliquoted as 500µl volumes into microcentrifuge tubes, and kept in long-term 
storage at -80oC.  This sample was then able to be processed for DNA extraction at a 
later date. 
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2.5 DNA extraction from sputum samples 
 
The homogenised sputum sample was retrieved from the -80oC freezer and thawed 
at room temperature for 20-25 minutes. Once thawing was completed, the samples 
underwent heat-killing at 90oC in a heat block (Dri-block, Techne, Staffordshire, UK) 
for 30 minutes.  The 500µl sample was then transferred to a fresh UV-sterilised 
1.5ml microcentrifuge tube.  Samples were spun in a microfuge (Eppendorf, 5415C) 
at 13000g for 10 minutes.  Supernatant was carefully decanted and the pellet was 
resuspended in 1ml of PBS (at a 1x working concentration), in a washing step.  
 
This suspension then underwent vortexing at maximum speed for 10 seconds to 
allow the pellet to mix with the PBS.  Samples were spun in a microfuge at 13000g 
for 10 minutes.  The supernatant was carefully decanted and the wash step 
repeated.  Following removal of the supernatant, the washed pellet was 
resuspended in 200µl of PCR-grade UV-sterilised water (Sigma-W4502).  The sample 
underwent vortexing at maximum speed for 10 seconds to allow thorough mixing 
to occur.  A volume of 200µl of 10% Chelex 100 (Sigma C-7901) was added to each 
sample – note that this required use of a 1000µl pipette tip as 200µl tips are not 
wide enough to easily take up 10% Chelex 100. 
 
The sample was then thoroughly vortexed for 20 seconds at maximum speed to 
ensure that the Chelex adequately mixed in with the sample.  It was then 
transferred to a heat block pre-heated at 56oC, where it was incubated for 20 
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minutes – this allowed Chelex to bind metal cofactors such as Mg2+ ions whilst 
limiting the activity of nucleases.   
 
Following incubation, the sample was vortexed for 10 seconds at maximum speed 
and then heated at 95oC for 5 minutes, in order to ensure denaturation of 
nucleases.  The sample was then cooled on (wet) ice prior to centrifugation at 
16000g for 10 minutes.  The supernatant, containing the extracted DNA, was 
transferred to a fresh UV-sterilised 1.5ml microcentrifuge tube and stored at 4oC. 
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2.6 PCR for detection and quantification of bacteria 
 
In total, 3 different PCR protocols were utilised:  (i) a multiplex PCR for the 
detection and quantification of the typical airway bacteria H. influenzae, S. 
pneumoniae and M. catarrhalis (Abdeldaim et al. 2008; Greiner et al. 2003; Garcha 
et al. 2012); (ii) a multiplex PCR for the detection and quantification of the atypical 
airway bacteria C. pneumoniae, L. pneumophila and M. pneumoniae (Ling & 
McHugh 2013); (iii) a PCR targeting a highly conserved region of the gene encoding 
16S ribosomal RNA, for the detection and quantification of all bacterial DNA (Erb-
Downward et al. 2011).   
 
Each PCR protocol employed hydrolysis probes (TaqMan probes; Tib MolBiol) in 
order to quantify the amount of bacterial DNA present in a sample (Table 2.1, Table 
2.7, Table 2.8).  As part of the current study, it was desired that the amount of 
bacterial DNA measured for each species be converted into the units of colony 
forming units (cfu)/ml, in order to more appropriately relate it to previous 
literature.  This was performed for the atypical and typical airway bacterial PCRs 
(with the exception of C. pneumoniae, for which copies/ml would be reported, due 
to fastidious growth conditions).   
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  Sequence (written 5' - 3') 
Typical primers   
Spn-F AgTCgTTCCAAggTAACAAgTCT 
Spn-R ACCAACTCgACCACCTCTTT 
    
Hin-F CCgggTgCggTAgAATTTAATAA 
Hin-R CTgATTTTTCAgTgCTgTCTTTgC 
    
Mor-F gTgAgTgCCgCTTTTACAACC 
Mor-R TgTATCgCCTgCCAAgACAA 
    
SPUD-F AACTTggCTTTAATggACCTCCA 
SPUD-R ACATTCATCCTTACATggCACCA 
    
Typical probes   
Spn-TM ROX-TACATgTAggAAACTATTTTCCTCACAAA--BHQ2 
Hin-TM 6FAM-ACAgCCACAACggTAAAgTgTTCTACg--DB 
Mor-TM 6JOE-TgCTTTTgCAgCTgTTAgCCAgCCTAA--BHQ1 
SPUD-P Cy5-TgCACAAgCTATggAACACCACgT--BBQ 
 
Table 2.1.  List of primers and probes used for typical airway bacterial PCRs. Typical 
primers/probes purchased from TIB MOLBIOL.   
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For the 16S gene PCR, the reported unit was copies/ml, as different bacterial 
species have varying copies of the 16S gene.  In each case, formation of relevant 
standard curves using positive controls was required. 
2.6.1 Correlation of colony-forming units with DNA concentration 
 
For the typical airway bacteria, as well as L. pneumophila and M. pneumoniae, ATCC 
strains of these species were subcultured onto relevant media and incubated to 
obtain pure plates. 
 
A selection of 10 colonies were picked up with a sterile plastic loop and inoculated 
into microcentrifuge tubes containing 600µl of PCR-grade H2O. Of this suspension, 
500µl was to be used to create a DNA extract.  This DNA extract was established 
using the same method as outlined in section 2.5.  The DNA concentration was then 
determined using a Nanodrop spectrophotometer (Thermo Scientific, Delaware, 
USA). The remaining 100µl of the suspension underwent serial dilution, as 
described in section 2.6.1.1. 
2.6.1.1 Quantification of colony forming units 
 
For each species, ten-fold serial dilutions were created from neat down to 10-8.  
Each of the serial dilutions were then plated as 20µl spots and incubated at 35oC 
with 5% CO2.  After 48 hours of incubation, bacterial colony counting was 
performed, using the Miles & Misra method (Miles et al. 1938). 
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2.6.2 Standard curve preparation to quantify PCR amplimers 
 
For the typical airway bacteria, as well as L. pneumophila and M. pneumoniae, 
standard curves for the quantification of PCR amplimers were prepared using the 
serial dilutions. These dilutions for each species underwent DNA extraction (see 
section 2.5), and 5µL of DNA extract underwent PCR amplification.  For C. 
pneumoniae, due to difficulty in performing routine microbiological culture, copies 
of the genome were purchased and used as the basis for the curve, following serial 
dilution.  
 
For the 16S PCR, a single species was used as the template for the standard curve 
(H. influenzae).  Extracted H. influenzae DNA was serially diluted down to 10-8 (in 
order to reduce genomic DNA content to insignificant amounts) and this 10-8 
dilution underwent conventional PCR in order to amplify the 16S target gene.  
Mastermix details are shown in Table 2.2, with 5µl of extracted DNA added to this 
mastermix.  Primer details for the 16S gene are located in Table 2.8.  Five 
microlitres of diluted H. influenzae was used as template DNA.  The following PCR 
conditions were utilised: 50oC for 2 minutes, 95oC for 10 minutes, 45 x (95oC for 15 
seconds, 60oC for 60 seconds).    
 
Positive controls were created by spiking negative sputum samples with ATCC 
strains of bacterial species, which underwent DNA extraction as described in 
Section 2.5.  
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Reagents   
 
Volume (µl) 
 
  
  Platinum qPCR supermix   
 
12.5 
 
  
  16S forward primer (10µM)   
 
0.5 
 
  
  16S reverse primer (10µM)   
 
0.5 
 
  
  H2O   
 
6.5 
    Table 2.2.  Mastermix for conventional 16S PCR amplification.  Platinum qPCR supermix 
obtained from Invitrogen (Cat. No. 11730-025). H2O obtained from Sigma (W4502) 
 
Following amplification, the PCR product underwent 1.5% agarose gel 
electrophoresis in 1x TBE buffer, to confirm presence of a band of the size expected 
from the 16S amplicon.  PCR purification (QIAquick PCR purification kit, Qiagen) was 
performed to clean up the PCR product for downstream real-time PCR analysis: 5x 
volume of buffer PB was added to 1x volume of PCR product.  The sample was then 
applied to a QIAquick spin column and centrifuged at 17900g for 60 seconds – flow 
through was discarded.  The DNA was then washed by addition of 0.75ml buffer PE 
and centrifugation at 17900g for 60 seconds.  This step was repeated to ensure 
removal of residual ethanol.  The QIAquick spin column was then placed into a fresh 
1.5ml microcentrifuge tube. Elution of DNA was carried out by adding 30µl of buffer 
EB to the QIAquick membrane in the column, leaving to stand for 60 seconds, and 
then centrifuging at 17900g for 60 seconds.  
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2.7 Quantitative PCR for typical airway bacteria  
 
Quantitative PCR (qPCR) was performed on S. pneumoniae, H. influenzae and M. 
catarrhalis using a multiplex PCR developed at the Centre for Clinical Microbiology, 
University College London (Garcha et al. 2012).  This was performed on either a 
Rotor-gene 3000 or Rotor-gene 6000 real-time PCR (Corbett Research UK, 
Cambridgeshire, UK).   
 
The gene targets for the three bacterial species are outlined in Table 2.3.  The 
targets for M. catarrhalis (Greiner et al. 2003) and S. pneumoniae (Abdeldaim et al. 
2008), had previously been validated as appropriate targets for the relevant 
species.  The H. influenzae gene target (Hel) was validated in-house at the UCL 
Centre for Clinical Microbiology.  This validation was performed by Dr Clare Ling and 
Julianne Lockwood.  
Species 
  
Gene target 
  
Reference 
       
       
H. influenzae 
  
Hel gene (encodes P4 
lipoprotein) 
  
In-house 
 
  
  
 
 
 
M. catarrhalis 
  
CopB (encodes outer 
membrane protein) 
  
Greiner et al (2003) 
 
     
 
S. pneumoniae 
  
spn9802 (gene fragment) 
  
Abdeldaim et al (2008) 
 
  
  
 
  Table 2.3.   Target genes for typical airway bacteria PCR.  
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An internal amplification control (IAC) was utilised in this PCR in order to detect any 
PCR inhibition, incorporated in the typical airway PCR mastermix (Table 2.4).  The 
IAC used was known as SPUD - this targeted the PhyB gene from the potato species 
Solanum tuberosum, as this had been previously validated for use as an IAC (Nolan 
et al. 2006). Primer/probe details for SPUD are described in Table 2.1.   
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Reagents     Volume (μl) 
 
  
  
Platinum qPCR Supermix   
 
12.5 
 
  
  
MgCl2 (50mM)   
 
1.5 
 
  
  
Forward primers for bacterial DNA (50μM)   
 
0.075 
 
  
  
Reverse primers for bacterial DNA (50μM)   
 
0.125 
 
  
  
 IAC forward primer (50μM)   
 
0.125 
 
  
  
IAC reverse primer (50μM)   
 
0.125 
 
  
  
 Probes for bacterial DNA (50μM)   
 
0.125 
 
  
  
IAC probe (50μM)   
 
0.1 
 
  
  
IAC   
 
1 
 
  
  
H2O   
 
3.675 
 
Table 2.4 Reagents used to make up mastermix for multiplex typical airway bacteria qPCR.  
This represents the volume required per PCR reaction. IAC = internal amplification control. 
 
As the IAC was placed directly into the PCR mastermix, each PCR tube contained 
equal quantities of this gene.  Therefore any significant fluctuation in detected 
concentration following the PCR would be due to inhibition, and could be corrected 
for.  
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2.7.1 Typical airway bacteria PCR protocol 
 
The mastermix illustrated in Table 2.4 formed the basis of each typical airway 
bacterial PCR reaction.  Twenty microlitres of mastermix was added to each tube.  
Samples were added to tubes in duplicate, at a volume of 5μl per tube, creating a 
total reaction volume of 25µl.  
 
As the standard curves for each species had already been created (as described in 
section 2.6), a single standard from this curve was required for use in each run, 
acting as a positive control, ensuring that the PCR reaction ran successfully.  It also 
allowed load quantification to be determined for any positive samples.  Cycling 
conditions for the typical airway bacterial PCR were as follows: 95oC for 3 minutes; 
45 cycles of (95oC for 10 seconds, 60oC for 45 seconds).  The primer and probe 
sequences are described in Table 2.1. 
 
Standard curves were then developed by running PCRs with dilutions of the 
individual species (Figure 2.1). 
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A 
 
B 
 
Figure 2.1. Standard curve generation for absolute quantification of bacterial load.  (A) Serial 
dilutions of known quantities of DNA ran on PCR. In the example in this figure, the dilutions of H. 
influenzae are illustrated. The concentration ranged from 156400 pg/µl, down to 0.5 pg/µl (the lowest 
concentration to show positivity was 1 pg/µl)  (B) Standard curve generated, relating DNA 
concentration to Ct value. 
  
   Chapter 2 - Methods 
87 
 
2.8 Quantitative PCR for atypical airway bacteria  
 
A quantitative multiplex PCR was established to detect the atypical airway bacteria 
C. pneumoniae, L. pneumophila and M. pneumoniae.  This PCR was developed at 
the Centre for Clinical Microbiology, University College London (Ling & McHugh 
2013).  This was performed on a Rotor-gene 6000 real-time PCR (Corbett Research 
UK, Cambridgeshire, UK).  The target genes are listed in Table 2.5, with primer and 
probe details described in Table 2.7. 
 
Species   
 
Gene target 
       
 
  
  C. pneumoniae   
 
RNA polymerase β-chain gene 
 
  
  L. pneumophila   
 
mip gene 
 
  
  M. pneumoniae   
 
P1 adhesin protein gene 
 
  
  Table 2.5. Target genes for typical airway bacteria PCR. 
 
Instead of using an IAC, the atypical PCR employed two mastermixes in order to 
detect and correct for any inhibition (Table 2.6).  This second mastermix contained 
1µl of a known amount of L. pneumophila DNA (5ng/µl).  This was substituted in for 
1µl of DNA extract.  For each DNA extract sample, both mastermixes were utilised.  
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Any concentration decrease seen in the cycle threshold value of L. pneumophila in 
the PCR results of the second mastermix would therefore be an indicator of 
inhibition.  Cycle conditions were as follows: 95oC for 3 minutes, 40 x (95oC for 12 
seconds, 60oC for 45 seconds). 
 
 
Reagent 
  
Spiked MM (1X) 
  
Unspiked MM (1X) 
       
Platinum Supermix 
  
12.5 
  
12.5 
       
MgCl2 (50mM) 
  
1.5 
  
1.5 
       
Forward primers 
(10µM)   
0.75 
  
0.75 
       
Reverse primers 
(35µM)   
0.357 
  
0.357 
       
Probe (10μM) 
  
0.625 
  
0.625 
       
Water 
  
0.803 
  
0.803 
       
Legionella DNA (5ng/μl) 
  
1 
  
N/A 
 
Table 2.6. Reagents used to make up mastermix for multiplex atypical airway bacteria qPCR.  
This represents the volume required per PCR reaction. MM = Mastermix 
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2.8.1 Atypical airway bacteria PCR protocol 
 
The mastermixes described in Table 2.6 were used as the basis for the PCR.  Each 
DNA extract sample was run in duplicate with the unspiked mastermix, and singly 
with the spiked mastermix. Five µl of sample was added to each unspiked 
mastermix, whilst 4µl of sample was added to each spiked mastermix.  Therefore 
each reaction had a total volume of 25µl.  Primer and probe sequence details for 
the atypical airway bacteria PCR are listed in Table 2.7. 
 
  Sequence (written 5' - 3') 
Atypical primers   
Lp-F AAAGGCATGCAAGACGCTAT 
Lp-R GTACGYTTTGCCATCAAATCTT 
Mp-F GGTCAACACATCAACCTTTTGGT 
Mp-R TGTGATTGTGCTCAGTGTTACCT 
Cp-F CATGGTGTCATTCGCCAAGT 
Cp-R CGTGTCGTCCAGCCATTTTA 
Atypical probes   
Lp-probe ROX-TGTTAAGAACGTCTTTCATTTGCTGTTCGG-BHQ2 
Mp-probe YAK-ACCCAGCCTTCAAGGCCTGTTTGTTCTTGT-DB 
Cp-probe 6FAM-TCTACGTTGCCTCTAAGAGAAAACTTCAAGTTGGA-DB 
 
Table 2.7. List of primers and probes used for atypical airway bacterial PCR. Primers/probes 
purchased from TIB MOLBIOL.   
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2.9 Quantitative PCR for 16S ribosomal DNA  
 
Quantitative PCR was performed, targeting a highly conserved region of the gene 
encoding 16S ribosomal RNA.  This region is ubiquitous amongst bacterial species, 
and so allowed for total bacterial load in a sample to be determined.  The protocol 
employed was a modified version of a previously-described procedure (Erb-
Downward et al. 2011).  The modification involved incorporation of an internal 
amplification control (SPUD). Optimisation for this modified protocol was 
performed by myself and Laura Wright (Centre for Clinical Microbiology, University 
College London). 
 
2.9.1 16S quantitative PCR optimisation 
 
The primers and probes utilised in the PCR are described in Table 2.8.  
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  Sequence (written 5' - 3') 
    
 primers   
    
16S-F TCCTACGGGAGGCAGCAGT 
16S-R GGACTACCAGGGTATCTAATCTT 
    
 probe   
    
16S-probe 6FAM-CGTATTACCGCGGCTGCTGGCAC-TAM 
    
  
Table 2.8. List of primers and probes used for 16S airway bacterial PCR. Primers/probes 
purchased from TIB MOLBIOL. 
 
The initial step towards optimisation involved confirming that the primers would be 
able to detect a wide range of bacterial species (Table 2.9). 
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Species (ATCC No.) 
  
Gram type 
  
Shape 
 
 
  
 
  Escherichia coli (700928) 
  
Gram-negative 
  
Rod 
       Streptococcus pyogenes 
(700294) 
  
Gram-negative 
  
Coccus 
       Enterococcus faecalis 
(19433) 
  
Gram-positive 
  
Rod 
       Pseudomonas aeruginosa 
(39324) 
  
Gram-negative 
  
Coccobacillus 
       Enterobacter cloacae 
(39978) 
  
Gram-negative 
  
Rod 
       Staphylococcus aureus 
(700699) 
  
Gram-positive 
  
Coccus 
       Klebsiella pneumoniae 
(31488) 
  
Gram-negative 
  
Rod 
       Haemophilus influenzae 
(10211) 
  
Gram-negative 
  
Coccobacillus 
 
Streptococcus pneumoniae 
(49619) 
  
Gram-positive 
  
Diplococci 
       
       
  
Table 2.9. Species tested to establish efficacy of 16S quantitative PCR.  A diverse range of 
bacteria were chosen for testing. 
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ATCC strains of these species were grown overnight in brain heart infusion broth in 
a shaking 37oC incubator with 5% CO2.  Ten-fold serial dilutions of these cultures 
were then performed, from neat down to 10-7.  Colony counting was then 
performed as described previously (section 2.6.1.1).  Simultaneously, 500µl of each 
broth underwent Chelex DNA extraction, as previously outlined (section 2.5). 
 
In a method identical to that previously discussed (section 2.6.1), cfu/ml was 
calculated for each species with the counts shown in Table 2.10 (N.B. H. influenzae 
and S. pneumoniae had already undergone this count, and this is recorded in Table 
3.3). 
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Species   
 
cfu/ml in neat sample 
       
 
  
  Escherichia coli   
 
1.93E+09 
 
  
  Streptococcus pyogenes   
 
5.20E+08 
 
  
  Enterococcus faecalis   
 
5.70E+08 
 
  
  Pseudomonas aeruginosa   
 
1.60E+09 
 
  
  Enterobacter cloacae   
 
3.10E+09 
 
  
  Staphylococcus aureus   
 
1.67E+09 
 
  
  Klebsiella pneumoniae   
 
3.67E+09 
 
  
  
 
  
  Table 2.10.  Colony counts for bacterial species used as test organisms to verify efficacy of 16S 
bacterial PCR 
 
2.9.1.1 DNA extraction and 16S PCR 
 
DNA extraction for the test organism was performed alongside colony counting, as 
previously described in section 2.5.  For the PCR, a mastermix was prepared (Table 
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2.11).  The cycling conditions were as follows: 50oC for 2 minutes, 95oC for 10 
minutes, 45 x (95oC for 15 seconds, 60oC for 60 seconds). 
 
Reagents 
  
Volume (µl) 
    Platinum supermix 
  
12.5 
    16S forward primer (10µM) 
  
0.5 
    16S reverse primer (10µM) 
  
0.5 
    IAC forward primer (50µM) 
  
0.125 
    IAC reverse primer (50µM) 
  
0.125 
    16S probe (10µM) 
  
0.625 
    IAC 
  
1 
    H2O 
  
4.625 
    
Table 2.11. Reagents used to make up mastermix for 16S bacterial qPCR.  This represents the 
volume required per PCR reaction. Primers and probes were obtained from TIB MOLBIOL. 
 
In order to analyse whether the 16S PCR would detect all species, test runs were 
performed examining the DNA extracts from the test organisms. The 16S rRNA gene 
was successfully detected in all species. One such test run is illustrated, with serial 
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dilutions of Pseudomonas aeruginosa, Enterococcus cloacae and Staphylococcus 
aureus (Figure 2.2).  
 
 
Figure 2.2.  Test run examining detection of the 16S rRNA gene in bacterial species.  Negative 
controls were not detected. 
 
It was noted that there was little inter-species correlation with regards to cycle 
threshold value and bacterial load.  For example, for Pseudomonas aeruginosa, 
109cfu/ml was detected at a cycle threshold value of ~16, whilst for S. aureus, 109 
cfu/ml was detected at a cycle threshold value of ~24.  This may partly be due to 
variations in the number of copies of the 16S rRNA gene in genomes of different 
species.  Overall, this indicated that cfu/ml would not be suitable as the unit of 
measurement of total airway bacterial load, as consistency amongst samples could 
not be verified.  It was therefore determined that a more appropriate measure 
would be to use the units of copies/ml.   
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In order to calculate copies/ml, a single species, H. influenzae, was used as the 
standard.  Extracted H. influenzae DNA was amplified in a conventional PCR. 
Identical cycling conditions to those used for the 16S PCR were utilised, with the 
following modifications:  no probes were used in the mastermix, with additional 
H2O added to make up the volume to 20µl, prior to the addition of 5µl H. influenzae 
DNA. Amplification of DNA was confirmed via gel electrophoresis.  
 
Having confirmed that DNA amplification was successful, the samples underwent 
PCR purification as described in section 2.6.2.  
 
2.10 Statistical analysis 
 
Data were analysed using SPSS Statistics V.21 (IBM Corp.). The Kolmogorov–
Smirnov test for normality was applied. Clinical data with normal distribution are 
described in mean (±SD). Differences between groups were analysed by 
independent-samples t test, paired-samples t test, Mann–Whitney U test, one-way 
ANOVA or Kruskal-Wallis, dependent upon the sample population being 
investigated. Relationships between continuous variables were analysed using 
Pearson's or Spearman's correlation in a univariate analysis, or by linear regression 
in a multivariate analysis. Frequency distribution was explored by χ2 analysis. A 
probability of p<0.05 was considered to be statistically significant. 
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  Comparison of Quantitative PCR and CHAPTER 3.
Routine Microbiological Culture as Techniques to 
Detect Typical Airway Bacteria Presence in COPD  
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 Introduction 3.1
 
The typical airway bacteria represent the most common causes of bacterial lower 
respiratory tract infections identified, both in the general population and in COPD.  
In order to effectively treat patients with a LRTI, rapid and accurate pathogen 
identification is imperative.  This has conventionally been performed using 
microbiological culture, with culture still in common use today.   
 
However, the advent of sensitive, specific and rapid molecular techniques indicates 
that well-designed comparisons are warranted to establish whether culture is still 
the most suitable method of bacterial identification of COPD.  These molecular 
techniques all involve nucleic acid amplification with different advantages and 
disadvantages, as summarised in Table 3.1.  
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Nucleic acid 
amplification 
technique 
 
  
Process 
  
 Advantages 
  
 Disadvantages 
  
 Reference   
 
  
 
  
 
  
   
  
  
 
  
 
  
                      
 
  
  
  
  
  
  
  
  
Conventional 
PCR 
  
 
Amplification of 
target DNA 
sequence 
  
 
Highly specific, 
Highly 
sensitive 
  
 Samples may 
contain PCR 
inhibitors, 
skewing 
results 
  
 
(Mullis et 
al. 1986) 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
                    
Real-time PCR 
(Quantitative 
PCR) 
  
 
Amplification of 
target DNA 
sequence with 
additional use of 
probe 
  
 Increased 
specificity over 
conventional 
PCR; multiple 
targets in a 
single PCR run 
  
 PCR inhibition; 
Limit to the 
number of 
probes which 
can be 
detected by 
thermocycler 
  
 
(Opel et 
al. 2010) 
  
 
  
 
  
 
  
   
 
  
 
  
 
  
   
 
  
 
  
 
  
   
 
  
 
  
 
  
   
 
  
 
  
 
  
                       
Microarray 
    
DNA is amplified 
before 
transferring to a 
surface containing 
multiple DNA 
'spot' sequences, 
targeting specific 
genes 
    
Allows rapid 
identification 
of a range of 
organisms 
    
Cross-
hybridisation 
may occur, in 
which DNA 
binds non-
specifically to 
DNA spots 
causing false-
positivity 
    
(Chen et 
al. 2006) 
  
 
  
 
  
 
  
   
 
  
 
  
 
  
   
 
  
 
  
 
  
   
 
  
 
  
 
  
   
 
  
 
  
 
  
   
 
  
 
  
 
  
   
 
  
 
  
 
  
                 
 
  
  
  
  
  
  
  
 
(Drago et 
al. 2004) Nested PCR 
  
 Amplification of 
DNA sequence 
using two primer 
sets 
  
 high specificity 
  
 Time 
consuming 
  
   
 
  
 
  
 
  
   
 
  
  
  
 
  
                     
   
  
  
  
  
 High level of 
background 
'noise' due to 
non-stringent 
temperature; 
inefficient at 
amplifying 
long-target 
sequences 
  
 
(Chang et 
al. 2012; 
Walker 
1993) 
Isothermal 
amplification 
  
 
Amplification of 
DNA at a constant 
temperature 
  
 
No 
requirement 
for 
thermocycler; 
extremely fast 
  
 
  
   
 
  
 
  
 
  
   
 
  
 
  
 
  
   
 
  
 
  
 
  
   
 
  
 
  
 
  
   
 
  
 
  
 
  
   
 
  
 
  
 
  
   
 
  
 
  
 
  
  
Table 3.1.  Description of nucleic acid amplification techniques. 
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Of the cycling amplification methods, a frequently used way to both detect and 
quantify DNA is quantitative real-time PCR (qPCR).  This technique detects and 
amplifies target DNA, such as a suspected bacterial infection.  This allows the 
quantity, or load, of pathogen to be accurately measured.  Inhibition in the PCR 
reaction can be corrected for by use of an internal amplification control (Nolan et 
al. 2006).  In the current study, expectorated sputum was used as the method of 
sampling. Alternatives for sampling method include protected specimen brush 
(PSB) sampling and broncho-alveolar lavage (BAL) fluid sampling.  However, both of 
these methods are invasive and so the ease of sampling provided by sputum was 
the overriding factor in this decision. 
 
One study has previously examined the rate of identification of bacteria using 
culture and PCR in 30 COPD patients (Curran et al. 2007).  However, that study 
identified presence of Haemophilus spp. as opposed to H. influenzae.  Given that 
non-typeable H. influenzae is frequently associated with COPD exacerbations (Sethi 
et al. 2002), it is important to specifically identify the rate of detection for this 
species by culture and PCR.  For S. pneumoniae, Curran and colleagues also targeted 
the ply gene in their PCR assay – however, this is known to also detect S. 
pseudopneumoniae and S. mitis (Abdeldaim et al. 2008).  A more specific target 
would be the spn9802 gene fragment, which is present only on S. pneumoniae and 
S. pseudopneumoniae (Abdeldaim et al. 2008). 
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3.1.1 Background of typical airway bacteria in respiratory disease 
 
 The typical airway bacteria, Haemophilus influenzae, Streptococcus pneumoniae 
and Moraxella catarrhalis are the most commonly identified bacterial community-
acquired respiratory pathogens, with each being causative agents of a number of 
LRTIs.  These species are frequent causes of pneumonia.  S. pneumoniae is the most 
frequent aetiological agent of bacterial pneumonia and such cases are referred to 
as pneumococcal pneumonia (Mufson & Stanek 1999).  Other airway pneumococcal 
infections (i.e. those infections caused by S. pneumoniae) include bronchitis and 
sinusitis.   
 
Streptococcus pneumoniae is designated in different serotypes, with each serotype 
being defined by cell surface antigens present on its capsule (Brito et al. 2003).  
There are more than 90 known serotypes of the bacterium, (Weinberger et al. 
2011), exhibiting varying degrees of pathogenicity.  The major serotypes associated 
with pneumonia are 3, 6A, 6B, 9N and 19F (Weinberger et al. 2010).   
 
Haemophilus influenzae is typed according to it capsule, with six types defined (a-f) 
(Lis & Górny 2012).  Those H. influenzae strains lacking a capsule are grouped into 
the classification of non-typeable Haemophilus influenzae (NTHi).  NTHi is 
commonly identified in exacerbations of COPD, with previous studies suggesting a 
rate of between 22-30% (Miravitlles et al. 1999; Rosell et al. 2005). 
 
 Chapter 3 – Quantitative PCR and culture: typical airway bacteria detection 
104 
 
Moraxella catarrhalis is a gram-negative organism known to cause pneumonia and 
otitis media, and it is also associated with acute exacerbations of COPD (Murphy & 
Parameswaran 2009). 
 
3.1.2 Prevention of typical airway bacterial infection 
 
For pneumococcal infection, a polyvalent vaccine (PCV-7) was introduced in the 
United States in 2000, and into the UK in 2006, as part of the routine childhood 
immunisation programmes (Tan 2012; Weil-Olivier et al. 2012).  This vaccine 
targeted seven serotypes of S. pneumoniae (serotypes 4, 6B, 9V, 14, 18C, 19F and 
23F), which were responsible for causing the majority of severe invasive 
pneumococcal disease (Hausdorff et al. 2005).  More recently, a vaccine targeting 
13 serotypes of S. pneumoniae has been developed.  The UK National Institute for 
Health and Clinical Excellence (NICE) recommends routine pneumococcal 
vaccination for COPD patients (NICE 2004, p.012). 
 
A vaccine exists for H. influenzae type b infection (Hib vaccine), and this has been 
part of the UK childhood immunisation programme since 1992 (Heath & McVernon 
2002).  However, no vaccine exists for the prevention of NTHi, which is the most 
prevalent form of H. influenzae infection in COPD. 
 
Despite considerable investigation, no vaccine currently exists for the prevention of 
M. catarrhalis infection (McMichael 2000; Riesbeck et al. 2006).     
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3.1.3 Typical airway bacteria in COPD 
 
Typical airway bacteria have been frequently isolated in patients with COPD, during 
both the stable state and at exacerbation, primarily through microbiological culture 
(Rosell et al. 2005; Papi et al. 2006).  A common pattern identified with these 
species is that, as expected, there is a higher prevalence detected at exacerbation 
compared with at the stable state.  The study by Rosell and colleagues involved a 
pooled analysis of a range of different studies, in which the samples were obtained 
PSB sampling.  In PSB, bronchoscopy is performed to obtain an uncontaminated 
lower airway sample, as previously described (Wimberley et al. 1979; Wimberley et 
al. 1982).  However, the studies did not all use the same definitions to define stable 
state and exacerbation, and this variation is identified below (Table 3.2).   
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Reference   
 
Stable COPD definition   
 
Exacerbation definition 
                 
  
  
  
  
   
 
(Monso et al. 
1995) 
  
 
40 COPD outpatients who had 
no evidence of change in 
sputum purulence/volume, or 
dyspnoea, in the previous 15 
days 
  
 29 COPD outpatients.  
Exacerbation state not 
defined 
 
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
  
  
 
  
               
  
  
  
  
   
 
(Zalacain et al. 
1999) 
  
 88 COPD outpatients with stable 
symptoms and had not taken 
antibiotics in previous 30 days or 
corticosteroids in previous 3 
months. Not admitted to 
hospital in previous 6 months 
  
 
N/A 
 
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
 
  
 
  
   
 
  
 
  
                
  
  
  
  
   
 
(Papi et al. 
2006) 
  
 
64 COPD outpatients. Stable 
state obtained 8-10 weeks post-
exacerbation 
  
 
64 hospitalised COPD 
patients. Exacerbation 
defined as increased 
dyspnoea, cough or 
sputum expectoration 
requiring medical 
attention 
 
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
 
  
 
  
                
  
  
  
  
   
 
(Soler et al. 
2007) 
  
 
N/A 
  
 50 hospitalised COPD 
patients, suffering 
marked increase in 
dyspnoea, cough and/or 
purulent sputum 
expectorate  
 
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
  
  
 
 
  
 
 
              
  
  
  
  
   
 
(Monsó et al. 
1999) 
  
 41 outpatients with chronic 
bronchitis. Patients had no 
evidence of change in sputum 
purulence/volume, or dyspnoea, 
in the previous 15 days 
  
 
N/A 
 
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
 
  
 
  
   
Table 3.2. Description of stable and exacerbation state definitions in the literature of bacterial presence in 
COPD. Each study used microbiological culture for detection. 
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Bacterial load has been less frequently explored, and this has principally involved 
the utilisation of quantitative culture techniques.  Qualitative culture involves 
assessing whether a specific organism shows growth during culture, irrespective of 
load.  Quantitative culture incorporates counting the number of colony forming 
units (CFU) growing on a plate and converting this into a value of CFU/ml (Miles et 
al. 1938).  There are a number of advantages and disadvantages associated with 
quantitative culture.  It is a relatively inexpensive method of identifying a diverse 
range of bacterial species, and also measures bacterial load.  However, there is a 
delay of at least 24-48 hours before any colony growth is identified, potentially 
delaying any therapeutic response.  Also, competition between bacterial species 
may result in some species not growing under culture conditions.  
 
ATCC strains of the three typical airway bacteria were used as standards to provide 
reference quantification markers of bacterial load, for the quantitative PCR (Table 
3.3).  This methodology has been described in section 2.6. 
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Organism   
 
ATCC Strain DNA concentration 
(pg/ul)   
 
CFU/ml 
                 
 
  
 
 
 
  
   Haemophilus 
influenzae   
 
 
10211 113500   
 
1.26E+09 
                 
 
  
 
 
 
  
   Moraxella 
catarrhalis   
 
 
25238 147200   
 
2.40E+10 
                 
   
 
     Streptococcus 
pneumoniae   
 
 
49619 18200   
 
4.60E+09 
 
 
  
 
 
 
  
    
Table 3.3. ATCC strains of the three typical airway bacteria were cultured in duplicate and DNA was 
extracted.  This table shows DNA concentration (pg/µl) of neat samples for the three typical airway 
bacteria.  This was then converted into CFU/ml measurements, using the culture data for reference. 
 
From the standard curve established as described in section 2.7, the minimum load 
at which bacteria could be accurately quantified was able to be determined (Table 
3.4). 
 
 
Species   
 
Lower detection limit (CFU/ml) 
        
 
  
  H. influenzae   
 
1.25E+04 
 
  
  M. catarrhalis   
 
2.07E+04 
 
  
  S. pneumoniae   
 
6.40E+04 
 
  
  
 
  
  Table 3.4. Quantification limit for typical bacteria.  Any samples which cross the cycle threshold below the 
lower detection limit are considered negative, as there is no positive control in the standard curve to verify their 
validity. 
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3.2 Subjects 
A total of 202 patients from the London COPD cohort participated in the study, with 
data contributed between January 2007 and November 2012.  Overall patient 
characteristics, in the stable state, are outlined in Table 3.5. 
 
 
Characteristic   
          
 
  
  
 
  
  Median age (range), years   
 
70.5 (43-92) 
 
  
  Male gender (%)   
 
64.5 
 
  
  Current smoker (%)   
 
30.8 
 
  
  Median pack-year smoking history (IQR)   
 
47 (30-70) 
 
  
  Mean FEV1 (SD), Litres    
 
1.25 (0.5) 
 
  
  FEV1 % predicted (SD)   
 
50.3 (18.9) 
 
  
  FEV1/FVC ratio (SD)   
 
0.47 (0.1) 
 
Mean FVC (SD), Litres   2.7 (0.9) 
 
  
   
Table 3.5. Baseline physiological characteristics of the 202 patients. 
 
3.2.1 Patient characteristics for culture & PCR comparison 
 
Quantitative PCR was used in this study as the method for identifying presence and 
load of the typical bacteria.  In a subset of patient samples, qPCR was compared 
against microbiological culture (culture previously performed by the Department of 
Medical Microbiology, Royal Free London Foundation Trust) to determine the 
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suitability of the methods (Table 3.6).  Routine microbiological culture and qPCR for 
H. influenzae, M. catarrhalis and S. pneumoniae were compared in 439 sputum 
samples (214 stable, 119 exacerbation and 106 recovery samples) from 143 
patients.  Recovery samples were obtained in the 5 weeks following exacerbation. 
Characteristic   
          
 
  
  
 
  
  Median age (range), years   
 
70.9 (47-92) 
 
  
  Male gender (%)   
 
62.7 
 
  
  Current smoker (%)   
 
28.2 
 
  
  Median pack-year smoking history (IQR)   
 
47 (28-72) 
 
  
  Mean FEV1 (SD), Litres    
 
1.2 (0.5) 
 
  
  FEV1 % predicted (SD)   
 
48.4 (18.9) 
 
  
  FEV1/FVC ratio (SD)   
 
0.45 (0.1) 
 
Mean FVC (SD), Litres 
 
 
 
2.6 (0.9) 
 
Table 3.6. Stable-state clinical characteristics of 143 COPD patients examined in this analysis. No 
significant differences are seen between these and the patients described in Table 3.5. 
 
Culture was performed by the Department of Medical Microbiology, Royal Free 
London Foundation Trust. Briefly, sputum was cultured onto suitable agar for 24 
hours at 37oC and 5% CO2.  Agar types used were Columbia blood agar (general 
growth media) (Ellner et al. 1966), Chocolate agar (growth of fastidious bacteria) 
(McLeod et al. 1927), MacConkey agar (growth of gram-negative bacteria) 
(Macconkey 1905), and COBA agar (growth of Streptococcus spp.) (Petts 1984).  S. 
pneumoniae was identified through optochin sensitivity testing. 
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3.3 Results 
3.3.1 Prevalence of typical airway bacteria using qPCR and routine 
microbiological culture 
 
In 439 sputum samples, typical airway bacteria were identified on 241 occasions 
using qPCR, whereas the same three bacterial species were identified on only 106 
occasions using culture (p<0.001). Of the 106 isolates detected by culture, 90 of 
these were also detected by PCR (20.5% of total; 85.1% concordance).  Additionally, 
PCR detected typical airway bacteria in 151/439 (34.4% of total) sputum samples, 
which did not show typical airway bacterial presence by culture.  A total of 16 
isolates (3.6%) were detected by routine culture but were undetected by PCR. 
 
A comparison of the two techniques was then performed examining each individual 
typical airway bacterial species, to confirm that the significant difference in the two 
methods was maintained across each of the three major typical airway bacteria.  It 
was found that H. influenzae was detected in 28.5% of samples with PCR, compared 
with 15.0% of samples using culture (p<0.001); S. pneumoniae was found in 15.3% 
of samples with PCR versus 6.8% of samples with culture (p<0.001); and M. 
catarrhalis was detected in 11.2% of samples with PCR compared with 2.3% of 
samples with culture (p<0.001) (Figure 3.1). 
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Figure 3.1. Comparison of culture and qPCR for the detection of three typical airway bacteria from 439 
sputum samples. Species: HI = Haemophilus influenzae; SP = Streptococcus pneumoniae; MC = Moraxella 
catarrhalis. 
 
3.3.2 Cases detected by PCR and culture 
 
It was identified that there were a number of cases where both PCR and culture 
detected a pathogen isolate (n=90, 20.5%), where PCR detected a pathogen which 
culture did not detect (n=151, 34.4%) and where culture detected a pathogen 
which PCR did not detect (n=16, 3.6%).   
 
3.3.3 Rate of detection of multiple bacterial species in samples by 
culture and qPCR 
 
One of the limitations cited for culture is the potential for one micro-organism to 
outcompete other species during incubation (Hibbing et al. 2010).  In order to 
combat this, various types of selective media are typically used to maximise the 
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possibility of detecting all clinically relevant pathogens.  However, limited testing 
has previously been performed against molecular techniques.   
 
In this study, qPCR was compared against culture in the same sample-set to see 
whether or not one method was more sensitive at detecting multiple typical 
bacterial species in a single sample (n=439).  It was found that qPCR identified at 
least one typical airway bacterial species in 200/439 sputum samples (45.6%). Of 
these samples, 39 were found to have multiple species (19.5%; 8.9% of total sample 
set).  On the contrary, culture detected typical airway bacteria in 95 of these 439 
sputum samples (21.6%), of which eleven samples were shown to have multiple 
species (11.6%; 2.5% of total) (Figure 3.2). 
 
   
Figure 3.2.  Detection rates of a single species or multiple species of typical airway bacteria (per sample), 
by PCR and by culture.  PCR detected significantly higher levels of typical airway bacteria compared with 
culture. *p<0.05 
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Overall, examining the dataset of 439 samples, it was established that detection of 
multiple species was significantly increased by PCR compared with culture (8.9% vs. 
2.5%; p<0.001).  When the dataset is limited to those samples which had presence 
of typical airway bacteria, the difference in detection of multiple species by PCR and 
culture misses statistical significance (19.5% vs. 11.6%; p=0.10). 
 
3.3.4 Prevalence of typical airway bacteria using a composite model 
compared with qPCR alone 
 
Given that there were 16 cases (3.6%) where culture identified a bacterial isolate 
but PCR did not, it is prudent to examine the merits of a composite test 
(combination of culture and PCR) against PCR alone. PCR detected bacteria in 
200/439 (45.6%) sputum samples, whilst the composite test detected bacteria in 
207/439 (47.2%) sputum samples, representing a negligible difference (96.6% 
concordance; p=0.64).  Of those isolates detected by culture alone, five were H. 
influenzae isolates, nine were S. pneumoniae isolates, and two were M. catarrhalis 
isolates. 
 
3.3.5 Bacterial load in patients dependent on detection outcome 
 
As considered in section 3.3.3, 200 samples were found to be positive for typical 
airway bacteria using PCR.  From these 200 samples, bacterial species were 
detected by culture in 88 samples (44%).  One possible reason for this discrepancy 
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may have been that growth on culture was dependent on bacterial load.  In order 
to test this hypothesis, a comparison was performed examining bacterial load 
(quantified by PCR) between those samples positive on culture (and positive on 
PCR) with those samples negative on culture (positive on PCR).  
 
It was found that the typical airway bacterial load was significantly different 
between the two groups: samples positive with both techniques had a mean 
(±SEM) cumulative bacterial load of 107.9(±0.1) CFU/ml, whilst samples positive on 
PCR alone had a mean cumulative bacterial load of 107.1(±0.1) CFU/ml (p<0.001).  
 
Following this finding, bacterial load of individual species was then compared in 
those samples which were positive via culture and those samples which were 
negative with culture.  All three species demonstrated higher PCR-determined 
bacterial load in culture-positive samples compared with those negative at culture.  
This difference was statistically significant for H. influenzae (107.3(±0.2) vs. 106.6(±0.2) 
CFU/ml, p=0.004), where a five-fold higher species load was identified in culture-
positive samples. A similar pattern was identified for M. catarrhalis (108.9(±0.2) vs. 
107.7(±0.3) CFU/ml; p=0.001), with a 16-fold higher species load found. However for S. 
pneumoniae, the difference was not significant (107.6(±0.2) vs. 107.2(±0.2) CFU/ml; 
p=0.159) (Figure 3.3). 
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Figure 3.3.  Bacterial load detected by qPCR segregated according to detection by culture.  Overall, typical 
airway bacterial load is significantly higher in those samples which were detected by culture and PCR, 
compared with those samples in which detection was solely by PCR.  When sub-divided by species type, 
this difference was maintained for HI and MC. Species: HI = Haemophilus influenzae; SP = Streptococcus 
pneumoniae; MC = Moraxella catarrhalis. 
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3.4 Discussion 
In this study, quantitative PCR has been compared with microbiological culture in 
order to assess the most appropriate method to identify typical airway bacteria.  
Alternative methods for assessment such as microarray analysis were not 
considered for a number of reasons – microarray analysis for pathogen 
identification typically requires an initial PCR step for amplification of DNA 
(Stoughton 2005) and so would not provide higher detection rate compared to PCR 
alone; also, both PCR and microarray analysis equipment would be required 
resulting in considerably higher initial cost.  One benefit of microarray analysis is 
that it would allow screening of more species than by PCR, but this was not a 
primary objective of the current study and so PCR was considered to be appropriate 
as the molecular method to compare against culture. 
 
Molecular techniques such as PCR offer higher sensitivity than culture.  The 
specificity of PCR is variable, dependent upon a number of factors involved in the 
setup of the PCR.  For example primers and/or probes need to be shown to be 
specific to the target organism.  There is also a possibility of PCR inhibitors being 
present in DNA extract, thereby limiting amplification when target DNA is present 
(Huggett et al. 2013).  This study has attempted to overcome such limitations – the 
multiplex typical airway bacteria PCR has previously been validated by screening 
against a range of airway bacteria and viruses (performed by Dr Clare Ling and 
Julianne Lockwood, Department of Medical Microbiology).  PCR inhibition was 
identified and corrected for by use of an IAC.  
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A previous study performed comparing PCR and culture in COPD (Curran et al. 
2007) and a larger study in LRTI samples (Kais et al. 2006) identified that PCR was 
significantly more effective at detecting typical airway bacteria.  The current 
investigation looked to validate a novel multiplex PCR assay as an appropriate 
method for bacterial identification.   
 
The study performed by Curran and colleagues differed from the current 
methodology on a number of key parameters, meaning that it was important to 
validate the current technique.  For example, the previous study had different gene 
targets to the ones used in this investigation. In particular, they targeted the ply 
(pneumolysin) gene for detection of S. pneumoniae – Kais and colleagues also 
targeted this gene.  However, this gene has since been shown to not be a suitable 
target for routine use in S. pneumoniae detection due to non-specific binding 
(Abdeldaim et al. 2010). In the current study, non-specific amplification was 
overcome by targeting species-specific genes/DNA fragments – for S. pneumoniae, 
the spn9802 gene fragment was targeted, and this is known to be a more specific 
target, and suitable for routine use in the detection of S. pneumoniae (Abdeldaim et 
al. 2008; Abdeldaim et al. 2010).  In the study by Kais and colleagues (Kais et al. 
2006), they detected typical airway bacteria in 37.7% of LRTI samples using PCR, 
compared with 23.7% using culture, constituting an increase of 59.1%.  
   
It has been demonstrated that quantitative PCR detects a higher number of typical 
airway bacteria than the current practice of routine microbiological culture.  In this 
study typical airway bacteria were detected using PCR in 54.9% of samples, whilst 
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culture detected typical airway in 24.1% of samples.  The samples examined for 
pathogens in this investigation were sputum samples.  The use of sputum samples 
is due to the fact that they are non-invasive to the patient and easily collectible. A 
limitation of sputum is that it can be contaminated with upper airway bacteria 
during expectoration.  
 
Other techniques which are often used in studies of lower airway bronchial 
colonisation (LABC) include PSB sampling and BAL fluid sampling.  Both PSB and BAL 
fluid sampling involve invasive bronchoscopy in order to obtain the relevant 
sample.  It can therefore be more difficult to obtain such samples, particularly 
during an acute exacerbation.  Furthermore in a study examining the concordance 
between sputum and PSB sampling, it was found that there was high concordance 
between these two techniques (Soler et al. 2007).  Taking all factors into account, 
sputum sampling is considered to be a suitable, non-invasive technique to assess 
LABC. 
 
The primary advantages of qPCR demonstrated in this chapter are that it gives a 
higher rate of detection than culture and also that it gives an objective measure of 
bacterial load, rather than relying on operator colony counts characteristic of 
culture quantification, which may be liable to error. 
 
Given the higher numbers of positive detections via PCR compared with culture, it 
was hypothesised that those samples which are detected by both methods have a 
higher bacterial load than those which were not detected by culture.  Through this 
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investigation, it was found that there was a significantly higher bacterial load in 
those samples detected by both methodologies, at 107.9 CFU/ml, compared with a 
load of 107.1 CFU/ml in those samples which were not detected by culture.  This 
constitutes an absolute load difference of six-fold and provides evidence which 
implicates lower bacterial load as a reason why culture may not detect all cases of 
typical airway bacteria presence.   
 
Examining species individually, it was seen that for H. influenzae and M. catarrhalis 
there was a significantly higher bacterial load in those samples detected by both 
methods, compared to those detected by qPCR alone. 
 
A small number of samples (3.6%) were found to be negative for typical airway 
bacteria using PCR but positive on culture.  This may be due to a number of 
reasons, including operator error in the PCR, point mutation in the target gene 
preventing primer binding, PCR inhibition, mis-identification of organism on culture, 
or contamination of culture plates.  A similar finding has been reported in a 
previous study examining PCR versus culture, with 4.8% of samples found to be 
negative with PCR and positive with culture (Kais et al. 2006).  Chaidir and 
colleagues compared PCR with microbiological culture for the detection of  
Mycobacterium tuberculosis, finding that 8% of culture-positive results were 
negative using PCR (Chaidir et al. 2012). In the current investigation, using a 
composite model combining PCR and culture methods provided negligible 
additional benefit compared with using PCR alone. 
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It is important to consider that while qPCR is the most appropriate method to 
establish prevalence and load of typical airway bacteria as required by this study, 
microbiological culture still has a significant role to play in bacteriology.  For 
example, culture allows antibiotic sensitivity testing to be performed in order to 
identify bacterial resistance profiles.  Furthermore, those organisms which are 
rarely seen in COPD may not be routinely screened for using qPCR, and so again, 
may be identified through culture.  Therefore, culture should by no means be 
wholly discounted from bacteriology assessment.   
 
It is also worthwhile to consider that whilst culture solely detects viable bacteria, 
qPCR detects both viable and non-viable bacteria.  This means that a subset of the 
qPCR-detected population may be non-viable bacteria (i.e. lysed bacterial cells with 
exogenous DNA).  However, there are various inbuilt defences in the airways to 
remove such exogenous DNA (Palaniyar et al. 2005).  Furthermore, it is currently 
unclear whether non-viable bacteria have any deleterious effects in their own right 
if they remain in the lungs, as endotoxins such as lipopolysaccharide may contribute 
to airway inflammation – this has previously been demonstrated in animal models 
(Okamoto et al. 2004). 
 
A major aim of this project has been to assess the technical ability of qPCR for the 
detection of lower airway bacterial species in COPD sputum samples.  To this end, it 
was compared in this study against the current standard technique of 
microbiological culture.  It was found that PCR was significantly more effective at 
detecting bacteria compared to culture.  This finding has previously been 
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demonstrated in a number of diseases (Dragsted et al. 2004; Boutaga et al. 2003; 
Kais et al. 2006; Curran et al. 2007).  However, this is the first time it has been 
demonstrated in a study solely consisting of COPD patients. 
 
Additionally, it was seen that in absolute numbers, qPCR detected multiple 
pathogens in samples more frequently than culture.  This finding that qPCR is more 
effective than culture at detecting co-infection could have important clinical 
implications, as it would allow physicians to ensure that all pathogens have been 
eliminated, or at minimum, reduced below detectable levels. 
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3.5 Conclusion 
 
Quantitative PCR is a more rapid method of detecting typical airway bacteria in 
sputum than routine microbiological culture, with greater detection rate also 
identified.  This has been shown to be the case for each bacterial species being 
investigated.  As such, subsequent analyses in this study will focus on results 
obtained by qPCR. 
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CHAPTER 4. Prevalence and load of typical airway 
bacteria in COPD patients at both stable and 
exacerbated states of disease 
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 Introduction 4.1
 
In the stable state, the majority of patients are kept on maintenance therapy, 
involving use of a bronchodilator (LABA/LAMA) and/or inhaled corticosteroids. 
Occasionally, patients may suffer AE-COPD, during which symptoms either emerge 
or increase in severity, more than seen during day-to-day variations.  Production of 
sputum varies in the COPD population.  The sub-population of chronic bronchitis 
sufferers in COPD makes up 34% of the COPD population (Snoeck-Stroband et al. 
2008), and chronic bronchitis is associated with chronic spontaneous sputum 
production for at least 3 months of the year, for two consecutive years.  Conversely, 
patients who express a mainly emphysematous phenotype tend not to 
spontaneously produce sputum during stable disease.  Many patients fall in 
between these two phenotypes and may occasionally expectorate sputum at the 
stable state (Kim & Criner 2013).  During exacerbation, the vast majority of patients 
in the London COPD cohort spontaneously expectorate sputum. Exacerbations are a 
significant clinical experience in the life of a COPD patient, contributing to lung 
function decline and being associated with increased risk of myocardial infarction 
and mortality (Donaldson et al. 2010). 
 
Presence of typical airway bacteria has been associated with exacerbations (Rosell 
et al. 2005; Monso et al. 1995).  This is because prevalence of such bacteria is 
higher in patients at exacerbation than at the stable state.  There is, however, 
presence of typical airway bacteria in a proportion of patients during stable state, 
with studies suggesting a rate of between 25% and 31% by microbiological culture 
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(Monso et al. 1995; Rosell et al. 2005; Zalacain et al. 1999).  Patients who had 
typical airway bacteria detected (by culture) during stable state demonstrated 
higher levels of airway inflammatory markers compared to those without presence: 
the sputum levels of myeloperoxidase and interleukin-8 (IL-8) are known to be 
significantly higher in infected COPD patients than in non-infected patients (Bresser 
et al. 2000).  The association of systemic inflammatory markers in stable and 
exacerbated COPD has previously been examined, and it has been shown that even 
at stable state, there are significantly higher levels of systemic inflammatory 
markers (TNF-α and IL-6) compared with healthy controls (Karadag et al. 2008).  
However, the relationship of systemic inflammation with presence or absence of 
typical airway bacteria in stable COPD has not previously been explored. 
 
It is also of importance to establish whether the bacterial load changes in patients 
between the two states. Previously, higher bacterial load has been seen at 
exacerbation, when compared to the stable state (Rosell et al. 2005; Wilkinson et 
al. 2006b) and there is precedent from other disease where it has been shown that 
higher bacterial load is related to greater disease severity, including meningococcal 
disease (Hackett et al. 2002), pneumococcal pneumonia (Rello et al. 2009; Werno et 
al. 2012) and gastric inflammation (Varbanova & Malfertheiner 2011).  However, in 
COPD, conflicting data suggests that bacterial load does not rise significantly at 
exacerbation (Sethi et al. 2007).  In those studies, culture colony counting was used 
as the method to determine bacterial load.  As demonstrated in Chapter 3, 
molecular techniques may provide a more appropriate method for the 
determination of bacterial load, and so in the current study, changes in bacterial 
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prevalence and load between the stable state and exacerbation were examined by 
qPCR.   
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 Analysis of typical airway bacteriology in sputum from 4.2
patients at either stable or exacerbation states 
 
Previous studies have addressed the issue of bacterial load in different states of 
COPD.  However, they were limited by one of a number of factors: the data 
involved unpaired analysis between stable and exacerbation states, meaning that 
there may have been a population bias and we cannot definitively say that the 
changes were caused by the change in state (Monso et al. 1995; Rosell et al. 2005); 
or intra-patient variations looked solely at those more severe exacerbations which 
result in hospitalisation (Papi et al. 2006).  The current study therefore examined 
intra-patient variations in COPD patients, irrespective of the severity of the 
exacerbation. The prevalence and load of bacteria in COPD patients using molecular 
techniques has also been relatively little-studied, both in paired and unpaired 
analyses.  As described earlier, quantitative PCR is more discriminatory than culture 
at detection of the commonly identified typical bacteria.  It also allows for absolute 
quantification of bacterial load in the two states.  Additionally, in a clinical setting, 
PCR offers a much more rapid turnaround time in identifying target organisms, 
compared to culture (Espy et al. 2006).  The current study has utilised qPCR to 
assess changes in typical airway bacterial prevalence and load in COPD patients 
between stable and exacerbation states. 
 
In the current study, patients expectorating sputum at either stable or exacerbation 
state had their typical airway bacterial levels assessed via qPCR.  In cases where 
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patients were unable to spontaneously expectorate sputum, it was induced in 
consenting patients, as described in section 2.4. 
4.2.1. Clinical assessment 
Serum C-reactive protein (CRP) quantification was performed by the Department of 
Clinical Biochemistry (Royal Free London NHS Foundation Trust) to assess systemic 
inflammation, using Modular Analytics E 170 Module (Roche, burgess Hill, UK).  
Patients recorded inhaled corticosteroid dosage and usage daily on diary cards.  
Due to variations in dosage by different medications, a beclomethasone-
equivalence dosage correction was applied, as previously described by our group 
(Hurst et al. 2006).  
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4.3. Results 
4.3.1. Sample acquisition 
In total, 544 stable state and 229 exacerbation state samples were analysed 
between January 2007 and October 2012, as part of the sample collection 
performed in the London COPD cohort. This involved a total of 202 patients, whose 
characteristics were previously described in Chapter 3 (table 3.5). 
 
4.3.2. Characteristics of patients with paired state data 
 
A sub-analysis of 61 patients, examining a pair of stable and exacerbation state 
sputum samples per patient, was performed to reduce bias which may occur when 
different patients are used to reflect changes in bacteriology in COPD states.  This 
sub-analysis involved stable state samples being obtained less than 365 days prior 
to an exacerbation, with median (IQR) number of days separating stable state and 
exacerbation being 103 (60-148) days.  Patient characteristics for these 61 patients 
are shown in Table 4.1. 
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Characteristic   
          
 
  
  
 
  
  Median age (range), years   
 
69.5 (47-83) 
 
  
  Male gender (%)   
 
62.3 
 
  
  Current smoker (%)   
 
26.2 
 
  
  Median pack-year smoking history (IQR)   
 
43.5 (27.5-57) 
 
  
  Mean FEV1 (SD), Litres    
 
1.18 (0.5) 
 
  
  FEV1 % predicted (SD)   
 
46.8 (18.5) 
 
  
  FEV1/FVC ratio (SD)   
 
0.44 (0.1) 
 
FVC (SD), Litres 
 
 
 
2.7 (1.0) 
 
  
  Table 4.1. Characteristics of 61 patients of the London COPD Cohort, who participated in a 
longitudinal study of typical airway bacterial presence in COPD. No significant differences are 
seen between these and the patients described in Table 3.5. 
  
   Chapter 4 – Typical airway bacteria in stable COPD and at exacerbation 
132 
 
4.3.3. Typical airway bacterial prevalence 
 
From a total of 544 stable state samples, 183 (33.6%) had presence of at least one 
typical airway bacterial species.  Of 229 exacerbation samples, 122 (53.3%) showed 
such presence, a significantly higher prevalence rate than at the stable state 
(p<0.001) (Figure 4.1). 
 
 
 
 
Figure 4.1. Comparison of typical airway bacteria prevalence at different phases of COPD. 
*p<0.05 
 
On an individual species basis, there were statistically significant increases in 
prevalence rate of both H. influenzae (p<0.001) and M. catarrhalis (p=0.003).  For 
H.influenzae, the prevalence increased from 20.0% at stable state, to 32.8% at 
exacerbation state.  For M. catarrhalis, the prevalence increased from 8.5% to 
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15.7% (Figure 4.2).   For S. pneumoniae, no significant increase was identified, with 
prevalence changing from 14.9% to 16.6% (p=0.55). 
 
 
Figure 4.2.  Prevalence of the three typical airway bacteria examined, at both stable and 
exacerbation states.  HI = Haemophilus influenzae, SP = Streptococcus pneumoniae, MC = 
Moraxella catarrhalis. *p<0.05 
 
4.3.4. Typical airway bacterial load 
 
Specifically examining samples with typical airway bacterial presence (n=183 at 
stable state; n=122 at exacerbation), it was identified that bacterial load was 
significantly higher at exacerbation than at the stable state (107.8(±0.1) vs 107.2(±0.1) 
CFU/ml; p=0.002), constituting a 4-fold higher typical airway bacterial load at 
exacerbation (Figure 4.3).  
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Figure 4.3. Mean (SEM) typical airway bacterial load in patients at stable and exacerbation 
states. *p<0.05 
         
 
Analysis of the data with respect to the individual typical airway bacterial species 
showed that in patients testing positive for these species, there was significantly 
higher load of H. influenzae and S. pneumoniae at exacerbation compared to the 
stable state (Figure 4.4). For H. influenzae, mean load was 106.7(±0.1) CFU/ml in 
patients positive at stable state, whilst for patients positive for the organism at 
exacerbation the mean bacterial load was 107.2(±0.2) CFU/ml (p=0.018).  In patients 
positive for S. pneumoniae during stable state, mean load was 106.9(±0.2) CFU/ml.  At 
exacerbation, mean load for S. pneumoniae-positive patients was 107.8(±0.2) CFU/ml 
(p=0.002).  No statistically significant difference was seen in the load of M. 
catarrhalis between the stable state and exacerbation.  At stable state, the mean 
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M. catarrhalis load of patients positive for the bacterium was 108.1(±0.3) CFU/ml, 
whilst at exacerbation, mean bacterial load was 108.3(±0.3) CFU/ml (p=0.60). 
 
 
    Figure 4.4.  Mean airway bacterial load of the three bacterial organisms studied, at both 
stable and exacerbation states.  HI = Haemophilus influenzae, SP = Streptococcus pneumoniae, 
MC = Moraxella catarrhalis. *p<0.05                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
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4.4. Paired sub-analysis examining changes in bacterial prevalence and 
load between stable and exacerbation states 
4.4.1. Typical airway bacteria prevalence in paired patients 
 
Cumulative prevalence of typical airway bacteria was determined in 61 patients 
with paired stable and exacerbation state data.  It was found that there was 
significantly higher cumulative prevalence of bacteria during exacerbation 
compared to stable state (68.9% vs 29.5%, p<0.001).  In terms of number of 
patients carrying at least one typical airway bacterial species, 15/61 (24.6%) of 
stable-state samples showed presence of typical bacteria, whilst 34/61 (55.7%) of 
exacerbation-state samples showed typical airway bacterial presence (p<0.001) 
(Figure 4.5). 
 
 
Figure 4.5.  Prevalence of typical airway bacteria in 61 patients at both stable and exacerbation 
states. *p<0.05 
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Thirty-nine patients (63.9%) had typical airway bacterial presence at either stable 
state or exacerbation state.  Of these, 10 patients (25.6%) showed presence at both 
sampling points, 5 patients (12.8%) showed presence only in the stable state, and 
24 patients (61.5%) showed presence only in the exacerbation state. 
 
Examining the changes in prevalence of individual typical airway bacteria between 
stable and exacerbation states in these 61 patients, it was found that there was a 
significant increase in prevalence in two of the three species under examination 
(Figure 4.6).  During the stable state, 4 patients (6.6%) showed presence of S. 
pneumoniae.  However, at exacerbation, 16 patients (26.2%) showed S. 
pneumoniae presence (p=0.003).  This group of 16 patients included two of the four 
patients who had previously shown presence at the baseline state.  Of the two 
patients who showed S. pneumoniae presence at baseline but not at exacerbation, 
one had acquired H. influenzae at exacerbation. 
 
M. catarrhalis was present in the sputum of 2 patients (3.3%) during the stable 
state.  At exacerbation, it was identified in 11 patients (18.0%) (p=0.008).  Neither 
of the 2 patients with M. catarrhalis at the stable state were positive for the 
organism at exacerbation. One of those patients had H. influenzae at exacerbation, 
and the other patient had S. pneumoniae at exacerbation. 
 
H. influenzae was seen in 12 patients (19.7%) at stable state, and in 15 patients 
(24.6%) during exacerbation, a non-significant change (p=0.51). Six of the 12 
patients (50%) positive for H. influenzae at stable state were also positive with the 
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bacterium at exacerbation.  Of the six patients who had H. influenzae solely at the 
stable state sample, two patients had S. pneumoniae at exacerbation.  The 
remaining four patients had no typical airway bacteria detected at exacerbation. 
 
 
 
Figure 4.6. Prevalence of the three typical airway bacterial species in paired stable and 
exacerbation data.  HI = Haemophilus influenzae, SP = Streptococcus pneumoniae, MC = 
Moraxella catarrhalis. *p<0.05 
 
4.4.2. Typical airway bacterial load in paired patients 
 
We were then able to compare changes in the bacterial load in these patients from 
whom we had paired stable and exacerbation state samples.  The fifteen patients 
who showed typical airway bacterial presence in the stable state had a mean 
bacterial load at that point of 107.4(±0.5) CFU/ml.  The 34 patients with presence in 
the exacerbation state had a mean bacterial load of 108.3(±0.2) CFU/ml. 
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Ten patients (16.4%) were positive for typical airway bacteria at both stable and 
exacerbation states.  Typical airway bacterial load was significantly higher in these 
patients at exacerbation state compared with stable state, 108.6(±0.2) CFU/ml versus 
107.2(±0.6) CFU/ml (p=0.02) (Figure 4.7). 
 
 
 Figure 4.7. Mean typical airway bacterial load in ten patients who had typical airway bacteria 
both at stable and exacerbation states. *p<0.05 
 
4.4.3. Effect of antibiotic therapy 
 
In the paired analysis, a comparison was performed to determine whether 
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available on 40/61 patients.  At exacerbation it was found that 15 patients had 
taken antibiotic therapy in the intervening period, of whom 9 (60%) showed 
presence of typical airway bacteria at exacerbation.  Twenty-five patients had no 
evidence of antibiotic therapy usage in the intervening period.  Of these 25 
patients, 13 (52%) showed typical airway bacterial presence at exacerbation.  This 
difference in prevalence was not statistically significant (p=0.62). 
 
Furthermore, there was no significant difference in bacterial load at exacerbation, 
regardless of antibiotic therapy (p=0.54). 
 
4.4.4. Changes in lung function between states 
 
Spirometry data measuring lung function was available in 48/61 patients at both 
stable and exacerbation states.  It was found that FEV1 decreased by a median of 
9.4% at exacerbation compared to the prior stable state. 
 
It was also seen that presence of H. influenzae at exacerbation was associated with 
a poorer outcome in lung function compared to exacerbations which did not have 
H. influenzae presence (-16.1% vs 1.7%; p=0.015).   
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4.5. Systemic inflammation at stable state and at exacerbation 
 
CRP data was available for 164 (30.1%) stable state samples and 69 (30.1%) 
exacerbation samples.  It was found that median (IQR) systemic inflammation, as 
measured by serum CRP, was significantly higher at exacerbation compared to the 
stable state: 10.0 (3-46) versus 3 (1-7) mg/L (Figure 4.8) (p<0.001). 
 
 
  
Figure 4.8.  Median (IQR) levels of C-reactive protein at stable and exacerbation states of 
COPD. The median level of CRP is significantly higher at exacerbation than at stable state. 
Outliers shown with a circle are >1.5 times outside the IQR; Outliers shown with a triangle are 
>3 times outside the IQR. *p<0.05 
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In order to determine whether systemic inflammation was related to bacterial 
prevalence and load at exacerbation, CRP levels were analysed in available samples 
(Table 4.2).  
 
Typical airway bacterial presence 
  
CRP data 
available (n) 
      
 
  
  No presence 
  
23 
    Presence of H. influenzae alone 
  
17 
    Presence of S. pneumoniae alone 
  
10 
    Presence of M. catarrhalis alone 
  
7 
     
Table 4.2.  Sputum samples obtained at exacerbation, with both CRP and PCR data available. 
 
 
Comparing those exacerbation samples which had presence of one typical airway 
bacterial species (n=34) with those which had no presence (n=23), there were 
significantly higher median (IQR) levels of CRP associated with those samples which 
had bacterial presence (17.5 (5.5-51.3) versus 3 (2-17) mg/L; p=0.009).  It was also 
found that median CRP level was found to be highest in those patients who had 
presence of H. influenzae, at 26.0 (7.5-69) mg/L.  This was significantly higher than 
in samples with no typical airway bacterial presence (p=0.004).   
 
S. pneumoniae had a median CRP level of 12.5 (1.75-68.5) mg/L whilst M. 
catarrhalis had a median level of 10 (6-42) mg/L (Figure 4.9).  Neither of these CRP 
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values differed significantly either from each other (p=0.96) or from that seen with 
H. influenzae presence (p=0.51 & p=0.46, respectively). 
 
 
Figure 4.9.  Median CRP levels of exacerbating COPD patients, separated into presence or 
absence of typical airway bacterial species. Outliers shown with a circle are >1.5 times outside 
the IQR; Outliers shown with a triangle are >3 times outside the IQR. *p<0.05. HI = 
Haemophilus influenzae, SP = Streptococcus pneumoniae, MC = Moraxella catarrhalis  
 
 
 
Twelve of the 61 patients (19.7%) with paired stable and exacerbation state 
samples also had levels of CRP recorded at both stages.  It was identified that in 
11/12 patients (91.7%), CRP was higher at exacerbation compared to stable state.  
As the CRP data was normally distributed, mean (SEM) values of CRP at stable state 
and exacerbation were compared. Levels of CRP were significantly higher at 
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exacerbation compared to the stable state: 44.4 (±15.6) versus 8.7 (±2.5) mg/L, 
p=0.037 (Figure 4.10).   
 
Additionally, it was established that in 8 of the 11 patients (72.8%) in whom CRP 
was higher at exacerbation, bacterial load was also higher at exacerbation – of the 
other three patients, two showed no signs of typical airway bacterial presence at 
either stable or exacerbation state, and one showed a fall in load from 108.1 CFU/ml 
at stable state to 107.5 CFU/ml at exacerbation state.   
 
 
 
Figure 4.10.  Changes in CRP values in 12 patients with paired stable state and exacerbation 
state data 
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4.5.1. Exacerbation symptoms and typical airway bacteria 
 
Sputum purulence was measured in 206/229 exacerbations (90.0%).  Typical airway 
bacteria were detected in 109 of these samples (52.9%) by qPCR.  Typical airway 
bacterial load was found to be significantly higher in those samples which were 
associated with an increase in sputum purulence compared with those which did 
not show an increase (108.0(±0.2) vs 107.1(±0.3) CFU/ml, p=0.01) (Figure 4.11).  No 
significant difference was identified in typical airway bacterial load between 
samples with increase in sputum volume (n=76) and those without an increase in 
sputum volume (n=33) (107.6(±0.2) vs 108.1(±0.3) CFU/ml; p=0.14). 
 
 
 
Figure 4.11.  Typical airway bacteria load split by presence or absence of purulent sputum at 
exacerbation.  Significantly higher load of typical airway bacteria was seen in purulent sputum. 
*p<0.05 
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One hundred and nine samples (52.9%) exhibited presence of typical airway 
bacteria, whilst 97 (47.1%) did not.  Of those samples with typical airway bacterial 
prevalence, 79 (72.5%) showed an increase in sputum purulence, whilst 60 (61.9%) 
samples, which did not have typical airway bacteria detected, showed an increase 
in sputum purulence.  This difference was not statistically significant (p=0.10) 
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4.6. Discussion 
 
This study investigated prevalence of typical airway bacteria, and the load of these 
species, in the airways of COPD patients, measured at both stable state and during 
an acute exacerbation, when patients suffer deterioration in symptoms.  Previous 
studies exploring this field have investigated a number of different facets of typical 
airway bacterial presence in COPD patients.  Presence of airway bacteria has 
previously been described as colonisation, when identified in stable COPD, and as 
infection when identified in acute exacerbations (Parameswaran et al. 2011; 
Pomares et al. 2011). However, the current study has eschewed such definitive 
descriptions, and any detection of typical airway bacteria is described as bacterial 
presence, with the rationale for this being that the precise role of bacteria in the 
stable and exacerbation states of COPD is not clearly defined. 
 
Bacteria are considered to be a major contributor to exacerbations in COPD 
(Beasley et al. 2012; Sethi 2010).  Rosell and colleagues compared bacterial 
prevalence and load in patients with stable and exacerbated COPD, examining a 
Spanish population (Rosell et al. 2005).  They identified significant increases in both 
bacterial prevalence and load at exacerbation.   
 
Looking specifically at the three typical airway bacteria most frequently identified in 
COPD patients, the Spanish study found a prevalence rate of 29.8% was seen at 
stable state, compared with 44.2% at exacerbation (Rosell et al. 2005).  However, 
this was determined solely by performing culture analysis, and looking at different 
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patients in each disease state. Bacterial load was described discretely rather than in 
a continuous manner i.e. samples were typed as having greater than 102, 103 or 104 
CFU/ml.  The implication for this on the data are that similar bacterial loads may be 
classed in different segments if some fall just below the threshold and others are 
slightly above the threshold.  The current study utilised the actual bacterial load to 
avoid any bias that may arise by choosing arbitrary threshold units. 
 
In the current chapter, it has been confirmed that typical airway bacteria presence 
does increase significantly between stable state and exacerbation.  Further analysis 
is important to confirm whether this increase is driving such exacerbation.   
 
An important component of the research performed in this chapter involved using 
both paired and unpaired data.  Unpaired analysis comparing differences in the 
bacterial population between stable and exacerbation states of COPD has been 
utilised in the key literature in this field (Rosell et al. 2005; Monso et al. 1995).  This 
is in large part due to the difficulties involved in conducting longitudinal studies, 
although these challenges were overcome in the current investigation.  This 
assessment found that patients were more than twice as likely to have typical 
airway bacterial presence at exacerbation as at stable state.  Furthermore, in those 
patients who had presence of typical airway bacteria at both stable state and at 
exacerbation, there was a mean increase in bacterial load of 25-fold at 
exacerbation.  This confirms that typical airway bacteria are associated with COPD 
exacerbations, and indicates that bacterial load may be a critical factor in 
contributing to exacerbations of COPD. 
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The current study also shows that presence of H. influenzae at exacerbation is 
associated with a marked decrease in FEV1 from stable state, which is not seen in 
those exacerbations without H. influenzae presence.  This is the first time that such 
a finding has been conclusively demonstrated, and confirms a trend previously 
suggested in the London COPD cohort (Wilkinson et al. 2006b). The potential 
importance of this discovery is that it may allow antibiotic therapy to particularly 
target those exacerbations confirmed to be associated with H. influenzae.  No such 
patterns were identified with the other typical airway bacterial species.  A recent 
phase 2 clinical trial has investigated the use of oral inactivated NTHi as a 
mechanism of vaccinating against strains of NTHi which may contribute to COPD 
exacerbations (Tandon et al. 2010).  The trial demonstrated that use of this oral 
vaccine reduced the rate of moderate-to-severe COPD exacerbation by 63%, and 
also reduced the mean duration of episodes from 22.7 days to 14.3 days.  It is 
therefore feasible that H. influenzae could be specifically targeted to reduce 
exacerbation frequency and length.   
 
There was no evidence to suggest that antibiotic therapy in the period between 
stable state and exacerbation impacted on bacterial prevalence or load at 
exacerbation.  However, the sample set was relatively small and so it may have 
been underpowered to detect any differences.  Daily diary cards provided records 
of patient symptoms at the time of exacerbation - previous work has indicated that 
sputum purulence and colour may be a surrogate marker for bacterial infection 
(Miravitlles et al. 2012; Stockley et al. 2000). In the current study, it has been 
demonstrated that load of typical airway bacteria is higher in patients with purulent 
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sputum than those without purulent sputum.  However, it is also important to note 
that 27.5% of samples with presence of typical airway bacteria did not show an 
increase in sputum purulence, implying that sputum purulence alone is not the 
most appropriate method for identification of typical airway bacterial presence in 
COPD.  
 
It has been shown that both bacterial prevalence and load increase significantly at 
exacerbation compared to stable state.  It was therefore necessary to establish 
whether these increases are associated with changes in the inflammatory response.  
Using C-reactive protein (CRP) as a surrogate marker for systemic inflammation, this 
response was assessed.  Systemic inflammation was shown to increase significantly 
at exacerbation compared to stable state.  Of 12 patients for whom paired stable 
and exacerbation state CRP data was available, 11 (92%) showed higher CRP levels 
than at stable state.  This is to be expected given that exacerbation represents a 
worsening of the disease, and this would typically manifest itself through an 
increased inflammatory response.  It was also demonstrated in this study that 
exacerbations associated with typical airway bacteria have significantly higher CRP 
levels compared to other exacerbations, and this has also recently been confirmed 
by a Chinese investigation (Peng et al. 2013). 
 
 
Presence of H. influenzae was found to be correlated with the highest rate of 
systemic inflammation, although both S. pneumoniae and M. catarrhalis also 
exhibited higher median CRP values compared with exacerbations which had none 
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of these typical airway bacteria detected.  The findings of the previously-described 
clinical trial with the oral inactivated H. influenzae vaccine showed a significant 
reduction in moderate-to-severe exacerbations and shorter duration of episodes 
(Tandon et al. 2010), and, coupled with the current study, this would indicate that 
H. influenzae may be driving the inflammatory process, rather than the 
inflammatory process paving the way for H. influenzae infection.  There is also 
precedent in cystic fibrosis where it was previously shown that H. influenzae was an 
important cause of inflammation, being associated with macrophage and 
neutrophil infiltration into the lungs (Armstrong et al. 1995). It has been illustrated 
in a number of studies that airway inflammation is also associated with airway 
bacterial presence in COPD.  In 2000, Hill and colleagues found that in stable 
chronic bronchitis patients, airway inflammation was strongly correlated with 
airway bacterial load (Hill et al. 2000), and it has also been shown that the presence 
of so-called ‘potentially pathogenic micro-organisms’ is associated with higher 
levels of neutrophils, with such neutrophils contributing to the inflammatory 
response (Soler et al. 1999). 
 
In conclusion, the evidence in this chapter has demonstrated that typical airway 
bacteria prevalence and load increases significantly from stable COPD to 
exacerbated COPD, and this is associated with a significant increase in CRP, a 
biomarker of systemic inflammation. At exacerbation, presence of typical airway 
bacteria was found to be associated with significantly higher levels of CRP than 
those exacerbations in which these bacteria were not detected.  Presence of H. 
influenzae at exacerbation was associated with a particularly high CRP level, 
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suggesting that therapy targeting H. influenzae may be particularly beneficial to 
reduce exacerbation severity. 
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CHAPTER 5. The relationship between typical airway 
bacterial load and clinical outcomes in stable COPD 
patients 
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5.1 Introduction 
 
As reported in Chapter 4 of the current study, 24.6% of stable-state samples 
exhibited presence of these typical airway bacteria.  It has previously been 
considered that bacteria have little effect in contributing to exacerbations 
(Hirschmann 2000).  Hirschmann discussed a number of concerns involved in the 
role of bacteria in COPD.  He highlighted that previous research used unpaired 
analysis to demonstrate an increase in bacterial presence at exacerbation 
compared with stable state, and this made interpretation uncertain.  This 
uncertainty has been answered in Chapter 4, where it was demonstrated that there 
is an increase in the prevalence rate of typical airway bacteria when examining the 
same patients at stable and exacerbation states.  Hill and colleagues have also 
shown that during stable COPD, airway inflammation is higher in those patients 
who have airway bacterial presence (Hill et al. 2000). Specifically, the authors found 
that airway bacterial load was correlated with levels of sputum myeloperoxidase (a 
surrogate marker for neutrophilia), neutrophil chemoattractants and elastase.  
 
The range of data collected in the London COPD cohort (Table 5.1) allows a number 
of clinical outcomes to be compared during the stable state.   
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Parameters 
  
 FEV1 
 
FVC 
 
Height 
 
Age 
 
Smoking status 
 
Therapy regimens 
 
qPCR bacterial loads 
 
Microbiological culture 
 
CRP 
 
Table 5.1.  Parameters available in the London COPD Cohort database. 
 
In stable COPD, patients are often on maintenance therapy to treat the chronic 
symptoms of the disease. Inhaled corticosteroid (ICS) therapy is frequently 
prescribed to patients as a maintenance therapy in COPD, and it has been shown to 
control both airway and systemic inflammation in stable COPD patients 
(Confalonieri et al. 1998; Sin et al. 2004).  The TORCH (Trial study ID: SCO30003) and 
INSPIRE (Trial study ID: NCT 00361959) randomised controlled trials have identified 
that ICS usage is related to higher rate of pneumonia development in COPD patients 
(Calverley et al. 2007; Wedzicha et al. 2008; Calverley et al. 2011).  However, no 
mechanistic rationale for such a finding has so far been postulated.  In the current 
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study, it was hypothesised that bacterial load is associated with ICS dosage in stable 
COPD patients.    
 
It is known that at exacerbation, systemic inflammation is significantly greater than 
at stable state, as measured by CRP, a biomarker of systemic inflammation (Perera 
et al. 2007) – this was confirmed in Chapter 4 of the current study.  In this chapter, 
it has been investigated whether systemic inflammation was also greater in patients 
with typical airway bacterial presence, than in those without, during the stable 
state.  The importance of this is that it will help inform whether or not typical 
airway bacteria contribute to systemic inflammation at stable state. 
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5.2 Patient characteristics 
 
A total of 90 patients of the London COPD cohort provided 164 stable state samples 
that also had levels of CRP recorded at the time of sampling (Table 5.2) – these 
patients represent a sub-population of the patients described in table 3.5. 
 
Characteristic   
          
 
  
  
 
  
  Median age (range), years   
 
70.4 (47.3-92.2) 
 
  
  Male gender (%)   
 
64.4 
 
  
  Current smoker (%)   
 
32.2 
 
  
  Median pack-year smoking history (IQR)   
 
47.0 (28.8-63.2) 
 
  
  Mean FEV1 (SD), Litres    
 
1.3 (0.5) 
 
  
  FEV1 % predicted (SD)   
 
52.6 (17.6) 
 
  
  FEV1/FVC ratio (SD)   
 
0.48 (0.1) 
 
  
  FVC (SD), Litres   
 
2.8 (0.8) 
 
  
  Table 5.2. Characteristics of 90 patients of the London COPD Cohort, who participated in a longitudinal 
study of typical airway bacterial presence in stable COPD and in whom CRP data was also available from 
the stable state sample. No significant differences are seen between these and the patients described in 
Table 3.5.   
For ICS data analysis, beclomethasone-equivalent dosage conversion was 
performed to directly compare different types of ICS.  Budesonide conversion 
involved multiplying the original dose by 0.8 to get a beclomethasone-equivalent 
dose, whilst fluticasone dose was multiplied by 2.0 for the same equivalence, as 
previously performed by our group (Hurst et al. 2006).  
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5.3 Results 
5.3.1 Systemic inflammation in stable COPD 
 
Of the 544 stable state samples examined in Chapter 4, 164 samples also had CRP 
data recorded.  Overall, median (IQR) CRP data for these stable samples was found 
to be 3 (1-7) mg/L, as reported in Chapter 4.  No clinically significant difference was 
identified in CRP data based on detection of typical airway bacteria:  The median 
CRP value for samples negative for bacteria (n=106) was 3 (1-7) mg/L, and for 
samples positive for bacteria (n=58) it was 2 (1-7.25) mg/L.  The CRP levels for 
patients with presence were subdivided according to species (Table 5.3).  
 
 
  
 
Median CRP (IQR) mg/L 
        
 
  
  SP positive only 
(n=17) 
  
 
2 (1-4) 
 
  
  HI positive only (n=20)   
 
3.5 (1-8.5) 
 
  
  MC positive only  
(n=8) 
  
 
2 (1-8) 
 
  
   Multiple (n=13)   
 
4 (2-17.5) 
   
Table 5.3.  Median CRP of stable state patients exhibiting presence of at least one typical bacterial species.  
HI = Haemophilus influenzae, SP = Streptococcus pneumoniae, MC = Moraxella catarrhalis. Multiple 
species relates to samples which contain more than one type of typical airway bacterial species. 
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5.3.2 Bacterial load and systemic inflammation 
 
Having identified that bacterial presence alone is not associated with systemic 
inflammation in the stable state, analysis was performed to assess whether or not 
the load of bacteria influenced systemic inflammation.  It was found that 
cumulative typical airway bacterial load (which represents the total typical airway 
bacterial load in a sample, following summation of each individual species load) 
positively correlated with systemic inflammation (rho=0.30; p=0.02) (Figure 5.1). 
 
 
 
Figure 5.1. Relationship of typical airway bacterial load and C-reactive protein (CRP) (rho=0.30; p=0.02). 
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5.3.3 Systemic inflammation and airflow limitation 
  
Given that there was a wide variation in CRP values for stable COPD patients, the 
sample population was assessed to determine whether there was a relationship 
between systemic inflammation and airflow limitation, measured by percentage 
predicted of expected FEV1 (FEV1% predicted).   Airflow limitation and CRP data was 
available on 158 (96.3%) samples. 
 
It was found that there was no correlation between systemic inflammation and 
airflow limitation (rho=-0.02; p=0.80).  Furthermore, there was no difference in 
systemic inflammation across different GOLD stages (p=0.870) (Figure 5.2). 
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Figure 5.2.  Correlation of CRP levels with GOLD stage. 
 
5.3.4 Airflow limitation and typical airway bacteria at stable 
state 
 
Typical airway bacterial load was previously found to be associated with systemic 
inflammation, in section 5.3.2.  This load was further assessed to determine 
whether it impacted upon lung function on stable COPD patients (n=158).  Initial 
analysis was performed to compare airflow limitation between those patients with 
typical airway bacterial presence (n=54, 34.2%) and those without (n=104, 65.8%). 
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 No significant difference was identified in FEV1% predicted in those patients with 
typical airway bacterial presence (FEV1 50.4% predicted) and those patients without 
presence (FEV1 55.4% predicted) (p=0.12).  The 54 patients with typical airway 
bacterial presence were further assessed to see whether the bacterial load was 
associated with severity of airflow limitation.  It was found that, in stable COPD 
patients exhibiting presence of typical airway bacteria, higher bacterial load 
correlated with more severe airflow limitation (r=-0.34; p=0.01) (Figure 5.3). 
 
 
 
 
Figure 5.3.  Relationship between typical airway bacterial load and airflow limitation (Rho= -0.34; 
p=0.01). 
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The patients were sub-divided according to infecting species (Figure 5.4).  There 
was no significant difference in lung function between patients infected with any 
one species of typical airway bacteria, compared to those with no typical airway 
bacterial presence.  However, it was found that lung function was significantly 
lower in patients co-infected with at least two types of typical airway bacteria (FEV1 
40.7% predicted) compared with patients without presence (FEV1 55.4% predicted) 
(p=0.02).  
 
 
 
Figure 5.4.  Comparison of percentage predicted of forced expiratory volume in 1 second (FEV1% 
predicted) dependent on typical airway bacteria presence. The ‘Multiple’ category relates to samples 
harbouring >1 type of typical airway bacterial species. *p<0.05 (versus no typical airway bacteria 
presence). 
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5.3.5 Systemic inflammation and inhaled corticosteroid 
therapy 
 
Of the 164 stable state samples with CRP data recorded, ICS data was also available 
for 152 samples (92.7%).   ICS treatment type is illustrated in Table 5.4.  
 
 
Corticosteroid   
 
% of 
samples 
        
 
  
  None   
 
19.7 
 
  
  
 
  
  Fluticasone   
 
57.9 
 
  
  
 
  
  Budesonide   
 
15.1 
 
  
  
 
  
  Beclomethasone   
 
7.2 
 
  
      
Table 5.4.  Inhaled corticosteroid usage in sampled patients from the London COPD Cohort. 
 
Fluticasone was the most commonly prescribed ICS, being utilised in 88 cases, with 
budesonide (23 cases) and beclomethasone (11 cases) also occasionally used.  
Thirty cases (19.7%) did not involve use of ICS therapy at stable state in this dataset.  
Median (IQR) beclomethasone-equivalent dose levels for the respective ICS 
therapies are shown below (Table 5.5).  Fluticasone prescription involved a 
significantly higher dose than budesonide and beclomethasone (both p<0.001). 
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Corticosteroid   
 
Median (IQR) beclomethasone-
equivalent ICS dose (µg) 
  
 
 
        
 
  
  
 
  
  Fluticasone   
 
2000 (1000-2000) 
 
  
  
 
  
  Budesonide   
 
640 (320-640) 
 
  
  
 
  
  Beclomethasone   
 
1000 (250-1000) 
 
  
   
Table 5.5. Median ICS dose prescribed for each ICS type. 
 
 
There was no significant difference in median (IQR) levels of systemic inflammation 
in those patients on maintenance ICS therapy (2 (1-7) mg/L) compared to those not 
on such therapy (3.5 (2-7) mg/L), p=0.36.  Additionally, there was no significant 
difference in systemic inflammation identified between different treatments of ICS 
(p=0.51) (Figure 5.5). 
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Figure 5.5.  CRP levels according to ICS prescription. Outliers shown with a circle are >1.5 times outside 
the IQR; Outliers shown with a triangle are >3 times outside the IQR. 
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5.4 Inhaled corticosteroid therapy during the stable state 
 
Given that there was no clinically significant difference in systemic inflammation 
identified with or without presence of typical airway bacteria, it was necessary to 
assess the anti-inflammatory regimens of these patients, to determine whether 
maintenance therapy was playing a major part in controlling such inflammation in 
patients at the stable state. 
 
 
In order to assess the correlation between ICS dose and clinical factors in stable 
COPD, the dosage for each ICS was standardised according to equivalence to 
beclomethasone.  Of the 152 samples which had ICS usage recorded, 30 (19.7%) did 
not have any ICS usage at the time of sampling. 
 
It was found that patients with stable COPD in whom typical airway bacteria were 
detected had significantly higher median (IQR) dose of ICS prescribed (Figure 5.6) 
compared with patients in whom no typical airway bacteria were detected: 2000 
(640-2000) µg versus 1000 (320-2000) µg (p=0.018). 
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Figure 5.6. ICS dosage prescribed, sub-divided according to typical airway bacterial presence. *p<0.05 
 
 
There was also a positive correlation between ICS dosage and typical airway 
bacterial load (rho=0.20; p=0.01).  However, there was no correlation between ICS 
dosage and CRP levels (rho=0.09; p=0.28) (Figure 5.7). 
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Figure 5.7.  Relationship between ICS dosage and CRP in stable COPD patients (n=152) (Rho= 0.09; 
p=0.28). 
 
In samples positive for typical airway bacteria and in whom ICS usage was 
measured (n=47), a univariate analysis found that there was a significant 
correlation between airway bacterial load and ICS dose (rho=0.38; p=0.01) (Figure 
5.8).  This relationship remains significant in a multivariate analysis which accounts 
for age, smoking status and FEV1 % predicted (p=0.022). 
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Figure 5.8.  Relationship of ICS dosage with airway bacterial load in stable COPD patients (n=47) (Rho= 
0.38; p=0.01). 
 
5.4.1 Inhaled corticosteroids and airflow limitation 
 
ICS dosage was compared amongst patients at differing COPD GOLD stages (Figure 
5.9). The performance of a Kruskal-Wallis test demonstrated that there was a 
significantly higher ICS dosage at higher GOLD stages (p=0.049). 
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Figure 5.9.  Inhaled corticosteroid dosage for stable COPD patients at different GOLD stages. 
 
There was also a correlation between ICS dosage and more severe airflow limitation 
(rho = -0.27; p=0.001), (Figure 5.10). 
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Figure 5.10.  Relationship between airflow limitation and ICS dosage (n=149) (Rho= -0.27; p=0.001) 
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5.5 Discussion 
 
There is a growing body of evidence demonstrating that presence of typical airway 
bacteria is associated with a more severe inflammatory response in stable COPD 
(Bresser et al. 2000; Hill et al. 2000; Sethi et al. 2006).   
 
The current chapter further examined this association between microbiological and 
clinical factors in stable COPD.  In particular, the link between typical airway 
bacterial prevalence and load with systemic inflammation was assessed, and the 
relationship between typical airway bacteria and prescription of ICS was also 
explored, with a consideration of how these factors may influence the airflow 
limitation identified in COPD.   
 
An initial finding of this study was that there was no difference in systemic 
inflammation between patients with typical airway bacterial presence and those 
without presence.  However, looking specifically at those patients with typical 
airway bacterial presence, there was found to be a fairly strong positive correlation 
between typical airway bacterial load and systemic inflammation (Figure 5.1), and 
although anticipated, to the author’s knowledge this is the first time that this 
relationship has been shown.  Additionally, severity of airflow limitation was not 
found to be related to CRP (Figure 5.2).   
 
It is debated whether bacterial presence is pathogenic or simply a commensal 
population (Hirschmann 2000; Murphy et al. 2000; Murphy 2006).  The evidence 
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from the current study indicates that whilst bacterial presence may not be 
pathogenic at low load, it is having a pro-inflammatory effect at higher loads.  
Indeed, at the stable state it was identified that bacterial presence is associated 
with a median CRP value of 2 mg/L, whilst bacterial infection is typically associated 
with a CRP value of >40 mg/L (Clyne & Olshaker 1999).  This suggests that either the 
typical airway bacterial presence seen is not sufficient to enact the sequelae of an 
acute bacterial infection (i.e. it is unable to initiate an exacerbation), or that ICS 
prescription is inhibiting the increase in systemic inflammation, or both.    
 
It was found that systemic inflammation, as measured by CRP, was positively 
correlated to the typical airway bacterial load in those stable COPD patients who 
had presence of at least one typical airway bacterial species (rho=0.30).   
 
Typical airway bacterial species are known to contribute to both local and systemic 
inflammation as part of their pathology during acute respiratory infections (Murphy 
2006; Yu et al. 2010) as well as during chronic disease (Hurst et al. 2005; Hill et al. 
2000).  Therefore, the positive correlation between CRP and bacterial load 
identified in the current investigation provides evidence that even during the stable 
state, this load is contributing to a pro-inflammatory response.  These findings have 
potentially profound implications for the treatment of COPD in the stable state, 
including the importance in considering the impact of prophylactic antibiotic 
therapy for patients with COPD, during the stable state, as this may reduce bacterial 
load in such patients.  Two recent trials have investigated the use of prophylactic 
therapy using macrolide antibiotics.  In 2008, Seemungal and colleagues published 
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data on the London COPD Cohort demonstrating that prophylactic treatment for 
one year with the macrolide antibiotic erythromycin led to a significant reduction in 
exacerbations compared with placebo, in a total of 109 outpatients (53 on 
macrolides, 56 on placebo) (Seemungal et al. 2008).  The authors did not find 
differences between macrolide and placebo groups in levels of airway and systemic 
inflammatory markers.  However, in that study, H. influenzae (in 27% of stable 
samples) was considered resistant to erythromycin, and this may have prevented 
bacterial load from being reduced.  A later trial by Albert and colleagues 
investigated azithromycin as the macrolide antibiotic, with a total of 1142 patients 
(570 on azithromycin, 572 on placebo)  (Albert et al. 2011). They also identified that 
macrolide treatment reduced exacerbation frequency.  They did not, however, 
examine airway or systemic inflammatory markers in these patients. It is important 
to note that the mechanism of how the antibiotic works in COPD has not yet been 
elucidated, as macrolides have both antibiotic and anti-inflammatory effects.  The 
current study suggests that prophylactic antibiotic treatment, using antibiotics to 
which typical airway bacteria are sensitive, would lower bacterial load in stable 
COPD patients and this would directly lead to lower systemic inflammatory 
markers.  
 
The current study has, for the  first time identified a correlation between airway 
bacterial load and ICS dosage in stable patients at the time of sampling (Figure 5.7), 
independent of age, smoking status and disease severity.  Previous findings from 
the TORCH and INSPIRE randomised clinical trials have suggested that ICS use is 
related to a higher frequency of pneumonia development in COPD patients 
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(Calverley et al. 2007; Calverley et al. 2011; Wedzicha et al. 2008).   In TORCH it was 
shown that in patients treated with salmeterol/fluticasone combination ICS, the 
rate of pneumoniae was 88 per 1000 treatment-years, compared with 52 per 1000 
treatment-years on placebo, an increase of 69%.  The current study shows that 
higher ICS dose is associated with higher airway bacterial load and this may play a 
part in increasing susceptibility to pneumonia in COPD. 
 
This study has considered the interlinked factors of typical airway bacteria 
presence, systemic inflammation and anti-inflammatory therapy in the disease 
outcome during stable COPD.  It has established that bacterial load is associated 
with higher levels of CRP, more severe airflow limitation, and also that co-infection 
with more than one typical airway bacteria specifically is associated with poorer 
lung function.  It has also identified that prescription of higher inhaled 
corticosteroid dosage is seen in patients with higher bacterial loads.  
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CHAPTER 6. Changes in Airway Bacteria Prevalence 
and Load at Exacerbation and during Exacerbation 
Recovery 
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6.1 Introduction 
 
It has been demonstrated that prevalence and load of typical airway bacteria 
increases from stable state to exacerbation, as highlighted in Chapter 4 of this 
thesis, building upon previous analyses in the literature using culture (Rosell et al. 
2005; Monso et al. 1995).  The changes that occur in bacterial prevalence and load 
during the recovery period following an exacerbation have not previously been 
defined in the literature, despite the use of antibiotic therapy in this period.  The 
role of antibiotic therapy during an exacerbation is controversial (Hirschmann 
2000), and this has previously been considered in chapter 5 of the current study. 
 
Historically, only small improvements were seen in trials comparing antibiotic 
versus non-antibiotic treatments for COPD exacerbations, in favour of treatment 
(Saint et al. 1995).  Saint and colleagues performed a meta-analysis on 9 trials, 
performed between 1957 and 1992, showing an overall summary effect size of 0.22 
in the antibiotic group compared to the placebo group, with 7 of the 9 trials 
analysed favouring antibiotic use.  A recent study by Llor and colleagues 
demonstrated that antibiotic therapy in mild-to-moderate exacerbations is both 
more effective at clinical cure within 9-11 days (74.1% vs 59.9%) and significantly 
lengthens time to next exacerbation (233 days vs 160 days) compared to placebo 
(Llor et al. 2012).  In addition, a retrospective study of almost 85,000 COPD patients 
investigating more severe exacerbations, resulting in hospitalisation, also 
demonstrated that patients treated with antibiotics had lower risk (1.1% vs 1.8%) of 
treatment failure (the necessity of ventilation treatment after the second hospital 
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day), lower inpatient mortality rates (1.0% vs 1.6%), and lower readmission rates 
(within 30 days of index exacerbation) for exacerbation events (7.91% vs 8.79%) 
compared to no treatment (Rothberg et al. 2010).  
 
Roede and colleagues examined the effect of corticosteroid treatment with or 
without antibiotic treatment following an exacerbation (Roede et al. 2009).  They 
found that time to next exacerbation was lengthened for those patients treated 
with antibiotics (258 days in antibiotic group versus 189 days in non-antibiotic 
group).  Each of these studies implicitly suggest that the impact of antibiotics on the 
microbial population is a positive factor in such clinical outcomes.  However, as of 
yet, no investigation of the mechanistic rationale for these changes have taken 
place.  During the stable state, it has also previously been demonstrated that 
antibiotic therapy for 5 days significantly reduces bacterial prevalence at two-weeks 
post-treatment start (Miravitlles et al. 2009). Miravitlles and colleagues found that 
moxifloxacin therapy was associated with the elimination of ‘potentially pathogenic 
microorganisms’ in 75% of patients, with placebo treatment associated with 
elimination in 30% of patients.  At the 8-week follow up, however, airway bacterial 
prevalence was similar in both groups (80% in placebo group, 75% in moxifloxacin 
group. 
 
Recurrent exacerbations are of major concern in COPD.  It has previously been 
identified that approximately 22% of patients suffer a recurrent exacerbation within 
50 days of an index exacerbation (Perera et al. 2007).  This indicates a major burden 
in terms of morbidity and mortality.  Perera and colleagues highlighted that the 
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presence of systemic inflammation, as measured by the biomarker C-reactive 
protein (CRP), is associated with such recurring events.  Serum CRP is also known to 
be related to presence of bacterial infections in COPD exacerbations (Peng et al. 
2013).   
 
COPD exacerbations are frequently treated with a course of antibiotics and 
systemic corticosteroids following diagnosis (Wenzel et al. 2012; Walters et al. 
2011), as discussed in section 1.2.1.   
 
The airways microbiome refers to the total bacterial population in the airways. This 
microbiome has been explored in recent years following the utilisation of molecular 
techniques such as restriction fragment length polymorphism, microarray analysis 
and sequencing (Hilty et al. 2010; Huang et al. 2010; Sze et al. 2012).  However, 
bacterial load has been little-studied, and in previous studies has involved very 
small numbers of subjects (median 8 subjects per sample group), leading to 
limitations in the interpretation of results (Sze et al. 2012).  The load of the airway 
microbiome at exacerbation presentation and its relationship to exacerbation 
severity is as yet unknown, and additionally, the impact of antibiotic therapy on the 
microbiome burden in the post-exacerbation recovery phase has not been 
analysed.  
 
According to the most recent GOLD COPD guidelines, antibiotics can shorten 
recovery time, and improve lung function (FEV1), as well as reducing the risk of a 
relapse and length of hospital stay (www.goldcopd.org).  A systematic review of 
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antibiotics during acute exacerbations of COPD demonstrated that antibiotic usage 
decreased in-hospital mortality by 78% (Quon et al. 2008). 
 
In order to study bacteriological changes during exacerbations, we investigated 
prevalence and load of H. influenzae, S. pneumoniae and M. catarrhalis, and load of 
the total airway bacterial population, during exacerbation recovery using qPCR. 
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6.2 Patient characteristics 
 
We collected sputum from 94 subjects in the London COPD cohort at exacerbation 
presentation (n=135), day 3 (n=41), day 7 (n=53), day 14 (n=53) and day 35 post-
exacerbation (n=38). Patient characteristics for these 94 patients is illustrated in 
Table 6.1 
 
Characteristic   
          
 
  
  
 
  
  Median age (range), years   
 
70.4 (47.4-87.5) 
 
  
  Male gender (%)   
 
60.6 
 
  
  Current smoker (%)   
 
22.3 
 
  
  Median pack-year smoking history (IQR)   
 
44.5 (27.5-63.2) 
 
  
  Mean FEV1 (SD), Litres    
 
1.14 (0.5) 
 
  
  FEV1 % predicted (SD)   
 
46.2 (17.7) 
 
  
  FEV1/FVC ratio (SD)   
 
0.44 (0.1) 
 
  
  Mean FVC (SD), Litres   
 
2.6 (0.9) 
 
  
   
Table 6.1. Baseline characteristics of 94 patients of the London COPD Cohort, who participated 
in a study of typical airway bacterial presence during acute exacerbations of COPD. No 
significant differences are seen between these and the patients described in Table 3.5.  
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6.3 Results 
6.3.1 Antibiotic treatment type and duration 
 
Of the 135 exacerbations, 126 (93%) were treated with antibiotics, prescribed at 
exacerbation presentation. Of the 9 patients not prescribed antibiotics, two (22.2%) 
had typical airway bacteria (H. influenzae, S. pneumoniae or M. catarrhalis) 
detected at exacerbation. The type of antibiotic course prescribed was based on 
clinical judgment of symptoms and patient history, and follows GOLD COPD 
guidelines (www.goldcopd.org).  Median antibiotic course length was seven days.  
Antibiotics prescribed are shown in Figure 6.1. 
 
 
Figure 6.1. Antibiotics prescribed to patients in this study (n=126).  A further 9 patients had no 
antibiotics prescribed at exacerbation visit. 
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6.3.2 Prevalence and load of typical airway bacteria during 
exacerbation recovery 
 
The prevalence of typical airway bacteria was found to be significantly greater at 
exacerbation presentation compared with the following two weeks of exacerbation 
recovery: versus Day 3 (50.4% vs 26.8%; p=0.008), day 7 (28.3%; p=0.006) and day 
14 (32.1%; p=0.02), whilst the difference in prevalence versus day 35 (39.5%) was 
not significant (p=0.21) (Figure 6.2).  When recurrent exacerbations were excluded 
from the analysis, the prevalence of typical airway bacteria was 51.5% at 
exacerbation (n=101) and 35.3% at day 35 (n=34), although this difference was still 
not significant (p=0.10)  
 
 
Figure 6.2. Bacterial prevalence at stable, exacerbation and recovery phases of COPD.  
Bacterial prevalence is highest at exacerbation presentation, declining significantly by three 
days post-presentation.  However, prevalence increases by day 35 post-presentation. 
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Typical airway bacterial load was examined using both longitudinal and cross-
sectional analyses.  In the longitudinal analysis, those patients who had a typical 
bacteria-positive exacerbation had this exacerbation sample paired with their 
samples at the respective recovery time points: load [median (IQR) Log10 CFU/ml] 
was significantly higher in patients at exacerbation visit than at day 3 (n=15): 
108.1(5.9-8.7) vs 100(0-4), p=0.001; day 7 (n=17): 108.2(6.3-8.8) vs 104.2(0-6.6), p=0.01; day 14 
(n=14): 108.0(6.3-8.7) vs 104.4(0-6.6), p=0.022; and day 35 (n=15): 107.7(5.7-9.3) vs 105.9(0-6.74), 
p=0.047 (Figure 6.3). 
 
Figure 6.3. Typical airway bacterial load changes in paired exacerbation and recovery samples.  
Each boxplot illustrates paired load analysis between the load seen at exacerbation presentation 
and the load seen at the respective timepoint (day 3, 7, 14, 35).  All episodes were positive for at 
least one typical airway bacterial species at exacerbation presentation.  
                      Chapter 6 – Airway bacteria at COPD exacerbation and during recovery 
187 
 
In the cross-sectional analysis, samples positive for at least one typical airway 
bacterial species at the respective time points were assessed.  Examining only these 
samples, bacterial load was found to be significantly higher at exacerbation 
compared to Day 3 (108.0(±0.2) vs 106.3(±0.5) CFU/ml; p<0.001), Day 7 (108.0(±0.2) vs 
107.0(±0.4); p=0.012), Day 14 (108.0(±0.2) vs 107.0(±0.3); p=0.005) and Day 35 (108.0(±0.2) vs 
106.9(±0.3); p=0.004) (Figure 6.4), echoing the findings of the longitudinal analysis. 
 
 
Figure 6.4. Cross-sectional analysis demonstrating differences in typical airway bacterial load at 
the respective recovery time points (n-value for each time point: Exacerbation (n=69), Day 3 
(n=11), day 7 (n=15), day 14 (n=17) and day 35 (n=15)). 
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6.3.3 Prevalence and load of airway microbiome during exacerbation 
recovery 
 
In a subset of the 320 sputum samples examined for typical airway bacteria, total 
load of the airway microbiome was also quantified by 16S rDNA qPCR, as described 
previously in section 2.9 (n=190). It was found that all samples had presence of a 
microbial population in the airways.   
 
A longitudinal analysis was performed to compare load at exacerbation and follow-
up time points: The microbiome burden was significantly higher at exacerbation 
presentation compared to Day 3 (109.1(±0.1) vs 108.2(0.3); p=0.02) and Day 35 (109.1(±0.3) 
vs 107.6(±0.7), p=0.02) (Figure 6.5). 
 
 
Figure 6.5. Airway microbiome load changes in paired exacerbation (black bars) and recovery 
(white bars) samples. *p<0.05 
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6.3.4 Typical airway bacterial load relationship to total microbiome 
load 
 
Total load of the airway microbiome was also quantified by 16S rDNA qPCR.  It was 
found that total microbiome load was significantly higher in samples where typical 
airway bacteria were present, compared to those samples where no typical airway 
bacteria were detected (median 109.7(1.5) vs 108.9(1.3) copies/ml, respectively; 
p<0.001), constituting a six-fold higher median microbiome population in patients 
with typical airway bacteria than in those without (Figure 6.6).  
 
Figure 6.6. Microbiome population size in presence or absence of typical airway bacteria. 
Outliers shown with a circle are >1.5 times outside the IQR *p<0.05 
 
* 
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In addition microbiome load was positively correlated to typical airway bacterial 
load in those samples which had presence of at least one typical bacterial species 
(rho=0.41; p<0.001) – for the purpose of direct comparison with microbiome load, 
the typical airway bacterial load was calculated in copies/ml (Figure 6.7). 
 
 
 
 
Figure 6.7. Association of microbiome load with typical airway bacterial load during COPD 
exacerbation and recovery (n=83). This illustrates that a rise in typical airway bacterial load is 
positively correlated to a rise in load of the overall microbiome population (rho = 0.41; p<0.001) 
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6.3.5 Systemic inflammation during exacerbation and recovery 
 
In order to establish whether changes in typical airway bacterial load were related 
to changes in systemic inflammation, total typical airway bacterial load was 
compared against levels of CRP, a marker of systemic inflammation. In total, 299 
samples had typical bacterial load and CRP data provided at exacerbation and 
recovery.  It was found that bacterial load is significantly correlated to CRP (r=0.25; 
p<0.001) (Figure 6.8).  This correlation is also seen when only those samples 
positive for typical airway bacteria and with CRP data available (n=119) are 
assessed (r=0.28; p=0.002). 
 
Figure 6.8.  Relationship between typical airway bacterial load and systemic inflammation 
(n=299).  Higher load is associated with higher inflammation (rho = 0.25; p<0.001).  This 
significance remains even with removal of outlier with CRP 360mg/l and bacterial load of 10
8.14
 
CFU/ml (rho = 0.245; p<0.001)   
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Exacerbations associated with typical airway bacteria had significantly higher 
median (IQR) serum CRP compared with exacerbations not associated with those 
bacteria (20 (7.25-52.75) mg/L vs 9.5 (3.25-22) mg/L; p=0.004) (Figure 6.9). 
 
 
 
Figure 6.9.  Difference in rate of systemic inflammation based on presence or absence of typical 
airway bacteria. Outliers shown with a circle are >1.5 times outside the IQR; Outliers shown 
with a diamond are >3 times outside the IQR. *p<0.05 
 
Each of the three typical airway bacteria were then studied in turn to determine if 
all showed a similar inflammatory response.  It was found that H. influenzae load 
was significantly related to CRP (r=0.21; p<0.001).  However neither S. pneumoniae 
(r=0.046; p=0.43) nor M. catarrhalis (r=0.097; p=0.09) showed a significant 
relationship to an inflammatory response.  
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No significant correlation was identified between load of the airway microbiome 
and systemic inflammation (r=0.021; p=0.77) (Figure 6.10). 
 
 
Figure 6.10.  Airway microbiome load is not related to systemic inflammation (n=190) (rho = 
0.021; p=0.77) 
 
 
Further analysis elucidated that systemic inflammation, as measured by CRP, is 
highest at exacerbation, before falling significantly by day 3 post exacerbation visit, 
and remaining low 35 days post-exacerbation (Table 6.2). 
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Table 6.2. Median levels of C-reactive protein at different phases of exacerbation recovery in an 
unpaired analysis (n=299). 
 
Additionally, in samples for which CRP and spirometry data was available, there was 
no association between airflow limitation and systemic inflammation at 
exacerbation presentation (r= -0.11; p=0.23). 
 
 
 
number of 
samples  
  
  
  
  
  
 CRP change from 
exacerbation   
 
Sample Type   
 
Median CRP (IQR) 
mg/L   
 
 
  
  
  
  
  
                      
123   
 
Exacerbation   
 
14 (5-31)   
 
N/A 
 
  
  
  
  
  
  40   
 
Day 3   
 
4.5 (2-9)   
 
-9.5 mg/L (p<0.001) 
 
  
  
  
  
  
  51   
 
Day 7   
 
3 (1-6)   
 
-11 mg/L (p<0.001) 
 
  
  
  
  
  
  48   
 
Day 14   
 
8 (3-17)   
 
-6 mg/L (p=0.005) 
 
  
  
  
  
  
  37   
 
Day 35   
 
3 (2-8.5)   
 
-11 mg/L (p<0.001) 
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6.3.6 Presence of typical airway bacteria during exacerbation recovery 
does not suggest increased risk of recurrent exacerbation 
 
Recurrent exacerbations - either reported to Cohort clinicians or unreported 
(recorded in diary cards) - were found to occur following 34/135 index 
exacerbations (25.2%), within 50 days of the index exacerbation.  Presence of 
typical airway bacteria was not seen to be related to the induction of a recurrent 
exacerbation at any time point, although the recurrent-exacerbation subset of 
samples may not have been sufficiently powered to identify variance at each and 
every time point.   Furthermore, there was no significant difference in mean (SEM) 
airway microbiome load in patients with recurrence and those without (108.9(±0.3) vs 
108.8(±0.2) copies/ml; p=0.73). 
 
 
6.3.7 Lung function during exacerbation recovery 
 
It was found that there was no significant difference in forced expiratory volume 
(FEV1% predicted) in patients at different stages of exacerbation recovery (p=0.33) 
(Figure 6.11). 
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Figure 6.11 .  Median FEV1%predicted does not significantly differ during exacerbation 
recovery. 
 
 
 
There was no significant difference in median (IQR) airflow limitation between 
samples with or without typical airway bacterial presence (FEV1% predicted 42.0% 
(31.5-56.5) vs 47.2% (33.2-59.3); p=0.19) (Figure 6.12). 
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Figure 6.12.  Airflow limitation measurements according to typical airway bacteria presence.  
No significant difference was identified. 
 
 
 However, in samples with typical airway bacterial presence, higher bacterial load 
did correlate with more severe airflow limitation during exacerbation and recovery 
(r = -0.22; p=0.02) (Figure 6.13).  
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Figure 6.13.  Relationship between typical airway bacterial load and airflow limitation, during 
exacerbation and recovery (n=118) (rho = -0.22; p = 0.02). 
 
 
Having found that typical airway bacterial load related to airflow limitation, the load 
of the overall microbiome was then assessed with airflow limitation.  No significant 
correlation was identified between microbiome load and airflow limitation (r=-0.12; 
p=0.11) (Figure 6.14).  
 
                      Chapter 6 – Airway bacteria at COPD exacerbation and during recovery 
199 
 
 
Figure 6.14.  Relationship between airflow limitation and load of the airway bacterial 
microbiome (n=185).  Microbiome load was not associated with airflow limitation (rho = -0.12; 
p=0.11). 
 
6.3.8 Systemic corticosteroid prescription 
 
Data on the prescription of systemic corticosteroids was available for 129 of the 
135 exacerbation presentation visits (95.6%).  In total, 105 exacerbations were 
treated with systemic corticosteroids (81.4%).  Median systemic corticosteroid 
dosage was 30mg and median course length was 7 days.  There was no difference in 
the median (IQR) serum CRP levels based on whether systemic corticosteroids were 
prescribed (13.5 (6-29) mg/L) or not prescribed (17 (6-49) mg/L) (p=0.69) (Figure 
6.15). 
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Figure 6.15.  Serum CRP levels at exacerbation presentation sub-divided based on whether 
systemic corticosteroids were prescribed.  No significant difference in CRP was identified 
between the two groups. 
 
Additionally, there was no difference in prescription rates of systemic corticosteroid 
based on presence (81.2%) or absence (81.7%) of typical airway bacteria (p=0.94).  
Bacterial load at exacerbation presentation had no bearing on systemic 
corticosteroid dosing (r=0.025; p=0.77) (Figure 6.16). 
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Figure 6.16.  Relationship between typical airway bacterial load and systemic corticosteroid 
dose prescription at exacerbation presentation (n=129).  No association between load and 
systemic corticosteroid prescription was seen (p=0.93). 
 
There was no significant difference in median (IQR) load of the airway microbiome 
at exacerbation presentation, irrespective of whether systemic corticosteroids were 
prescribed (108.8 (8.0-9.8) copies/ml) or not (109.1 (8.3-9.8) copies/ml) (p=0.46). 
 
There was found to be a significant correlation between systemic corticosteroid 
prescription and airflow limitation, with prescription associated with more severe 
limitation (p=0.03) (Figure 6.17). 
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Figure 6.17.  Relationship between airflow limitation and systemic corticosteroid dose 
prescription at exacerbation presentation (n=120).  *p<0.05 
 
  
* 
                      Chapter 6 – Airway bacteria at COPD exacerbation and during recovery 
203 
 
6.4 Discussion 
 
This investigation has shown, for the first time, that typical airway bacterial load 
falls significantly during recovery from an exacerbation over a 35 day period, 
following commencement of antibiotic therapy.  There is also a significant fall in 
typical airway bacterial prevalence for at least 14 days post-exacerbation.  
Conversely, the airway microbiome is not eradicated following antibiotic therapy, 
demonstrating that the airways remain colonised with a commensal microbiota, 
although the load is reduced.  It has also been demonstrated that systemic 
inflammation (as measured by the biomarker CRP) peaks at exacerbation before 
falling to stable state levels within 3 days of treatment.  Systemic corticosteroid 
prescription and dosage was not associated with either systemic inflammation or 
with bacterial load at exacerbation presentation, although it was associated with 
airflow limitation.  A plausible explanation for this may be that physicians use 
airflow limitation to guide dosage of systemic corticosteroids. 
6.4.1 Typical airway bacterial load falls following antibiotic therapy 
 
This study is the first to conclusively demonstrate, both in longitudinal and cross-
sectional analyses, that typical airway bacterial load falls significantly following 
exacerbation presentation.  The role of antibiotic treatment following exacerbation 
presentation may play a part in this fall, although it cannot be confirmed as the 
study was not placebo-controlled (which would have taken into account the effect 
of the immune system on load).  The study has also shown that bacterial load is 
associated with systemic inflammation.  Therefore from a clinical viewpoint, 
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antibiotic therapy, alongside systemic corticosteroids, may be an important means 
of controlling systemic inflammation in an exacerbating host. 
6.4.2 Typical airway bacteria load is related to the load of the airway 
microbiome 
 
The current study has, for the first time, compared the bacterial load of those 
bacteria frequently associated with COPD exacerbations (typical airway bacteria) 
with the load of the airway microbiome, which has in the last few years been found 
to be an inherent constituent of the human airways (Hilty et al. 2010; Huang et al. 
2010; Erb-Downward et al. 2011; Sze et al. 2012).  It has been hypothesised that 
this microbial community may contribute to disease pathogenesis and progression 
(Erb-Downward et al. 2012).  Whilst the airway microbiome has been well defined 
as a component of both healthy and COPD airways, no studies up to now have 
explored changes in load.  The current investigation is the first to examine the 
airway microbiome load in relation to typical airway bacterial load (Figure 6.7), 
demonstrating that in patients with typical airway bacterial presence, there is a 
positive correlation between airway microbiome load and typical airway bacterial 
load.  This suggests that typical airway bacteria are not simply displacing the 
commensal microbiome population, but instead are growing in addition to it.   
6.4.3 Typical airway bacteria dominate the load of the airway 
microbiome when present 
 
Microbiome load was found to be six-fold higher in samples with typical airway 
bacteria than in those without.  The implication of this data is that typical airway 
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bacteria flourish in addition to the commensal airway microbiome, rather than 
simply displacing it, and that this microbiota is dominated by typical airway 
bacteria. 
 
6.4.4 Microbiome load falls following antibiotic therapy but it is not 
eradicated 
 
 
Following presentation of an exacerbation, the microbiome load falls by eight-fold 
within three days post-therapy commencement, in a paired analysis.  From the 
findings of this study, we also know that in paired samples, there is elimination of 
typical airway bacteria in the majority of patients within three days of treatment 
following a typical bacteria-associated exacerbation.  It follows that elimination of 
typical airway bacteria contributes largely to the fall in microbiome load, 
particularly given that the microbiome load is six-fold higher when typical airway 
bacteria are present.  However, the microbiome, which is known to consist of 
species as diverse as Streptococcus, Prevotella, Pseudomonas, Moraxella, 
Haemophilus, Acinetobacter, Fusobacterium, and Neisseria in COPD patients 
(Cabrera-Rubio et al. 2012; Huang et al. 2010), is never completely eliminated.  This 
demonstrates that antibiotics do not target all species in this microbiota.  The most 
frequently utilised antibiotic in this study was amoxicillin, either alone or in 
conjunction with the β-lactamase inhibitor, clavulanic acid.   Acinetobacter and 
Pseudomonas are examples of genera of bacteria which are known to be resistant 
to the penicillin family of antibiotics (Shakibaie et al. 2012; Gad et al. 2008), and 
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they could be part of the core commensal species which remain despite antibiotic 
treatment.  
 
6.4.5 Systemic inflammation biomarkers fall following commencement 
of systemic corticosteroids 
 
Serum CRP was found to fall within three days of systemic corticosteroid therapy.  It 
has previously been demonstrated that systemic corticosteroid usage significantly 
reduces median CRP levels in the seven days following an exacerbation 
presentation (Dentener et al. 2001).  Given the previous findings in the current 
study that typical airway bacterial load also falls following exacerbation 
presentation, this decline in bacterial numbers may be another plausible 
mechanism to explain the decrease in systemic inflammation identified, and so it 
may not be solely an effect of the systemic corticosteroids. 
 
6.4.6 Typical airway bacteria presence is associated with systemic 
inflammatory biomarker levels 
 
Higher serum CRP levels were associated with presence of typical airway bacteria, 
providing evidence that serum CRP may be a useful clinical biomarker in the 
diagnosis of bacterial-associated exacerbations of COPD.  This finding has been 
supported by work performed by Peng and colleagues in a Chinese population.  
They found that exacerbations with serum CRP levels in excess of 19.6 mg/L were 
associated with presence of bacteria, which they termed ‘potentially pathogenic 
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micro-organisms’ (Peng et al. 2013).  In the current study, we have also found that 
typical airway bacterial load is related to systemic inflammation.  Typical airway 
bacteria have a number of virulence mechanisms which would cause this systemic 
inflammatory response, with presence of Moraxella spp. and Haemophilus spp. 
upregulating secretion of pro-inflammatory cytokines including IL-23 and IL-12 
(Larsen et al. 2012).  The pro-inflammatory response may be activated by detection 
of bacterial lipopolysaccharide, which stimulates an immune response 
(Moghaddam et al. 2011).  
  
6.4.7 Airway microbiome load is not associated with systemic 
inflammatory biomarker levels 
 
Given that there was a relationship between typical airway bacteria and systemic 
inflammation, the investigation then explored whether airway microbiome load 
was associated with a similar inflammatory response, using CRP.  It was found that 
there was no such relationship.  This illustrates that the typical airway bacteria 
cause a specific pathogenic response.  It was also found that higher load of typical 
airway bacteria related to more severe airflow limitation, whilst there was no 
correlation between microbiome load and airflow limitation. 
 
Taking these data together, there is evidence to suggest that during an 
exacerbation, typical airway bacterial species have pathogenic effects both locally 
in the airways and systemically via an increased inflammatory response, whilst the 
airway microbiome has little impact in terms of disease pathogenesis.  The results 
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in this chapter do not consider the changes in the airway microbiome between 
stable and exacerbation state, and that is explored in Chapter 7. 
 
At day 14 post-exacerbation presentation, median CRP levels increase to 8 mg/L, 
from just 3 mg/L at day 7.  Given that it has previously been shown that CRP levels 
fall following systemic corticosteroid usage (Dentener et al. 2001), this rebound of 
CRP may be an effect of cessation of systemic corticosteroid therapy at day 7.   
 
6.4.8 Typical airway bacterial prevalence falls following antibiotic 
therapy 
 
Typical airway bacterial prevalence was found to almost halve in COPD patients, to 
26.8%, in the three days following commencement of antibiotic therapy.  This fall in 
prevalence was maintained for at least two weeks following an exacerbation.  
However at the five-week recovery time point, the prevalence reached 39.5%.  It is 
possible that this increase in prevalence may be associated with recurrence of an 
exacerbation, as seen in 25% of the sample population.  However, the frequency of 
recurrence is too low to confirm or refute this.  Analysis of the population excluding 
recurrent exacerbations showed a decrease in prevalence of typical airway bacteria 
(39.5% to 35.3%).  However this was still not significantly below prevalence of 
typical airway bacteria at exacerbation (prevalence of 51.5%). 
 
Bacterial load was found to be significantly lower at all recovery time points 
compared to at exacerbation presentation, up to and including five weeks post-
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presentation.  Following on from the findings of Chapter 4, this demonstrates that 
there is a clear association between bacteria-associated COPD exacerbations and 
high bacterial load, relative to bacterial association at other time points. 
 
This study showed that serum CRP peaked at exacerbation presentation before 
reducing significantly within 3 days.  A previous study in the London COPD Cohort 
reported that in 77% of patients, symptoms recovered to baseline by day 35, and, 
as with this study, recovery was associated with a fall in CRP levels (Perera et al. 
2007).  The current investigation demonstrated that CRP fell markedly at days 3 and 
7, before rebounding slightly at day 14 (still significantly below the level seen at 
exacerbation presentation).   
 
The absence of a relationship between bacterial presence and recurrence of an 
exacerbation may be due to a number of reasons.  It may be a further indicator of 
the efficacy of antibiotics at reducing bacterial load down to a level below the 
threshold required to trigger a bacterial exacerbation – this would be borne out by 
the evidence that bacterial load has been shown to fall in paired time course 
samples.  It is also likely that many recurrent exacerbations may not be bacterial in 
origin.  For example, whilst antibiotics may mitigate the threat from bacteria, 
opportunistic viral infections may be more likely to occur in a recovering host.  
However, this is speculative and further investigations would be required to ensure 
sufficient power to identify whether there is statistical significance.  
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6.4.9 Typical airway bacterial load is not associated with dosage levels 
of systemic corticosteroid 
 
COPD exacerbations are routinely treated with systemic corticosteroids to control 
inflammation.  As described earlier, systemic inflammation was associated with 
presence and load of typical airway bacteria.  It was therefore hypothesised that 
typical airway bacterial load may be associated with dosage of systemic 
corticosteroids.  However, no relationship between load and dosage was identified.  
This may be a consequence of the fact that the vast majority of exacerbations 
(81.4%) were treated with systemic corticosteroids, and there was little variability 
in dosing regimens.  Dosage was, however, associated with airflow limitation at 
exacerbation presentation.  This suggests that clinicians are using spirometry data 
to support dosing levels at time of an exacerbation. 
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6.5 Conclusion 
 
This chapter has indicated for the first time that antibiotic therapy may be effective 
at limiting typical airway bacterial prevalence and load following an exacerbation 
whilst having a limited impact on the airway microbiome as a whole.  Furthermore, 
it has shown that pathogenesis is associated specifically with these typical airway 
bacteria, and differences in the microbiome are likely of little significance in terms 
of pathogenic potential. 
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CHAPTER 7.  Changes in the airway microbiome 
between stable COPD and exacerbation 
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 Introduction 7.1
 
The airway microbiome can be described as the entire flora of airway micro-
organisms.  In this study, the airway microbiome relates specifically to bacterial 
micro-organisms.   Until relatively recently, the lungs were considered to be 
maintained in a sterile state, or at most, ‘insignificantly colonised’ (Cabello et al. 
1997).  However, this orthodoxy has been overturned by molecular techniques such 
as plasmid-based sequencing, terminal-restriction fragment length polymorphism 
and microarray analysis (Hilty et al. 2010; Rogers et al. 2009; Huang et al. 2010), as 
well as by the evidence presented in Chapter 6 of the current study.   
 
The human intestines are known to contain at least ten-fold greater bacterial cells 
than there are human cells in the entire body, constituting a total of 1014 bacterial 
cells (Festi et al. 2011).  This gut microbiome is now known to be a vital component 
of digestion, allowing the degradation of plant polysaccharides and other dietary 
compounds, in a symbiotic interaction (Hooper et al. 2012).     
 
The relationship of the host immune system with colonisation by the gut 
microbiome has been extensively studied in literature (Hooper et al. 2012; Festi et 
al. 2011).    Understanding this relationship may provide a useful comparator to the 
interactions between the immune system and the airway microbiome.  The 
majority of gastrointestinal tract microbiome species are strict anaerobes, with 
colonisation commencing at birth (Sekirov et al. 2010). The commensal intestinal 
bacterial species play an essential role in modulating the intestinal immune system, 
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ensuring survival of this microbiome.  This ‘cross-talk’ between the host and these 
bacterial species is essential for a number of reasons.  It allows maintenance of an 
intestinal barrier and provides an appropriate environment for appropriate immune 
system stimulation (Abt & Artis 2013).   Maintenance of the intestinal barrier 
involves commensal species competing with pathogens, both for available nutrients 
and for attachment sites located on the intestinal brush border (Festi et al. 2011).  It 
has, however, been acknowledged that this high density of micro-organisms may 
itself pose a threat to the host, via opportunistic invasion, potentially leading to 
inflammation and sepsis (Hooper et al. 2012).   
 
In addition to the gut and airway microbiomes, the skin (Chiller et al. 2001; Percival 
et al. 2012) and genitourinary tract (Ma et al. 2012; Hyman et al. 2013) are also 
known to be host to bacterial microflora. A summary and brief description of 
known commensal microbiomes in humans is described (Table 7.1). 
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Microbiome 
location   
 
Description   
 
References 
               
  
  
  
  
  
  
  
  
  
   
 Gastrointestinal 
tract 
  
 
Contains ~1014 bacterial cells.  Majority 
of species are strict anaerobes and this 
microbiome plays an important role in 
digestion of plant polysaccharides.  
They also compete with pathogens, 
reducing the risk of infection 
  
 
(Festi et al. 
2011) 
 
 
  
 
  
   
 
  
 
  
   
 
  
 
  
   
  
  
  
  
   
 
Skin 
  
 
Commensal bacteria are largely gram-
positive organisms, such as 
Staphylococcus spp. (primarily S. 
epidermis) and Micrococcus spp.. 
Commensal skin bacteria presence 
reduces the risk of cutaneous or 
systemic infection from pathogens  
  
 Chiller et al 
(2001); 
Percival et al 
(2012) 
 
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
  
  
  
  
   
 
Genitourinary 
tract 
  
 
The vagina is host to a commensal 
microbiome, largely characterised by 
the dominant presence of Lactobacillus 
spp. in the majority of women. 
Lactobacilli produce lactic acid, 
lowering the pH of the vagina - this 
provides a hostile environment for 
pathogens 
  
 
Ma et al 
(2012); 
Hyman et al 
(2013) 
 
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
 
  
 
  
  
  
  
  
  
    
Table 7.1 Commensal microbiomes of the human body  
 
Due to the relatively recent identification of the airway microbiome, research is still 
at an early stage in terms of elucidating the role of this microbiome (Erb-Downward 
et al. 2012). 
 
In 2010, Hilty and colleagues demonstrated that the bronchial tree contains a 
microbial flora which is characterised by the subject’s health status (Hilty et al. 
2010).  It was later suggested that subjects with poor lung function exhibited 
                   Chapter 7 – Airway microbiome in stable COPD and exacerbation 
216 
 
reduced microbial diversity compared to healthy smokers (Erb-Downward et al. 
2011).  However, this research contrasts with more recent findings by Pragman and 
colleagues, which indicated that COPD patients had a higher degree of microbiome 
diversity than controls (although in this case, not all controls were smokers) 
(Pragman et al. 2012).  It has been acknowledged that there is limited evidence to 
support any functional role for the airway microbiome (Marsland et al. 2013). 
 
Studies exploring the microbiome in COPD have focused particularly on diversity of 
species in this microflora, whilst the overall bacterial burden has not been 
investigated.  The results presented in this chapter will explore the load of the 
airway microbiome at stable and exacerbation states to provide novel insights into 
the microbiome at these different stages of COPD. 
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 Patient characteristics 7.2
 
We collected sputum from 47 patients in the London COPD cohort at stable state 
(n=32) and at exacerbation (n=68).  Patient characteristics are illustrated in Table 
7.2. 
 
 
Characteristic   
          
 
  
  
 
  
  Median age (range), years   
 
70.7 (47.4-83.6) 
 
  
  Male gender (%)   
 
63.8 
 
  
  Current smoker (%)   
 
23.4 
 
  
  Median pack-year smoking history (IQR)   
 
43.5 (16.4-60.5) 
 
  
  Mean FEV1 (SD), Litres    
 
1.2 (0.5) 
 
  
  FEV1 % predicted (SD)   
 
46.5 (18.7) 
 
  
  FEV1/FVC ratio (SD)   
 
0.44 (0.1) 
 
                 Mean FVC (SD), Litres 
  
                         2.7 (0.9) 
 
Table 7.2. Characteristics of 47 patients of the London COPD Cohort, who participated in a study of the 
airway microbiome at stable and exacerbation states. No significant differences are seen between these and 
the patients described in Table 3.5. 
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 Results 7.3
 Airway microbiome load in stable and exacerbated 7.3.1
COPD 
 
No significant difference was identified in microbiome load between the stable 
state (n=32) and exacerbated state (n=68) in an unpaired analysis (109.2(±0.2) vs 
108.8(±0.1) copies/ml; p=0.10) (Figure 7.1). 
 
 
  
Figure 7.1.  Airway microbiome load at stable (n=32) and exacerbation (n=68) states of COPD in an 
unpaired analysis. 
 
 
In a longitudinal analysis involving 18 of these patients, airway microbiome load 
was assessed in both the stable and the exacerbation state, whereby the stable 
state sample was obtained less than 365 days prior to the exacerbation sample; 
median (IQR) = 119.5 (86.25-209.75) days prior.   
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As suggested with the inter-patient analysis above, it was found that there was also 
no significant intra-patient variation in airway microbiome load between stable and 
exacerbated state (109.2(±0.2) vs 108.8(±0.2) copies/ml; p=0.13) (Figure 7.2). 
 
 
Figure 7.2. Intra-patient changes in airway microbiome load between stable and exacerbation states.  
Stable state sputum sample was obtained <365 days prior to exacerbation sample. 
 
In stable COPD, there was found to be no significant difference in mean (SEM) load 
of the airway microbiome, irrespective of typical airway bacteria presence or 
absence (109.0(±0.3) vs 109.3(±0.2) copies/ml, respectively; p=0.43) (Figure 7.3).   
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Figure 7.3.  Airway microbiome load in the presence or absence of typical airway bacteria, in the stable 
state. 
 
 Airway microbiome load and airflow limitation at 7.3.2
exacerbation 
 
Airflow limitation data characterising the fall in FEV1 at exacerbation compared to a 
previous stable state was assessed in 54/68 patients (79.4%).  Patients were 
excluded from this subset if the exacerbation preceded any available stable 
spirometry data, if FEV1 data was not available at both stable and exacerbation 
states, or if the stable state data was >365 days prior to the exacerbation sample.  
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The median (IQR) number of days separating the stable state reading from the 
exacerbation state reading was 99.5 (55.3-162.3) days.   
 
The median (IQR) percentage change in FEV1 at exacerbation was -5.6 (-20.6 to 
3.4)%.  There was found to be no significant correlation between microbiome load 
at exacerbation and change in FEV1; rho= -0.04, p=0.76
 (Figure 7.4). 
 
 
 
Figure 7.4.  Airway microbiome load at exacerbation was not found to be related to FEV1 fall from stable 
state to exacerbation, r= -0.04, p=0.76 (n=54) 
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This demonstrated that microbiome load at exacerbation was not related to 
changes in FEV1 between stable and exacerbation states.  
 
The previous microbiome analysis did not assess whether changes in the load of the 
microbiome between stable and exacerbation states related to changes in FEV1.  
This was explored in those patients from whom stable and exacerbation state 
microbiome data had been obtained, and who also fulfilled the spirometry inclusion 
criteria as outlined earlier in this section.  Fourteen of the 18 patients (77.8%) with 
paired data fulfilled these criteria.   
 
The median (IQR) number of days separating stable state from exacerbation state 
was 119.5 (82.5-230.3) days.  The median (IQR) percentage change in FEV1 at 
exacerbation was -11.3 (-17.9 to 6.8) %.  Twelve of these 14 patients (85.7%) 
demonstrated a fall in airway microbiome load at exacerbation compared to stable 
state.   No significant correlation was identified between change in airway 
microbiome load and change in FEV1 status, between stable state and exacerbation 
(rho= -0.15; p=0.62).   
 Airway microbiome load and sputum volume/purulence 7.3.3
 
Patient diary card availability allowed symptom data to be compared with airway 
microbiome load at exacerbation.  Of the 68 exacerbations, 46 demonstrated an 
increase in sputum purulence.  Sputum purulence at exacerbation was not 
associated with any difference in airway microbiome load, with mean airway 
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microbiome load of 108.8(±0.2) cfu/ml, both with and without sputum purulence 
(Figure 7.5).   
 
 
 
Figure 7.5.  Airway microbiome load split by presence (n=46) or absence (n=22) of purulent sputum at 
exacerbation.  No difference was seen in airway microbiome load, irrespective of sputum purulence  
 
 Relationship of airway microbiome load at stable and 7.3.4
exacerbation state with biomarkers of systemic 
inflammation 
 
Nineteen samples (19%) had levels of CRP recorded.  No correlation was identified 
between airway microbiome load and CRP (rho= -0.05; p=0.85) (Figure 7.6). 
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Figure 7.6. The relationship of airway microbiome load and CRP. (rho = -0.05; p=0.85) 
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 Discussion 7.4
 
Bacterial microbiomes are known to be of importance in a number of different 
tracts and surfaces of the human body.  The microflora of the gut, skin and 
genitourinary tracts has been well characterised (Festi et al. 2011; Chiller et al. 
2001; Ma et al. 2012; Hyman et al. 2013).  These characterisations have highlighted 
both the protective effects of these bacteria under normal conditions, as well as the 
pathogenic effects of opportunistic bacterial infection.  However, the protective 
and/or pathogenic effects of the airway microbiome have not previously been 
investigated. 
 
Current knowledge of the airway microbiome describes the diversity of bacterial 
species in considerable detail, looking at COPD patients, non-smokers and healthy 
smokers (Hilty et al. 2010; Huang et al. 2010; Erb-Downward et al. 2011; Sze et al. 
2012).  However, there had previously been no investigation into the changes of the 
airway microbiome load in COPD patients between the stable state and the 
exacerbation state. It was therefore important to do this investigation to establish if 
there was any evidence to indicate whether changes in the load of the airway 
microbiome have a protective or pathogenic effect in COPD. 
 
In this study, a number of findings of the airway microbiome have been described 
for the first time.  It has been shown that the microbiome is constitutively present 
in the airways of COPD patients and that the burden of this microbiome is not 
related to disease state.  It was also found that there was no link between airway 
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microbiome load at exacerbation with changes in FEV1 between exacerbation and 
the previous stable state.  Furthermore, it has been demonstrated that microbiome 
load does not change significantly within patients from stable state to exacerbation 
state, showing that change in the microbiome load alone is not associated with 
disease severity.  It is likely that the changes in the prevalence and load of particular 
species may be of more importance. It has been seen that in the stable state, 
presence of typical airway bacteria is not associated with a higher airway 
microbiome load. This contrasts with the findings at exacerbation, as described in 
section 6.3.4, where typical airway bacteria presence was associated with a six-fold 
higher airway microbiome load.  No relationship was found between airway 
microbiome load and the systemic inflammatory biomarker CRP.   
 
Sputum purulence is an indicator of bacterial infection in COPD, and is used as a 
guide for antibiotic therapy in COPD exacerbations (Stockley et al. 2000; Anthonisen 
et al. 1987).  In order to assess whether or not the airway microbiome was a 
contributor to bacterial symptoms in COPD, the microbiome load was assessed in 
samples exhibiting or not exhibiting purulent sputum.  There was found to be no 
difference in airway microbiome load, regardless of sputum purulence.  
 
These data concerning the airway microbiome are in contrast to the previous 
findings highlighted in the current study examining the typical airway bacteria.  
Presence of the typical airway bacteria, are associated with a fall in FEV1 from 
stable state to the following exacerbation, and the load of typical airway bacteria 
significantly increases at exacerbation (Chapter 4).  Furthermore, typical airway 
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bacterial load was shown to be associated with CRP levels (section 5.3.2).  It is also 
known that higher typical airway bacterial load is associated with sputum purulence 
(section 4.5.1). 
 
Taken together this body of evidence indicates that typical airway bacteria 
prevalence and load, but not the airway microbiome, is associated with a more 
severe systemic inflammatory response and poorer airflow limitation, both at the 
stable state and at exacerbation.  Therefore the importance of the airway 
microbiome may lie in changes in the presence and load of key bacterial species, of 
which the typical airway bacteria make up a major subset. 
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CHAPTER 8. Prevalence and Load of Atypical 
Airway Bacteria at Stable and Exacerbation States of 
COPD 
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8.1 Introduction 
 
Atypical airway bacteria have previously been found to be causal agents of 
community-acquired pneumonia (Cunha 2006).  However, they have previously 
been seldom identified in patients of COPD.  In the field of COPD, atypical bacterial 
species which have been implicated in causing disease exacerbation are 
Chlamydophila pneumoniae, Legionella pneumophila and Mycoplasma 
pneumoniae.   
 
Chlamydophila species exist in distinct forms depending on whether they are extra- 
or intra-cellular (Hammerschlag 2002). The free-living, extracellular form is known 
as an elementary body.  In this state, the bacterium is able to infect mucosal 
epithelium cells.  Once the bacterium is endocytosed it is contained within a 
phagosome, and this is prevented from fusing with the lysosome (this fusion would 
otherwise destroy the bacterium). These elementary bodies are then able to 
differentiate into reticulate bodies during conditions of immune stress.  Reticulate 
bodies are forms of Chlamydophila species which exist and persist intracellularly.  
When there is no immune stress, the reticulate bodies can redifferentiate back into 
elementary bodies, triggering cell lysis and subsequent further infection (Kalayoglu 
et al. 2002). 
 
In a similar mechanism, Legionella pneumophila (L. pneumophila) is able to colonise 
alveolar macrophages.  This adaptation in L. pneumophila is thought to have been 
driven by its evolution in response to bacteria-consuming amoebae found in 
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aquatic environments, with significant conservation between macrophages and 
amoebae allowing Legionella to persist in both cell types (Molofsky & Swanson 
2004).  
 
Mycoplasma pneumoniae (M. pneumoniae) is one of the smallest known bacterium, 
with a genome size of 816 kb.  Upon discovery, it was not readily identified as a 
bacterium and was termed Eaton’s Agent, following discovery by Monroe Eaton 
and Colleagues in 1944 (Eaton et al. 1944). By the 1960’s however, further analysis 
confirmed that it was indeed a bacterium, and it was ultimately given its current 
nomenclature (Chanock 1963).  M. pneumoniae is able to infect and persist in cells 
of the respiratory epithelium (Collier & Clyde 1971; Waites & Talkington 2004). 
 
8.1.1 Pathogenesis 
 
Atypical airway bacteria have been shown to be a frequent cause of community-
acquired pneumonia (Maartens et al. 1994).  However, they act through differing 
mechanisms to produce this pneumonic phenotype.  
 
Chlamydophila pneumoniae (C. pneumoniae; previously designated as Chlamydia 
pneumoniae) is a well-known cause of acute respiratory infection (Burillo & Bouza 
2010).  It is also a causative agent in bronchitis, pharyngitis and sinusitis (Blasi et al. 
2009).  Furthermore, recent studies indicate that C. pneumoniae is associated with 
both lung cancer and Alzheimer’s disease (Zhan et al. 2011; Shima et al. 2010).    In 
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COPD, it has been hypothesised that chronic C. pneumoniae infection may assist 
infection with different pathogens in the lower airways, enhance smoking-mediated 
inflammation in the bronchi and stimulate development of irreversible airway 
obstruction (Karnak et al. 2001). 
 
Legionella pneumophila (L. pneumophila) is ubiquitous in freshwater environments, 
and can also survive in air-conditioning systems (Newton et al. 2010).  Legionnaire’s 
disease is a severe acute pneumonia caused by L. pneumophila, and is associated 
with smokers, the elderly and immunosuppressed individuals (Yu et al. 2004).  
There are a number of mechanisms by which L. pneumophila exerts its pathogenic 
effects:  it causes pore formation in macrophages and erythrocytes, resulting in 
cytotoxicity (Kirby et al. 1998); it also has a number of virulence factors 
characteristic of most bacterial pathogens, such as lipopolysaccharide, flagella, pili 
and outer membrane proteins (Newton et al. 2010). 
 
Mycoplasma pneumoniae targets respiratory epithelial cells for infection (Hu et al. 
1977).  The bacterium is able to produce hydrogen peroxide (as a final metabolite 
of glucose), leading to the lysis of erythrocytes (Arai et al. 1983).  The release of 
hydrogen peroxide also triggers the production and secretion of interferon (IFN) by 
lymphocytes and phagocytes.  IFN secretion is known to be involved in the 
pathogenesis of chronic inflammatory disease following its stimulation of 
macrophages.  The reason for this is that activated macrophages secrete tumor 
necrosis factor (TNF), which triggers apoptosis (Yarilina & Ivashkiv 2010).  
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8.1.2 Atypical bacteria in COPD: Current knowledge 
 
A number of techniques have been performed to attempt to identify presence of 
atypical airway bacteria in COPD.  Routine microbiological culture is insufficient as 
standard culture media is not designed to encourage growth of these atypical 
airway bacteria.  A number of studies have utilised serology to attempt to 
overcome this limitation (Lieberman et al. 2002a; Lieberman et al. 2001a; 
Lieberman et al. 2002b; Soler et al. 1998).   
 
Serological analysis indicated a potential association of these atypical airway 
bacteria with acute exacerbations of COPD.  These analyses were all based on 
positivity of sera to the suspected organism at different dilutions (titres).  It was 
found that chronic C. pneumoniae infection was detected in 33.3% of COPD 
patients compared with 7% of controls (Lieberman et al. 2001a).  In that study, 
chronic C. pneumoniae infection was defined as having specific IgG titre ≥1:28 and 
specific IgA titre ≥1:64.  Furthermore, in 31 patients who had two hospitalisations in 
the study period, it was found that there was evidence of acute C. pneumoniae 
infection in 11.3% of hospitalisations (Lieberman et al. 2001a).  Soler and colleagues 
identified presence of C. pneumoniae antibodies in 18% of patients suffering severe 
exacerbations of COPD, in whom a seroconversion titre ≥ 1:512 or an IgM titre 
≥1:32 was used to define C. pneumoniae antibody positivity  (Soler et al. 1998).  
Another serological study identified acute C. pneumoniae infection in 34% of COPD 
patients undergoing an acute exacerbation (Karnak et al. 2001), with the acute 
infection defined as having specific IgG antibody ≥ 1:512 or specific IgM antibody 
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≥1:16.  In that study, non-COPD smokers were used as controls, and in that group 
only 5% were positive for C. pneumoniae antibody.  These studies show that there 
is wide variation in detection of C. pneumoniae antibody in different populations.   
 
Legionella spp. presence has also been investigated by serology, in a study which 
examined paired exacerbation and subsequent convalescence serum samples 
(mean 24.7 days apart) in COPD patients (Lieberman et al. 2002a).  In 16.7% of 
paired samples, the antibody titre of either IgG or IgM was four-fold higher at 
exacerbation than at convalescence.  In a control group consisting of post-trauma 
patients admitted to the hospital in the study period, only 3% showed a significantly 
higher titre of Legionella spp. at admission.  M. pneumoniae (14.2%) antibodies 
(IgG, IgA or IgM) have also been detected in patients hospitalised with AE-COPD, 
with antibody titers defined according to commercially available kits used in that 
study (Lieberman et al. 2002b).  The seroprevalence of C. pneumoniae and M. 
pneumoniae has also been established in stable COPD patients (Park et al. 2005).  
Seroprevalence to C. pneumoniae, defined as IgG titre ≥ 1:512 or IgM titre ≥ 1:20, 
was identified in 3.4% of patients.  Seroprevalence to M. pneumoniae, defined as an 
antibody titre ≥1:64, was identified in 16.9% of patients, comparable to the 
seroprevalence identified in acute exacerbations of COPD (Lieberman et al. 2002b). 
 
However, a more-recent PCR-based analysis performed in The Netherlands, 
examining 126 exacerbation sputum samples, showed no evidence of C. 
pneumoniae or M. pneumoniae infection, and only one case of Legionella spp.  
infection, with a non-pneumophila strain (Diederen et al. 2007).  In that study, 
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Diederen and colleagues targeted a region of the outer membrane protein A gene 
of C. pneumoniae, a region of the macrophage infectivity potentiator (mip) gene for 
L. pneumophila, and a region of the P1 adhesin gene for M. pneumoniae, in three 
separate PCRs –TaqMan probes were utilised for detection and quantification.  
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8.2 Atypical respiratory PCR methodology 
 
In the current study, a multiplex qPCR was utilised for the detection of atypical 
airway bacteria as described in section 2.8, and as previously detailed (Ling & 
McHugh 2013). 
 
8.2.1 Analysis of patient samples for atypical respiratory 
bacteria at various time-points of disease severity 
 
A total of 176 samples, from 80 patients of the London COPD cohort, were 
investigated for presence of the atypical respiratory bacteria (Chlamydia 
pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae).  Of these, 97 
were stable samples and 79 were exacerbation samples.  Patient characteristics 
were obtained through reference to the COPD cohort database (Table 8.1). 
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Characteristic   
          
 
  
  
 
  
  Median age (range), years   
 
71.8 (43.3-85.1) 
 
  
  Male gender (%)   
 
66.7 
 
  
  Current smoker (%)   
 
25 
 
  
  Median pack-year smoking history (IQR)   
 
50 (35.25-72.5) 
 
  
  Mean FEV1 (SD), Litres    
 
1.1 (0.5) 
 
  
  FEV1 % predicted (SD)   
 
45.5 (17.8) 
 
  
  FEV1/FVC ratio (SD)   
 
0.44 (0.1) 
 
  
  Mean FVC (SD), Litres   
 
2.6 (0.9) 
 
  
   
Table 8.1. Mean characteristics of patients whose samples were analysed for atypical 
bacteria (n=80).  There were no significant differences between the characteristics of 
these patients and the characteristics of the patient characteristics described in Table 
3.5. 
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8.3 Results 
8.3.1 Atypical airway bacterial prevalence and load 
 
In total, six atypical bacteria positive samples were detected, in six separate 
patients.  Of these, five were Legionella pneumophila and one was Mycoplasma 
pneumoniae (Figure 8.1).   
 
 
Figure 8.1.  Prevalence of atypical airway bacteria in airways of COPD patients at stable (n=97) and 
exacerbation (n=79) states. CP = Chlamydophila pneumoniae, LP = Legionella pneumophila, MP = 
Mycoplasma pneumoniae 
 
Bacterial load was quantified using the multiplex atypical airway qPCR (section 2.8), 
by correlating the positive samples to the standard curve of the respective species.  
Legionella pneumophila was found to have a mean (SEM) bacterial load of 104.7 (±0.2) 
CFU/ml (Figure 8.2).  The five cases were found to range from 104.3 CFU/ml to 105.1 
CFU/ml.  Four of the positives were from stable samples and one was from an 
exacerbation sample.  The highest bacterial load for L. pneumophila was from the 
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exacerbation sample. The single Mycoplasma pneumoniae-positive sample had a 
bacterial load of 107.4 CFU/ml, and related to a stable sample. 
 
 
Figure 8.2.  Bacterial load of patients with positivity for L. pneumophila (n=5) and M. pneumoniae (n=1).  
LP = Legionella pneumophila; MP = Mycoplasma pneumoniae. 
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8.4 Discussion 
 
Detection of atypical respiratory bacterial infection is sought by methods other than 
culture.  There are a number of disadvantages to using culture alone. For example, 
microbiological culture of M. pneumoniae is known to be laborious and expensive, 
with several passages required using specialised growth media and incubation 
periods of several weeks (Waites & Talkington 2004). Additionally, culture growth 
of M. pneumoniae has been shown to have only 61.5% specificity compared with 
PCR (Ieven et al. 1996).  L. pneumophila growth is best identified using buffered 
charcoal yeast extract agar, and this growth can take at least three days to become 
apparent (Feeley et al. 1979).  Alternative methods are therefore often employed 
for detection of such organisms.  For example atypical airway bacteria are 
frequently detected by serology, as described in section 8.1.2.  However, this 
technique is only able to detect presence of antibodies to these micro-organisms 
once seroconversion has occurred (i.e. antibodies to the respective bacterium 
develop).  As such, antibody seroconversion can be an indicator of past infection as 
well as present infection, as antibodies remain present following resolution of an 
infection.  Therefore it can be difficult to elucidate an association between 
serological detection and COPD exacerbations.  Serology requires two sampling 
points 2-3 weeks apart, delaying diagnosis (McDonough et al. 2005).  
 
In order to overcome these difficulties, molecular techniques such as PCR are 
considered more suitable to detect presence or absence of atypical airway bacteria 
at the time of sampling (Ieven et al. 1996; Cloud et al. 2000; McDonough et al. 
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2005).  PCR is able to detect traces of DNA of these pathogens during an infection.  
Surfactant proteins in the lung assist clearance of exogenous DNA by macrophages, 
suggesting that any DNA detected relates to an ongoing infection (Palaniyar et al. 
2005).   
 
Serology-based studies have demonstrated that antibodies to atypical airway 
bacteria exist in a significant minority of COPD patients, in the region of 30% 
(Lieberman et al. 2001b; Murphy & Sethi 1992).  However, Diederen and colleagues 
had previously explored the presence of atypical airway bacteria in stable and 
exacerbated COPD, finding little evidence of these organisms, in a population in the 
Netherlands (Diederen et al. 2007).  In that study, there was detection of Legionella 
spp. (non-pneumophila) in 1/122 (0.8%) stable state sputum samples and detection 
of Legionella spp. (non-pneumophila) in 1/126 (0.8%) exacerbation state sputum 
samples.  No detection of C. pneumoniae or M. pneumoniae was identified in any 
sample. 
 
The evidence presented in this study supports the findings of the Netherlands 
study, with very low prevalence seen (6/176 samples, 3.4%).  Furthermore, the 
current study is the first to describe the bacterial load in patients positive for 
atypical airway bacteria, showing that L. pneumophila was present at very low load.  
In comparison with the mean (SEM) load of typical airway bacteria identified in the 
stable state in section 4.3.4, the load of L. pneumophila was 300-fold lower 
(107.2(±0.1) vs 104.7 (±0.2) CFU/ml). Furthermore, the presence of atypical airway 
bacteria was not related to clinical symptoms and so suggests that this was sub-
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clinical in most cases.  One case of L. pneumophila-presence was associated with an 
exacerbation but no conclusions can be drawn from this as it was only a single case.  
These findings of low prevalence are further supported by a recent study 
performed by Perotin and colleagues in France, where they found no cases of 
atypical respiratory pathogens in 45 cases of acute exacerbations of COPD (Perotin 
et al. 2013). 
 
The current study has investigated the rate of atypical airway bacteria in COPD 
patients.  It has established that there is low prevalence and low load of atypical 
airway bacteria, and that presence of these bacteria was not related to clinical 
symptoms.  It has therefore identified that atypical airway bacteria are not a major 
cause of pathogenesis in COPD, in either the stable or exacerbation state, and so do 
not require specific therapy. 
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CHAPTER 9. Summary and Future Work 
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The overall aim of this thesis was to investigate the relationship between bacterial 
presence and severity of COPD.  Certain bacterial organisms (typical airway 
bacteria) have previously been shown to be associated with acute exacerbations of 
COPD.  Haemophilus influenzae, Streptococcus pneumoniae and Moraxella 
catarrhalis are the pathogens most commonly associated with COPD exacerbations 
(Hunter & King 2001; Sethi et al. 2002).  Molecular techniques such as PCR have 
come to the forefront of identification of bacterial species in a range of diagnostic 
scenarios (Chaidir et al. 2012; Curran et al. 2007; Brito et al. 2003).  However, there 
was an absence of literature exploring changes in the prevalence and load of typical 
airway bacteria between the stable state and exacerbation state utilising PCR, as 
well as during the recovery period in the weeks following an exacerbation.  
 
Previously there has been conflicting data of the association of the atypical airway 
bacteria, namely Legionella pneumophila, Chlamydophila pneumoniae and 
Mycoplasma pneumoniae, in COPD, and this required further analysis.  The airway 
microbiome is now known to be an inherent component of both healthy and COPD 
lungs (Hilty et al. 2010; Erb-Downward et al. 2011; Sze et al. 2012).  However, there 
has previously been no consideration of changes in the prevalence and load of this 
microbiome between stable COPD, acute exacerbation, and recovery.   
 
Changes in prevalence and load of typical airway bacteria between stable and 
exacerbation states has previously been done before utilising culture, although this 
was performed either in different groups of patients at the two states (Monso et al. 
1995; Rosell et al. 2005), or, in the case of a study involving paired stable and 
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exacerbation state samples from patients, it was only performed in exacerbations 
which resulted in hospitalisations, therefore representing more severe 
exacerbations, and involved stable state samples obtained post-exacerbation (Papi 
et al. 2006).  The hypothesis was that prevalence and load of typical airway bacteria 
was higher at exacerbation, and that typical airway bacteria were associated with 
more severe clinical outcomes in COPD.  The first strand of the investigation 
compared microbiological culture with PCR for the detection of typical airway 
bacteria.  The second strand of the investigation utilised PCR for the detection and 
quantification of typical airway bacteria, atypical airway bacteria, and finally all 
bacteria of the airway microbiome.  The findings of the study are summarised 
below. 
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9.1 Main Findings 
 
 Conventional microbiological culture was compared with a quantitative 
multiplex PCR in Chapter 3. In a population of 439 sputum samples, it was 
found that qPCR identified more than double the number of typical airway 
bacteria compared with culture.  PCR also has the benefit of being a more 
rapid technique, with results available on the same day as the sample is 
obtained, and may therefore be successfully utilised to identify typical 
airway bacteria in the sputum of COPD patients     
 
 In Chapter 4, it was found that prevalence of typical bacteria was 
approximately twice as high during COPD exacerbation compared with at 
the stable state.  This was identified both in an unpaired analysis (53.3% vs 
33.6%; p<0.001), as well as in an analysis which utilised paired stable and 
exacerbation sputum samples from the same patient (68.9% vs 29.5%; 
p<0.001) 
 
 Haemophilus influenzae was identified as the most prevalent typical airway 
bacterial species, both at stable state (20.0%) and at exacerbation (32.8%), 
as shown in section 4.3.3 
 
 It was also found in Chapter 4 that typical airway bacterial load was 
significantly higher at exacerbation than at stable state, with 10 patients in 
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whom typical airway bacteria was detected in both states showing a mean 
increase in typical airway bacterial load of 25-fold (p=0.02) 
 
 In section 4.4.4 it was seen that exacerbations with presence of H. 
influenzae were associated with a poorer outcome in lung function 
compared to non-H. influenzae associated exacerbations (-16.1% vs 1.7%; 
p=0.015) 
 
 Median levels of the systemic inflammatory biomarker C-reactive protein 
were significantly higher at exacerbation compared to stable state (10.0 vs 
3.0 mg/L; p<0.001), and this is illustrated in Figure 4.8 
 
 At exacerbation, median levels of the systemic inflammatory biomarker C-
reactive protein were significantly higher in samples exhibiting typical 
airway bacterial presence, compared to those in which no presence was 
detected (17.5 vs 3.0 mg/L; p=0.009), as shown in section 4.5 
 
 In section 4.5.1 sputum purulence was shown to be associated with typical 
airway bacterial load (108.0(±0.2) CFU/ml with purulence, vs 107.1(±0.3) CFU/ml 
without purulence, p=0.01)  
 
 It was found that inhaled corticosteroid dosage was significantly higher in 
patients with typical airway bacteria detected compared to those without 
typical airway bacteria in the stable state (2000 µg vs 1000 µg; p=0.018), and 
this is described in section 5.4 
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 In section 5.4 it was also seen that there was a positive correlation between 
ICS dosage and typical airway bacterial load (rho = 0.20; p = 0.01) 
 
 This correlation was particularly strong when only patients who were 
positive for typical airway bacteria were analysed (rho = 0.38; p= 0.01) 
(section 5.4) 
 
 ICS dosage was shown to be related to GOLD stage (p=0.049), and ICS dose 
was also seen to be correlated to more severe airflow limitation (rho = -
0.27; p=0.001), as measured by FEV1, in section 5.4.1 
 
 In section 6.3.2, it was seen that typical airway bacterial prevalence fell 
significantly during exacerbation recovery, from 50.4% at exacerbation 
presentation to 26.8% at day 3 post-therapy commencement (p=0.008), and 
this significant reduction in prevalence remained for at least 14 days (32.1%, 
p=0.02) 
 
 The airway microbiome was found to persist despite antibiotic therapy 
following an exacerbation, although load does fall in the three days 
following therapy commencement (109.1(±0.1) vs 108.2(0.3); p=0.02), and this is 
described in section 6.3.3 
 
 Presence of typical airway bacteria in patients at exacerbation and recovery 
was associated with a six-fold higher median (IQR) airway microbiome load 
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compared to those patients without any presence of typical airway bacteria 
(109.7(±1.5) vs 108.9(±1.3) copies/ml, p<0.001) and there was also a positive 
correlation between typical airway bacterial load and airway microbiome 
load, in patients positive for typical airway bacteria (rho=0.41; p<0.001), as 
noted in section 6.3.4   
 
 In section 6.3.5, it was shown that load of H. influenzae, but not S. 
pneumoniae or M. catarrhalis, was found to be correlated to levels of CRP 
(rho = 0.21; p<0.001) 
 
 Conversely in section 6.3.5, load of the airway microbiome was not found to 
have any correlation to CRP (rho  = 0.021; p=0.77) 
 
 In the five weeks following an exacerbation, CRP levels were significantly 
below those seen at exacerbation, as described in Table 6.2 
 
 In section 6.3.5 it was identified that airflow limitation was not related to 
CRP levels at exacerbation presentation (rho = -0.11; p=0.23) 
 
 
 It can be seen in Figure 6.13 that in those samples with typical airway 
bacteria, higher load of such bacteria during exacerbation and recovery is 
associated with more severe airflow limitation (rho = -0.22; p=0.02) 
 
 Airway microbiome load showed no correlation to airflow limitation (rho = -
0.12; p = 0.11), as described in section 6.3.7 
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 No significant difference in CRP levels were seen at exacerbation 
presentation between those patients who were (13.5 (6-29) mg/L) and 
those who were not prescribed (17 (6-49) mg/L) systemic corticosteroids 
(p=0.69), and this is described in section 6.3.8 
 
 It can be seen in section 7.3.1 that the load of the airway microbiome does 
not significantly differ between the stable state and COPD exacerbation 
(109.2(±0.2) vs 108.8(±0.1) copies/ml; p=0.10), and this was confirmed using intra-
patient data at the two states (109.2(±0.2) vs 108.8(±0.2) copies/ml; p=0.13) 
 
 Figure 7.3 illustrates that airway microbiome load in stable COPD does not 
significantly change when typical airway bacteria is present or absent 
(109.0(±0.3) vs 109.3(±0.2) copies/ml, respectively; p=0.43).  This is in contrast to 
the findings of section 6.3.4, which had found that in exacerbation and 
recovery, typical airway bacterial presence is associated with a six-fold rise 
in airway microbiome load 
 
 Airway microbiome load at exacerbation was not associated with change in 
FEV1 between that exacerbation and a previous stable state FEV1 reading 
(rho= -0.04, p=0.76), as described in section 7.3.2 
 
 Figure 7.5 illustrates that sputum purulence was not associated with airway 
microbiome load.  Again, this is in contrast to the findings with typical 
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airway bacteria described in section 4.5.1, where it was shown that purulent 
sputum had a higher typical airway bacterial load than non-purulent sputum 
 
 Atypical airway bacteria were detected, using qPCR, in 6/176 samples (3.4%) 
and this is described in section 8.3.1.  L. pneumophila was detected in 5 
samples, with M. pneumoniae detected in 1 sample 
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9.2 Additional findings 
 
 There was no significant difference in airway microbiome load between 
those patients who suffered a recurrent exacerbation within 50 days of the 
index exacerbation, and those who did not, as shown in section 6.3.6 
(108.9(±0.3) vs 108.8(±0.2) copies/ml; p=0.73) 
 
 Figure 6.11 illustrates that airflow limitation does not change significantly 
during the 5-week recovery period post-exacerbation 
 
 In section 6.3.7, airflow limitation across the exacerbation recovery period 
was not found to be related to presence or absence of typical airway 
bacteria (42.0 vs 47.2% FEV1% predicted; p=0.19) 
 
 Section 6.3.8 shows that typical airway bacteria presence or load has no 
effect on the systemic corticosteroid prescription or dose levels 
 
 Airway microbiome load has no bearing on whether or not systemic 
corticosteroids are prescribed, as detailed in section 6.3.8  
 
 Higher systemic corticosteroid dosage was found to be related to more 
severe airflow limitation at time of exacerbation presentation (rho = -0.25; 
p=0.01) as illustrated in Figure 6.17  
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 Airway microbiome load in the stable state was not related to CRP (rho= -
0.05; p=0.85), as shown in section 7.3.4    
 
 Mean load of L. pneumophila was found to be 104.7 (±0.2) CFU/ml, as shown in 
figure 8.2 
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9.3 Clinical implications of findings 
 
o The initial finding of this study verified the utility of quantitative PCR as a more 
sensitive method than microbiological culture for the detection of typical airway 
bacteria (Chapter 3). Conventionally, microbiological culture has been used as 
the primary method for the detection of airway bacteria. There are a number of 
disadvantages associated with the use of culture.  Culture takes days, or even 
weeks to identify slow-growing organisms, and this may require highly selective 
media (Prakash et al. 2013).  In clinical practice, this may delay necessary 
antibiotic treatment.  Also, competition between bacterial species for the 
nutrients provided may result in one species outcompeting other species, 
thereby preventing their growth (Hibbing et al. 2010).  There are also 
advantages to utilising culture, and this study by no means attempts to devalue 
the technique.  For example, microbiological culture can be used to quantify 
antibiotic resistance in colonies and is also able to identify species that may 
otherwise not be looked for.   
 
For the purposes of this study, the aim was to identify the prevalence and load 
of known typical and atypical airway bacteria, or the entire airway microbiome.  
Quantitative PCR was therefore the most appropriate technique and is also 
likely to be of benefit in routine clinical practice when specific bacterial species 
are being targeted. 
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o There was previously doubt about the association of typical airway bacteria 
with exacerbations of COPD.  This doubt was primarily due to the fact that 
typical airway bacteria are also isolated from sputum of stable COPD patients 
(Hirschmann 2000).  The current study provides evidence to implicate typical 
airway bacteria in contributing to disease severity in COPD.  Firstly, it has been 
shown that the prevalence of typical airway bacteria is significantly higher at 
exacerbation than at stable state.  Secondly it has been shown that load of 
typical airway bacteria was 25-fold higher in patients suffering an acute 
exacerbation compared to the load found in those same patients at stable state 
less than one year prior.  These two components indicate that typical airway 
bacteria are associated with exacerbation.  Further evidence shown in this study 
went on to demonstrate how the typical airway bacteria, particularly H. 
influenzae, may be contributing to disease severity: at exacerbation, typical 
airway bacterial presence was associated with significantly higher levels of the 
systemic inflammatory biomarker, CRP, compared with samples in which no 
typical airway bacteria were detected; Haemophilus influenzae-associated 
exacerbations were associated with a much greater fall in airflow limitation 
from stable state compared to other exacerbation types. 
 
Whilst the evidence implicates typical airway bacterial prevalence and load in 
severity of COPD, there was no evidence to suggest that changes in the airway 
microbiome as a whole contributes to severity.  Airway microbiome load was 
not associated with levels of CRP, or with sputum purulence, suggesting that 
neutrophilic infiltration is not increased when microbiome load increases.  
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There was also no association between airway microbiome load and airflow 
limitation.  Therefore, the findings of this study suggest that antibiotic therapy 
targeting the typical airway bacteria is of particular importance in reducing the 
severity of COPD. 
 
o It was found that exacerbation recovery was associated with a significant 
reduction in both the prevalence and load of typical airway bacteria, in the days 
following presentation with an exacerbation of COPD.  This is associated with 
antibiotic treatment, and placebo-controlled studies would demonstrate 
whether the antibiotics are responsible for this reduction.  A reduction in CRP 
was also identified over this time period, although that was presumably due to 
the anti-inflammatory nature of systemic corticosteroids also prescribed – the 
reduction in typical airway bacterial load may also play a part in this.  It is 
therefore important to consider the potential benefit of prophylactic antibiotic 
therapy as a pro-active approach to prevent typical airway bacteria from 
infecting COPD patients.   
 
Previous studies have demonstrated that long term antimicrobial therapy is of 
benefit to patients to COPD.  Examining the macrolide class of antibiotics, two 
major studies examined long term antibiotic therapy, finding that daily 
administration of erythromycin and azithromycin for 1 year reduced 
exacerbation frequency compared to placebo (Seemungal et al. 2008; Albert et 
al. 2011).  Given that macrolides have both antibiotic and anti-inflammatory 
capabilities, it was not clear by which mechanism they were acting.  
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Intermittent fluoroquinolone therapy has also been investigated in the PULSE 
study (Trial No. NCT00473460).  In this trial, patients received moxifloxacin 
once-daily for 5 days (Sethi et al. 2010).  This was repeated every 8 weeks for 48 
weeks.  It was shown to reduce odds of exacerbation by 20% in the intention-to-
treat population.  Encouragingly, there was also no evidence of development of 
resistance.  A recent study explored the efficacy of antibiotics in mild-to-
moderate exacerbations of COPD, finding that therapy with co-amoxiclav had a 
higher recovery rate than placebo (74.1% vs 59.9%) and had a longer median 
time to next exacerbation (233 days vs 160 days). The current study suggests 
that by reducing infection with typical airway bacteria, inflammation may also 
be directly reduced, providing clinical benefit. 
 
o With typical airway bacteria being shown to be associated with acute 
exacerbations of COPD in this study, the attention must in future turn towards 
exploring vaccine development for COPD patients.  Streptococcus pneumoniae 
vaccines are currently available and in the UK this is recommended for COPD 
patients, as was discussed in Chapter 3.  The difficulty with S. pneumoniae is in 
the number of different serotypes, with more than 90 known (Weinberger et al. 
2011).  The pneumococcal vaccine, however, only targets 23 of these serotypes.  
A recent trial has indicated that oral therapy with inactivated non-typeable H. 
influenzae may show efficacy at reducing mild-to-moderate COPD exacerbations 
by 63%, in 38 patients (Tandon et al. 2010). The authors acknowledged that 
they needed to explore efficacy in a larger group representing a broader range 
of subjects with COPD.    
                                                                                  Chapter 9 – Summary and future work 
259 
 
9.4 Conclusion 
 
This study has explored the role of airway bacteria in chronic obstructive pulmonary 
disease.  It has demonstrated that typical airway bacteria are more prevalent and 
seen at higher load at exacerbation than stable state, and also present a greater 
burden of symptoms than atypical airway bacteria or the airway microbiome.  
Furthermore, antibiotic therapy at exacerbation presentation is associated with a 
marked decline in typical airway bacteria prevalence and load. Therapy aimed at 
alleviating bacteria-associated symptoms in COPD patients should be primarily 
targeted towards the typical airway bacteria. 
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9.5 Future Work 
 
o It has not yet been conclusively demonstrated whether typical airway bacteria 
are causing exacerbation or whether they are simply involved in contributing to 
severity once an exacerbation arises.  Analysis of samples taken at the ‘stable’ 
state in the prodrome phase prior to an exacerbation will provide evidence as to 
whether or not typical airway bacteria increase in this phase, and may therefore 
be triggering an exacerbation. 
 
o In an experimental model it has been shown that viral infection induces an 
acute exacerbation and this leads to an increase in the load of the airway 
microbiome (Molyneaux et al. 2013).  It would be of interest to identify, in a 
natural model, whether viral infection leads to an increase in typical airway 
bacterial prevalence, as antibiotic therapy may then prove to be a useful means 
to treat virus-associated exacerbations. 
 
o Long-term antibiotic therapy trials have shown a reduction in exacerbation 
frequency following treatment.  An examination of exacerbation frequency in 
relation to typical airway bacterial load would indicate whether it is an 
antibiotic or an anti-inflammatory mechanism which is resulting in this 
reduction. 
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o Sequencing of bacterial species which are detected in sputum would be useful 
as it would allow strain identification to occur and this could show whether or 
not strain switching is contributing to the increase in load seen at exacerbation. 
 
o  Given that typical airway bacterial load was higher at exacerbation than at 
stable state, further analysis may help determine the load at which typical 
airway bacteria trigger clinical symptoms such as CRP increase and airflow 
limitation. 
 
o Sequencing of the airway microbiome may be a useful means to identify if any 
species is having a protective effect i.e. disease severity is higher in its absence.  
This may pave the way for probiotic therapy. 
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APPENDIX 
Study Number
THE LONDON COPD STUDY
NEXT
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.am
DATE l2.u '20*"a 2l tnu 22 *i
Peak Flow
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CHANGE in
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Hours out of the home
DATE 23,r:i
Peak Flow
CHANGE in
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CHANGE in
Treatment
Hours out of the home
fnstructions for filling in the DIARY CARDS
EVERY DAY...
1. After taking morning medications record the best of 3 atternpts at the PEAK FLOW
blowing test in the box on the sheet.
2. Please record any WORSENING of symptoms ABOVE YOUR USUAL daily
level. The symptoms we are interestcd iu are fisted below, just put the appropriate
letter in the box on the sheet. Continue recording until tlre symptom has gone away
or got back to ihe level you consider'normal'.
Letter Svmntom
A increased BREAT'IILES SNES S.
BI increased SPUTLM COLOUR.
B2 increased SPUTI-M AMOUNT.
C a COLD (such as a nmny or blocked nose).
D increased WIfrEZE or CIIEST TIGHTNESS.
E1 SORE THROAT.
E2 increased COUGI{.
F FEVER.
If you experience a worsening in any of these symptoms please
phone us to arrange an assessmenf visit, and do this BEFORX
starting any andbiotic or steroid tubletsi-Tire phone uurabcr !s
07762 038662.
Anant or Alex will have the phone and we can usually arrange to see you
later the same day or the following morning.
Please phone if you are not sure what tro write down or you have any questions.
3. Please record any CHANGE to your usual treatment for as many days as it applies.
the ate letter in the box on the sheet.
Letter Treatment
H I am in Hospital.
I I am taking more than usual INHALED STEROID (red / brorvn/purple)
R I needed to take e>,1ra RELIEVER (blue / green / grey / nebuliser).
HOW MAI{Y PUFFS? Write. es 'PJ'for 3 puffs, 'R2'for 2 etc
S I arn taking STEROID (Prednisolone) TABLETS.
HOW MANY TABLETS? Write. es'56'for 6 tablets. 'S5'for 5 etc
X I am taking ANTIBIOTIC TI\BLETS.
PLEASE RECORD WHICH (write the name on the diarv card).
4. Finally, please estimate the time that you were out of your own home on the previous
day.
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Changes in prevalence and load of airway bacteria
using quantitative PCR in stable and
exacerbated COPD
Davinder S Garcha,1 Sarah J Thurston,1 Anant R C Patel,1 Alexander J Mackay,1
James J P Goldring,1 Gavin C Donaldson,1 Timothy D McHugh,2 Jadwiga A Wedzicha1
ABSTRACT
Background Prevalence and load of airway bacteria in
stable and exacerbated chronic obstructive pulmonary
disease (COPD) has been previously studied using
microbiological culture. Molecular techniques, such as
quantitative PCR (qPCR), may be more informative.
Methods In this study, 373 sputum samples from 134
COPD outpatients were assessed for prevalence and load
of typical airway bacteria (Haemophilus influenzae,
Streptococcus pneumoniae, Moraxella catarrhalis) by
multiplex qPCR, with 176 samples analysed for atypical
bacteria. Paired stable and exacerbation typical bacteria
data were compared in 52 patients. We compared
routine culture with qPCR in 177/373 samples.
Results Typical bacteria were more prevalent in
exacerbation than stable-state paired samples: 30/52
(57.7%) vs. 14/52 (26.9%); p¼0.001. In patients who
were bacteria-positive at both time points, mean
(61 SEM) load was significantly higher at exacerbation
than stable state ( vs. cfu/ml),
constituting a 20-fold increase (p¼0.011). qPCR was
more discriminatory at detecting typical bacteria than
microbiological culture (prevalence 59.3% vs. 24.3%;
p<0.001). At stable state, higher airway bacterial load
correlated with more severe airflow limitation (FEV1%
predicted) (r¼0.299; p¼0.033) and higher inhaled
corticosteroid dosage (r¼0.382; p¼0.008). Mean
C-reactive protein was higher in bacterial-associated
exacerbations (35.0 Vs 25.1 mg/L; p¼0.032).
Conclusions Airway bacterial prevalence and load
increase at COPD exacerbations and are an aetiological
factor. qPCR is more discriminatory than culture,
identifying higher airway bacterial prevalence.
Exacerbations associated with bacterial detection
showed a higher mean C-reactive protein level. In the
stable state, airway bacterial load is related to more
severe airflow limitation and higher inhaled corticosteroid
dosage used.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is
an inﬂammatory condition caused by an abnormal
response to noxious gases and particles.1 COPD
is associated with considerable morbidity and
mortality and has been projected to become the
fourth highest cause of death by 2030.2 Acute exac-
erbations of COPD are episodes which are charac-
terised by a worsening of respiratory symptoms
associated with variable degrees of physiological
deterioration.3 These events are a major cause of
morbidity and mortality globally, and COPD exac-
erbations are a leading cause of hospital admissions.3
Lower airway bacterial colonisation (LABC) is
a common and important feature of COPD, and the
commonly isolated organisms are S pneumoniae,
H inﬂuenzae and M catarrhalis,4 5 although most
studies investigating LABC have used culture
techniques. LABC has been shown to be related to
an increase in airway inﬂammation, exacerbation
frequency and lung function decline.5e8
Previous studies suggest that the majority of
exacerbations have an infectious aetiologydwith
approximately half these events associated with
culture of potentially pathogenic airway bacteria,
similar to those found in the stable state.9 Positive
cultures of Pseudomonas aeruginosa have also been
shown to be associated with COPD, but more
commonly in advanced disease.10
Key messages
What is the key question?
< Is there a change in prevalence and load of
airway bacteria in COPD patients between the
stable state and exacerbation, and what is the
association between bacteria and lung function,
inhaled corticosteroid dosage and systemic
inflammation?
What is the bottom line?
< Airway bacterial prevalence and load, as
detected by qPCR, increases significantly at
COPD exacerbation, with quantitative molecular
techniques offering a more accurate reflection of
prevalence and load compared with conven-
tional methods. Higher bacterial load is corre-
lated with poorer lung function and higher
inhaled corticosteroid dosage in stable COPD
patients; bacterial presence at exacerbation is
associated with higher systemic inflammation.
Why read on?
< Increased airway bacterial load is a key aetio-
logical factor in acute exacerbations of COPD,
and also relates to disease severity in the stable
state. Inhaled corticosteroid usage may affect
bacterial colonisation, and thus increase
susceptibility to pneumonia.
< An additional appendix is
published online only. To view
this file please visit the journal
online (http://dx.doi.org/10.
1136/thoraxjnl-2012-201924).
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To date, the vast majority of analysis of bacterial prevalence
and load has been based on culture, but there is little on PCR
comparison with culture. The use of culture-independent tech-
niques, such as quantitative PCR (qPCR), has not been exten-
sively studied in the context of atypical airway bacteria, which
are characteristically difﬁcult to culture (C pneumoniae, L pneu-
mophila andM pneumoniae), with one previous study showing no
association with COPD exacerbations.11 Conversely, serological
analysis has suggested an association,12 13 and further exami-
nation is warranted.
The objective of this study was to investigate the prevalence
and load of typical and atypical airway bacteria in COPD using
modern molecular techniques. We also analysed prevalence and
load at the stable and exacerbation states, and compared qPCR
with routine microbiological culture.
METHODS
Recruitment criteria
This study involved 134 subjects enrolled in the London COPD
cohort between January 2007 and March 2011. The patients
form part of a rolling cohort used to prospectively investigate
the mechanisms and aetiology of COPD exacerbations, as
previously described by our group.14 Patients were included if
the forced expiratory volume in one second (FEV1) was #80%
predicted and FEV1/forced vital capacity (FVC) ratio was <0.7,
in keeping with GOLD stages IIeIV.1 A history of chronic
symptoms (dyspnoea, sputum production, wheeze and cough)
was taken, as well as smoking history (number of pack-years
smoked, current smoking status). Patients with a history of any
other signiﬁcant respiratory diseases were excluded, as were
those unable to complete daily diary cards.
Definitions of clinical states
An exacerbation was deﬁned as new or increased respiratory
symptoms for two or more consecutive days, with at least one
major symptom (dyspnoea, sputum purulence and sputum
volume), and another major or a minor symptom (wheeze, cold,
sore throat and cough), the ﬁrst day of which was deﬁned as the
day of onset of the exacerbation. Stable state was deﬁned as no
symptom-deﬁned exacerbations for the preceding 4 weeks and
the subsequent 2 weeks post-clinic visit.
Clinical assessment
Spirometry was performed in accordance with ATS/ERS
guidelines, using a volumetric storage spirometer (Vitalograph
2160, Maids. Moreton, Buckingham, UK). FEV1 was expressed
as a percentage of that predicted from age, height and sex. Serum
C-reactive protein (CRP) quantiﬁcation was performed to assess
systemic inﬂammation, using Modular Analytics E 170 Module
(Roche, Burgess Hill, UK). Patients recorded inhaled corticoste-
roid dosage and usage daily on diary cards. Due to variations in
dosage by different medications, we applied beclomethasone-
equivalence dosage correction, as previously performed by our
group.15
Sputum collection and processing
Sputum was spontaneously expectorated into a sterile pot in the
stable state and/or at exacerbation. All exacerbation visits
occurred within 7 days of exacerbation symptom onset. Patient
samples were used in a number of different analyses (ﬁgure 1).
Following expectoration, sputum plugs were separated from
saliva using sterile forceps, with one-third being taken for
culture analysis where there was sufﬁcient quantity. The
remaining sputum was weighed and suspended in nine times
volume of standard isotonic phosphate-buffered saline (PBS).
Glass beads were added to this suspension and it underwent
homogenisation by vortexing for 15 s, rocking for 15 min (IKA
Vibrax VXR, Staufen, Germany) and additional vortexing for
15 s. Aliquots of 500 ml were taken for storage at 808C for
subsequent batch processing.
Routine microbiological culture
Qualitative bacterial culture was carried out by the Department
of Medical Microbiology, Royal Free Hampstead NHS Trust,
London. Brieﬂy, sputum was cultured onto suitable agar for 24 h
at 378C and 5% CO2. Agar types used were Columbia blood agar
(general growth media), Chocolate agar (growth of fastidious
bacteria), MacConkey agar (growth of Gram-negative bacteria),
and COBA agar (growth of Streptococcus spp.). S pneumoniae was
identiﬁed through optochin sensitivity testing.
DNA extraction
Homogenised sputum samples underwent heat-kill treatment at
908C for 30 min before being microfuged at 13 000 g for 10 min.
The pellet was washed in 1 ml PBS and spun at 13 000 g for
10 min before removal of supernatant and re-suspension of the
pellet in 200 ml of PCR-grade UV-sterilised water (Sigma-
W4502). To each sample, 200 ml of 10% Chelex 100 (Sigma C-
7901) was added. Samples were incubated for 20 min in a heat
block at 568C. Samples were heated at 958C for ﬁve minutes
prior to cooling on ice. Samples were then spun in a microfuge at
16 000 g for 10 min. Supernatant, containing extracted DNA,
was transferred to a fresh UV-sterilised 1.5 ml tube and stored at
48C.
Multiplex qPCR detection of bacteria
Real-time multiplex qPCR was performed on S pneumoniae,
H inﬂuenzae andM catarrhalis, targeting Spn9802 (gene fragment),
H inﬂuenzae P4 lipoprotein gene, and copB outer-membrane-
protein gene, respectively. Both Spn980216 and copB17 proﬁles used
previously validated qPCR primers and probes, ensuring no cross-
reactivity with related oral species. The H inﬂuenzae P4 lipoprotein
gene target was established in-house. This was conﬁrmed to have
no cross-reactivity with other Haemophilus species as well as
a number of Streptococcus spp., M catarrhalis, Bordatella pertussis,
Candida spp., P aeruginosa, Escherichia coli, Neisseria meningitidis,
Acinetobacter spp., Legionella pneumoniae, Klebsiella pneumoniae,
methicillin-resistant Staphylococcus aureus and Corynebacterium
diphtheriae. An internal ampliﬁcation control (IAC), targeting the
Figure 1 COPD patient groups analysed. Patients may have been in
more than one subanalysis. For paired analysis, stable samples were
obtained <365 days prior to exacerbation (the nearest stable sample to
the exacerbation was used).
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PhyB gene of Solanum tuberosum, was used in order to detect any
PCR inhibition, incorporated in the PCR mastermix.18 The
following positive control strains were used: S pneumoniae ATCC
strain 49619;H inﬂuenzae ATCC strain 10211;M catarrhalis ATCC
strain 25238. The minimum limit of detection used in this study
was 104 colony-forming units (cfu)/ml.
A separate multiplex qPCR was performed to detect C
pneumoniae, L pneumophila and M pneumoniae, targeting RNA-
polymerase b-chain gene, MIP gene and P1 adhesin protein gene,
respectively. C pneumoniae primer/probe set was a previously
validated set.19 M pneumoniae and L pneumophila were developed
in-house and shown to have no cross-reactivity with related
species and other oral ﬂora. The PCR was performed with two
types of mastermix, one of which was spiked with an IAC
(L pneumophila DNA). Primer and probe details are listed in web-
only ﬁles in the appendix. Normalisation of qPCR results was
performed by correcting Ct values of the IAC in positive samples
according to its corresponding value in no-template-control
samples.
Statistical analysis
Data were analysed using PASW Statistics V.18 (SPSS Inc.). The
KolmogoroveSmirnov test for normality was applied. Clinical
data with normal distribution are described in mean (6SD).
Differences between groups were analysed by independent-
samples t test, paired-samples t test, ManneWhitney U test or
one-way ANOVA, dependent upon the sample population being
investigated. Relationships between continuous variables were
analysed using Pearson’s or Spearman’s correlation in a univar-
iate analysis, or by linear regression in a multivariate analysis.
Frequency distribution was explored by c2 analysis. A proba-
bility of p<0.05 was considered to be statistically signiﬁcant.
Ethical considerations
The study was approved by the Royal Free Research Ethics
Committee, and all patients gave informed written consent.
RESULTS
Patient characteristics
Sputum samples from 134 COPD patients were examined. There
were no clinically or statistically important differences in stable-
state clinical characteristics between the subgroups (table 1).
Typical bacteria prevalence and load determined by qPCR
Typical bacterial prevalence by qPCR was higher in exacerbation
sputum samples compared with stable samples (74/131 bacterial
isolates (56.5%) vs 107/242 (44.2%) respectively, p¼0.024).
In samples positive for bacteria, mean (61 SEM)-typical
bacteria count was signiﬁcantly higher during exacerbation, at
108.3(60.2) cfu/ml (in absolute numbers 23108 cfu/ml), compared
with the stable state, with 107.3(60.2) cfu/ml (in absolute numbers
23107 cfu/ml), a 10-fold increase, and signiﬁcantly different
(p<0.001) in an unpaired analysis (ﬁgure 2). H inﬂuenzae was the
most prevalent species, both in the stable state (21.9%) and at
exacerbation (26.0%). M catarrhalis was signiﬁcantly more prev-
alent at exacerbation (16.8%) compared with the stable state
(7.4%) (p¼0.005). Mean (61 SEM) bacterial load of both S
pneumoniae and H inﬂuenzae was signiﬁcantly higher at exacerba-
tion than at stable state: 108.1(60.3) vs 107.2(60.3) cfu/ml, p¼0.043
and 108.2(60.2) vs 107.0(60.2) cfu/ml, p<0.001, respectively.
Typical bacteria prevalence and load in paired stable and
exacerbation samples
Fifty-two pairs of stable and exacerbation samples from 52
patients showed signiﬁcantly higher cumulative prevalence of
typical bacteria at exacerbation compared with the stable state
(67.3% vs 30.8%; p<0.001). Fourteen stable-state samples
(26.9%) were positive for at least one bacterium compared with
30 exacerbation-state samples (57.7%) (p¼0.001). In paired
samples which were bacteria-positive at both stable and exac-
erbation state (n¼12), the mean load was approximately 20-fold
higher at exacerbation than in the stable sample (108.5(60.3) vs
107.2(60.5) cfu/ml) (p¼0.011) (ﬁgure 3B).
The species detected with highest prevalence was H inﬂuenzae
at stable state (11/52, 21.2%), with S pneumoniae most frequently
Figure 2 Quantitative PCR comparison of load of typical airway
bacteria in stable COPD (n¼242) and exacerbation (n¼131) in unpaired
samples. Species: SP ¼ Streptococcus pneumoniae; MC ¼ Moraxella
catarrhalis, HI ¼ Haemophilus influenzae.
Table 1 Stable-state clinical characteristics of COPD patient subgroups
COPD patient subgroups
Typical bacteria
analysis (n[134)
Culture analysis
(n[74)
Atypical bacteria
analysis (n[80)
Paired analysis
(n[52) p Value
FEV1 (l) 1.22 (60.52) 1.20 (60.5) 1.11 (60.50) 1.15 (60.50) 0.407
FEV1/FVC (%) 45.8 (612.9) 45.2 (612.6) 43.8 (613.4) 43.4 (613.4) 0.596
Predicted FEV1 (%) 48.5 (618.1) 48.5 (18.3) 45.4 (617.8) 46.4 (617.5) 0.582
Current smoker (%) 28 32 25 29 0.860
Age (years) 69.8 (68.7) 69.8 (68.3) 70.1 (68.9) 68.7 (68.5) 0.840
Male sex (%) 64 69 68 61 0.773
Pack years smoking 52.5 (634.6) 55.9 (638.2) 57.1 (634.9) 42.8 (624.2) 0.118
No significant differences were seen between the groups. Paired analysis refers to patients with paired stable and exacerbation-state
samples (the nearest stable-state sample prior to exacerbation was used in this analysis). Data is presented as percentage value or
mean6SD as appropriate.
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seen at exacerbation (13/52, 25%) (ﬁgure 3A). M catarrhalis
showed a signiﬁcant increase in prevalence at exacerbation (10/52,
19.2%), increasing from 2/52 (3.8%) at the stable state (p¼0.014).
S pneumoniae prevalence was signiﬁcantly higher at exacerbation
(13/52, 25.0%) than during stable state (3/52, 5.8%) (p¼0.002).
Comparison of qPCR with culture for the detection of typical
bacteria
Culture and qPCR for typical bacteria were compared in 177
samples (105 stable and 72 exacerbation samples) from 74 patients.
qPCR was far more discriminatory at detecting typical
bacteria than culture (105/177 positive samples (59.3%), vs
43/177 (24.3%), p<0.001). This ﬁnding was replicated in terms
of individual bacterial species: H inﬂuenzae 30.5% PCR-positive
versus 15.8% culture-positive, (p¼0.001); S pneumoniae 14.1%
versus 5.1%, (p¼0.004); M catarrhalis 14.7% versus 3.4%,
(p<0.001) (ﬁgure 4).
Positive culture identiﬁcation and negative qPCR identiﬁca-
tion was seen for H inﬂuenzae in 4/177 samples (2.3%); for S
pneumoniae in 4/177 samples (2.3%); for M catarrhalis in 1/177
samples (0.6%).
Effect of typical bacteria on lung function in stable state and at
exacerbation
Higher bacterial load was signiﬁcantly correlated to disease
severity in the stable state (FEV1 % predicted); r¼0.299;
p¼0.033 (ﬁgure 5). In a multivariate analysis, the relationship
between FEV1 and airway bacterial load remains signiﬁcant after
allowance of either age (p¼0.036) or smoking status (p¼0.046),
although it just misses statistical signiﬁcance when both age and
smoking status are included in the model (p¼0.057).
Percentage (6SD) change in FEV1 (from stable state) with H
inﬂuenzae-associated exacerbations (n¼10) was17.4% (615.8%),
and in exacerbations which had no H inﬂuenzae presence (n¼47),
the change was 5.9% (620.0%). This difference was not
statistically signiﬁcant (p¼0.09).
Airway bacterial load association with inhaled corticosteroid
usage
Forty-seven (92.2%) patients who had bacteria detected in the
stable state had inhaled corticosteroid usage recorded. Median
(IQR) beclomethasone-equivalent dosage was 2000 (640e
2000) mg daily. In a univariate analysis, higher airway bacterial
load was also signiﬁcantly correlated to higher inhaled cortico-
steroid dosage (corrected for beclomethasone equivalence);
Figure 4 Comparison of culture and qPCR detection of three typical
airway bacteria in sputa from 177 COPD patients (105 stable, 72
exacerbation). Species: HI ¼ Haemophilus influenzae, SP ¼ Strepto-
coccus pneumoniae; MC ¼ Moraxella catarrhalis.
Figure 5 Association of bacterial load with FEV1 in stable colonised
patients (n¼51). This illustrates the association of lower FEV1 status in
patients with higher bacterial loads. Data with FEV1% predicted >80%
were from patients who had FEV1% predicted <80% at recruitment.
Figure 3 (A) Prevalence of typical airway bacteria in paired samples
from COPD patients at both stable and exacerbation (n¼65). (B) Overall
bacterial load at stable state and exacerbation, in patients positive for
typical airway bacteria at both states (n¼12). Species:
SP ¼ Streptococcus pneumoniae; MC ¼ Moraxella catarrhalis,
HI ¼ Haemophilus influenzae.
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r¼0.382; p¼0.008. This relationship remains signiﬁcant in
a multivariate analysis including age, smoking status and FEV1
% predicted (p¼0.022).
Systemic inflammation is related to airway bacterial presence
during exacerbations
Levels of CRP, a marker of systemic inﬂammation, were signif-
icantly related to presence of typical airway bacteria at exacer-
bation. CRP was measured in 119 exacerbation samples.
Exacerbations with bacterial detection (n¼58) showed signiﬁ-
cantly higher mean CRP compared with exacerbations with no
bacterial detection (n¼61); 35.0 versus 25.1 mg/l, p¼0.032.
Analysis of COPD patient samples for atypical bacteria
A total of 176 samples, from 80 patients, were investigated for
presence of the atypical bacteria (C pneumoniae, L pneumophila, M
pneumoniae). Of these, 97 were stable samples, and 79 were
exacerbation samples. Five samples were positive for L pneumo-
phila (four stable, one exacerbation), and one stable sample was
positive for M pneumoniae. No relationship was observed
between atypical bacterial load and clinical outcome: Mean
bacterial load for L pneumophila was 104.4(60.4), and for the M
pneumoniae sample it was 107.4 cfu/ml.
DISCUSSION
This is the largest study, to date, to use molecular techniques for
detection of airway bacteria, and also the ﬁrst to complimen-
tarily evaluate typical and atypical bacteria in a well-
characterised cohort of COPD patients. We have explored the
relationship between airway bacterial prevalence and load in
stable COPD patients and at exacerbations. At exacerbation,
there was a marked increase in bacterial load in colonised
patients, with an absolute increase in the region of 20-fold being
identiﬁed in positive samples. We have conclusively demon-
strated that qPCR is more discriminatory than culture at
detecting typical airway bacteria. The role of atypical pathogens
in COPD is minor, having been detected at low prevalence and
load in very few samples.
We have found that in the stable state, there is a total prev-
alence rate for the three typical bacteriadanalysed togetherdof
44.2%. H inﬂuenzae was the most prevalent species identiﬁed. H
inﬂuenzae is also the most prevalent species in culture-based
studies.4 20 The prevalence rate using qPCR in this study was
higher than prevalence seen in such culture studies. This work
also highlights the association of airway bacteria with a poorer
disease outcome in COPD and supports our previous ﬁndings,
that increased airways inﬂammation may relate to airway
bacterial colonisation5 and is associated with faster FEV1
decline.8 In the stable state, we found signiﬁcant correlation
between higher bacterial load and more severe airﬂow limitation,
independent of age or smoking status.
One previous study compared detection frequency of typical
airway bacteria by qPCR and routine microbiological culture in
COPD patients evaluating 30 samples.21 In a larger dataset, we
have now conﬁrmed that qPCR is signiﬁcantly more discrimi-
natory than culture at detecting each of these three main airway
bacteria. It is known that H inﬂuenzae is able to persist intra-
cellularly in the respiratory tract, with possible resultant
culture-negative sputum.22 23 There were some instances in this
study where a sample was culture-positive and PCR-negative,
and there are a number of potential explanations for this,
including technical issues with the primer targets, operator error
or sampling, although the rates of such culture-positive PCR-
negative samples were actually very low in our study. qPCR is,
therefore, the most appropriate method to determine bacterial
prevalence and load, with little additional sensitivity to be
gained from running both methods in tandem.
The advantage of qPCR is that it gives a higher rate of
detection than culture. Using this technique, this study
demonstrates that exacerbations in COPD are characteristically
associated with both increased prevalence and load of typical
bacteria. This conﬁrms previous data suggesting that the
increase in load and acquisition of bacteria seen at exacerbation
is driving such exacerbations.24 Microbiological culture is,
however, useful in other aspects of bacteriology, such as in the
identiﬁcation of antibiotic resistance, and so should not be
wholly discounted. One limitation of PCR microbiological
technique is that they can detect both viable and non-viable
bacteria, while culture detects viable bacteria alone. However, to
our knowledge, no studies have shown non-viable bacteria to be
present at levels of 104 cfu/ml (the lower limit of detection for
our PCR assays). Alveolar macrophages are responsible for
clearance of DNA from the lungs, and so it is unlikely that DNA
from lysed cells would persist for long periods.
It has also been previously demonstrated that airway bacterial
presence is associated with increases in inﬂammatory cyto-
kines.7 25 26 We have found that bacterial presence at exacerbation
detected by PCR is signiﬁcantly associated with higher systemic
inﬂammation using serum CRP. We also found a trend to
increased fall in FEV1 with HI-associated exacerbations, probably
due to increased airway inﬂammation, and this is consistent with
our previous data.24 Many exacerbations of COPD also have
a viral aetiology, and prior studies have demonstrated that exac-
erbations involving coinfection with bacteria and viruses are
associated with a more impaired lung function.24 27
We also conclusively quantiﬁed typical airway bacteria in
a cohort of COPD patients, with a concomitant illustration of
signiﬁcant increases in prevalence and load of three of the most
commonly isolated bacteria seen in such subjects, at exacerba-
tion. This provides further support to previous studies which
hypothesise that alterations in ‘normal’ bacterial colonisation
may trigger acute exacerbations of COPD.28 This study has not
examined the strain-switching hypothesis previously put
forward.29 However, strain acquisition is associated with an
increase in bacterial load. Further work is needed to explore
whether differences in stable and exacerbation loads are related
to the same strain or different strains of speciﬁc bacterial species.
For the ﬁrst time, we have also shown a signiﬁcant relation-
ship between airway bacterial load and inhaled corticosteroid
dosage at the time of sampling in stable patients; this effect was
independent of age, smoking status and disease severity. Find-
ings from the TORCH and INSPIRE randomised controlled
trials have indicated that inhaled corticosteroid use is related to
increased frequency of developing pneumonia in COPD
patients.30e32 Our data suggests that the increase in airway
bacterial colonisation may play a part in increasing susceptibility
to pneumonia in COPD.
This study was limited to the three most commonly detected
organisms, and it is probable that other organisms also contribute
to the microbiome. However, recent detailed studies in small
numbers of subjects have identiﬁed only the presence of
commensals in addition to the common bacteria we studied,
and it is unlikely that other bacteria are playing a signiﬁcant
role.28 33 34 P aeruginosa was not studied in this analysis as its
culture detection rate was very low in the London COPD cohort
(<1%). It is difﬁcult to differentiate between those strains that
were infective and those which were colonising, due to the fact
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that colonising strains are very likely to also appear at exacer-
bation. The different methodological approaches required are
beyond the scope of this study.
The potential role of atypical bacteria in COPD was impor-
tant to investigate with qPCR, as they are characteristically
difﬁcult to culture, and if found at high prevalence or load, could
have major implications for therapy. A previous study found
little evidence of atypical bacteria colonisation in a qPCR anal-
ysis of 248 sputum samples from COPD patients, with just one
sample positive for Legionella spp.11 The current study investi-
gated the rate of these bacteria in COPD patients and found low
prevalence, with one exacerbation sample (1.3%) identiﬁed with
presence of L pneumophila. Atypical bacteria are, therefore, not
major pathogens in COPD, either in the stable state or at
exacerbation, and do not need speciﬁc therapy.
This study shows that at COPD exacerbations, airway
bacterial prevalence and load increase signiﬁcantly, and are an
important aetiological factor driving the event. The presence of
increased total bacterial load in the stable state and relationship
to disease progression suggests that targeted antibiotic therapy
for colonised patients may be beneﬁcial. qPCR is more discrim-
inatory than culture, identifying higher airway bacterial preva-
lence, and thus, should have an important role in routine clinical
microbiological practice.
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interventional trials. Participants in this CF study had a ﬁeld-based
estimate of exercise capacity and objective measurement of physical
activity at each study visit.
Methods Participants wore a pedometer for 7 days prior to each
visit. At each visit, London patients performed a standard incre-
mental shuttle-walk test and Edinburgh patients a modiﬁed shuttle
test (in which running was allowed). Data are expressed as mean (SD).
Results Data were analysed from 192 patients over 648 visits. Age
at enrolment was 24 (11.9) years (London) and 20.8 (9.9)
(Edinburgh) (p¼0.052); FEV1 was 67 (17.7)% and 79 (19.5)% for
each site respectively (p<0.001). Daily step count at visit 1 was
7491 (2887) in London and 8872 (4089) in Edinburgh (p¼0.04)
and this difference persisted across subsequent visits. The
coefﬁcient of variation (CV) in step counts between visits was
21.3%. Number of shuttles completed in London was 61 (15),
and Edinburgh 90 (33) with no trend over the four visits (CV¼10
and 16% respectively). In Edinburgh there was a correlation
between mean step count and the number of completed shuttles
(r¼0.46, p<0.001). Step count from both sites, and the number of
shuttles completed in Edinburgh, correlated with FEV1 % predicted
(r¼0.24, p<0.001 and r¼0.27, p<0.001 respectively) and with age
(r¼0.28, p<0.001 and r¼0.30, p<0.001 respectively). Such
correlations were either weaker or not observed in London, however,
in this group, number of shuttles correlated with height (r¼0.51,
p<0.001).
Conclusions No changes were detected in exercise capacity or daily
activity levels over time. Between site differences were observed in
both measures; however, these populations also differ in age and
FEV1. The modiﬁed shuttle test performed in Edinburgh appeared to
better correlate with clinical markers than the standard incremental
shuttle test performed in London, and is independent of height. We
believe that testing exercise capacity is important in CF and we plan
to investigate the other testing methods in the run up to our Multi
Dose Gene Therapy Trial.
Funding Funded by the UK CF Trust.
COPD: sputum and exacerbations
P110 QUANTITATIVE PCR-BASED DETECTION AND
QUANTIFICATION OF ATYPICAL BACTERIA AT BASELINE
AND EXACERBATION OF COPD
doi:10.1136/thx.2010.150987.11
1D S Garcha, 1S J Thurston, 1A R C Patel, 1J J P Goldring, 2T D McHugh,
1G C Donaldson, 1J A Wedzicha. 1Academic Unit of Respiratory Medicine, University
College London Medical School, London, UK; 2Centre for Clinical Microbiology,
University College London Medical School, London, UK
Introduction Airway bacterial infections are associated with exacer-
bations of COPD. The potential role of atypical bacteria as a trigger
for exacerbations is not well understood. Atypical bacteria such as
Chlamydophila pneumoniae (CP), Legionella pneumophila (LP) and
Mycoplasma pneumoniae (MP) are difﬁcult to culture as they are
intracellular pathogens. LP can be detected by urinary antigen, and
serology can be performed for MP, but these techniques give no
indication as to the atypical bacterial load. Quantitative PCR
(qPCR) offers an alternative approach to identiﬁcation and quanti-
ﬁcation of bacteria in sputum.
Methods Multiplex qPCR was used to detect and quantify CP, LP
and MP in 238 samples prospectively collected from 87 patients in
the London COPD Cohort: mean (6SD) age 71.4 (68.1); predicted
FEV1 43.4% (617.5%); male gender 47.9%; current smoker 49.2%.
Baseline (n¼104), exacerbation (n¼95), and follow-up (n¼39)
samples were tested: Baseline was deﬁned as at least 6-weeks
without exacerbation, and exacerbation was deﬁned as 2 consec-
utive days of two symptoms (Anthonisen criteria), at least one of
which is a major symptom (dyspnoea; sputum purulence; sputum
volume). Follow-up involved taking samples 2 or 5 weeks post-
exacerbation onset. Using a qPCR developed by our clinical diag-
nostic service, the CP, MP and LP gene targets were RNA-polymerase
b-chain; P1 adhesin protein; and MIP respectively. Routine micro-
biological analysis was also performed on these samples.
Results No samples were positive for the atypical organisms using
culture. With qPCR analysis 6/238 samples (six separate patients)
were positive for LP (2.5%), four at baseline and two at exacer-
bation/follow-up. One baseline sample was positive for MP (0.42%),
and no samples were positive for CP. Atypical bacteria were present
at 0.83% of exacerbations. Median (IQR) bacterial load was
4.3x104 cfu ml1 (2.0x104e8.55x104) for LP PCR-positive samples;
the MP-positive sample load was 2.64x107 cfu ml1.
Conclusion Quantitative PCR was more sensitive and informative
than standard microbiological culture for the detection of atypical
bacteria. Atypical bacteria in sputum were detected at very few
exacerbations of COPD; moreover, when they were detected by
qPCR, the load was low, indicating little or no signiﬁcance in the
aetiology of these events.
P111 FTIR SPECTROSCOPIC PROFILING OF COPD SPUTUM:
IDENTIFICATION OF DISTINCT SPECTRAL SIGNATURES
AND CORRELATION TO COPD STATUS
doi:10.1136/thx.2010.150987.12
1N Patel, 1P Coleborn, 1A Hampton, 1V Campbell, 1M Allen, 2A Gahkani, 1M Spiteri.
1Directorate of Respiratory Medicine, Institute of Science & Technology in Medicine,
University Hospital of North Staffordshire, Stoke on Trent, England; 2Bruker UK,
Coventry, England
COPD remains common and complex with huge costs on the NHS
and disruption to patients’ daily lives. This presents a challenge for
an effective, non-invasive test to enable determination and moni-
toring of COPD status. Fourier transform infrared (FTIR) spectro-
scopy for sputum proﬁling is timely. FTIR identiﬁes and measures
chemical bond vibrations within functional groups in complex
biological mixtures by producing infrared absorption spectra. Iden-
tifying COPD-relevant spectra in sputum could provide sensitive
rapid information on status and exacerbations. To address this, we
randomly recruited 102 patients independent of severity. Sputum
was collected at initial visit and in each of subsequent 2 weeks.
Dyspnoea and sputum scores were obtained; FEV1, serum CRP and
exhaled NO measured; any intervening chest infection or treatment
change documented. Patients was stratiﬁed by FEV1; 26 patients had
mild COPD (FEV1$80%); 41 moderate (FEV1 49e79%); 35 severe
(FEV1 #50%). FTIR was performed using an Alpha-T spectrometer
(Bruker UK); transmission mode in 4000 to 900 cm1 region; 4 cm1
resolution. All COPD sputa gave reproducible biological IR spectra
with distinct signatures in 5 key regions at 3300e3280 cm1
(assigned as amide A), 3000e2800 cm1, 1660e1600 cm1 (Amide
I), 1560e1520 cm1 (Amide II) and 1180e1000 cm1 (glyco-
proteins). Multivariate analysis showed signiﬁcant correlation
between spectral proﬁles and FEV1 and smoking habit. The accuracy
of differentiating mild from severe COPD was consistently greater
than 70% (AUC under ROC curve); speciﬁcally we observed peak
shifts in Amide A towards 3300 cm1 as COPD worsened
(p<0.001). Also 68/102 patients exhibited a clear band around
2060 cm1; the remaining 34 showed no band in this region. There
was a signiﬁcant association (p¼0.012) between peak presence and
COPD severity; with mild COPD patients more likely to have a
peak, and severe sufferers having 2060 cm1 signal absence. 35/102
patients had exacerbations during the study. Separate spectral
analysis showed signiﬁcant increase in glycoprotein max peak
during COPD exacerbation (p<0.03). This study has important
implications for future near-patient COPD monitoring. FTIR
A124 Thorax December 2010 Vol 65 Suppl 4
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Quantitative Pcr-Based Detection Of Typical And Atypical Bacterial Strains In COPD Patients And
Relationship To Culture
, S. J. Thurston , A. R.C. Patel , J. J. Goldring , T. D. McHugh , G. C. Donaldson , J. A. WedzichaD. S. Garcha1 1 1 2 1 1 2
UCL Medical School, London, United Kingdom, UCL, London, United Kingdom1 2
Corresponding author's email: d.garcha@medsch.ucl.ac.uk
Rationale: Bacterial infections are common in chronic obstructive pulmonary disease (COPD). Typical bacterial species include 
 (SP),  (HI) and  (MC). The potential role of atypical bacteria such asStreptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis
 (CP),  (LP) and  (MP) has not been investigated in detail,Chlamydophila pneumoniae Legionella pneumophila Mycoplasma pneumoniae
largely due to difficulty culturing. Confirmation of infection for MP is by serology and LP is by detection of urinary antigen, but these
techniques give no indication of bacterial load. We examined quantitative real time PCR (qPCR) as an alternative approach to identification
and quantification of typical and atypical bacterial species in sputum.
Methods: Multiplex qPCR was used to detect and quantify SP, HI, MC, CP, LP and MP in 86 sputum samples prospectively collected from 52
patients in the London COPD cohort. The samples were divided for PCR and routine microbiological culture. Two multiplex PCRs were
used to test for the typical and atypical gene targets. SP, HI and MC gene targets were Spn9082;  P4 lipoproteinHaemophilus influenzae
gene; and copB outer-membrane-protein gene, respectively. CP, MP and LP gene targets were RNA-polymerase β-chain; P1 adhesin
protein; and macrophage infectivity potentiator respectively.
Results: Patient characteristics were: mean (±SD) age 71.8 (±8.1) years; predicted FEV  41.4% (±15.6%); male gender 73.3%; current smoker1
25.6%. Culture analysis detected a total of 24 positive samples in a total of 22 patients (27.9% of total) from compared to 50 positive
samples in 35 patients (58.1% of total) using qPCR (p<0.001). For individual species, qPCR detected a significantly greater proportion of SP
and LP (Table 1). Mean (±SD) bacterial loads for the typical bacteria were not significantly different from one another: SP (7.4±1.4 log10
cells ml ) Vs HI (7.3±1.6) Vs MC (7.9±1.2). The bacterial load of LP (4.37±0.4) was found to be significantly lower compared with each of-1
the three typical bacteria (p<0.001).
Comparison of bacterial strains detected by qPCR and by conventional microbiological culture
Median bacterial load given from qPCR analysis. n = 86 samples. Definition of abbreviations: SP = Streptococcus pneumoniae; HI
= Haemophilus influenzae; MC = Moraxella catarrhalis; CP = Chlamydophila pneumoniae; LP = Legionella pneumophila; MP =
Mycoplasma pneumoniae. Significant differences at p<0.05.
Conclusion: Quantitative PCR is able to identify and quantify more positive samples than standard microbiological culture. There was no
significant difference between the mean bacterial loads of the typical bacteria, as identified by qPCR. Atypical bacteria are infrequently
identified in COPD sputum samples at a relatively low load, indicating a low clinical relevance.
This abstract is funded by: Medical Research Council
Am J Respir Crit Care Med 183;2011:A3024
Internet address: www.atsjournals.org Online Abstracts Issue
Conclusions Molecular proﬁling identiﬁes heterogeneity in the
airway microbiome of COPD patients, with dominance of patho-
gens routinely identiﬁed at culture. However, a precise role for
bacteria in COPD remains unclear.
S17 IMPACT OF COPD SEVERITY AND SPUTUM PRODUCTION
ON ANTIBIOTIC RESISTANCE
doi:10.1136/thoraxjnl-2011-201054b.17
1S J Thurston, 1G C Donaldson, 2T D McHugh, 1J A Wedzicha. 1Academic Unit of
Respiratory Medicine, UCL Medical School, Royal Free Campus, London, UK; 2Clinical
Centre for Microbiology, UCL Medical School, Royal Free Campus, London, UK
Introduction Bacterial infections are a well-known trigger for exac-
erbations of COPD. A variety of antibiotics are regularly prescribed
for this group of patients but the risk and frequency of antibiotic
resistance in the COPD population is less understood. Routine
culture data can be evaluated to establish resistance prevalence and
patterns.
Methods Culture data were collected from the sputum samples of
293 patients in the London COPD cohort over a period of 5 years
(01/01/2006e31/12/2010) mean (6SD) months in study 28.4
(619.9); age 69.9 years (68.9); predicted FEV1 47.8% (616.5); male
gender 58%; exacerbation samples 48.9%; sputum producers 77.5%.
Identiﬁcation of bacterial presence was established and where clin-
ically indicated drug sensitivity tests (DSTs) were performed. A
resistant sample was reported as any bacterial isolate resistant to at
least one antimicrobial agent.
Results 92/293 (31.4%) patients had at least one bacteria positive
sample over the study period. 87/92 (94.6%) patients had samples
where DSTs were performed on bacteria positive samples. Resist-
ance was observed in 69/87 (79.3%) patients. 30/293 (10.2%)
patients were resistant to all samples where DSTs were performed.
227/293 (77.5%) of patients were sputum producers. There was no
signiﬁcant relationship between predicted FEV1 and antibiotic
resistance frequency in this cohort (X2-test; p¼0.577). Patients who
were classiﬁed as regular sputum producers were more likely to
exhibit resistance in culture positive bacteria (p¼0.048).
Conclusion Results from this analysis conclude that an estimated
23.5% of COPD patients will develop resistance to an antimicrobial
agent within 28.4 months of follow-up with sputum producers
being at a higher risk. This study highlights the importance of
investigating sputum samples with determination of resistance
patterns. Information on resistance patterns and transmission of
resistance in COPD can allow more appropriate and targeted anti-
biotic therapy for COPD exacerbations with improved outcomes.
S18 A COMPARISON OF PREVALENCE AND LOAD OF AIRWAY
BACTERIA IN COPD PATIENTS WITH PAIRED STABLE AND
EXACERBATION STATE SAMPLES
doi:10.1136/thoraxjnl-2011-201054b.18
D S Garcha, S J Thurston, A R C Patel, A J Mackay, J J P Goldring, T D McHugh,
G C Donaldson, J A Wedzicha. University College London, London, UK
Introduction Airway bacterial infections are associated with COPD
exacerbations. The most frequently identiﬁed bacteria in COPD are
Haemophilus inﬂuenzae (HI), Moraxella catarrhalis (MC) and Strepto-
coccus pneumoniae (SP) (Wilkinson et al, 2006), though studies have
used culture techniques, with little data available on PCR method-
ology in airway infection. Using the London COPD cohort, we
aimed to assess and quantify bacterial prevalence and load via
quantitative PCR, in paired baseline and exacerbation sputum
samples.
Methods Quantitative PCR was utilised, measuring prevalence and
load on paired baseline and exacerbation samples, with baseline
samples obtained within 1 year prior to its paired exacerbation. SP,
HI and MC gene targets were Spn9082; Haemophilus inﬂuenzae P4
lipoprotein gene; copB outer-membrane-protein gene, respectively.
The baseline state was deﬁned as being at least 6 weeks after, and
2 weeks before, an exacerbation. Exacerbation was deﬁned as two
consecutive days of at least two increased symptoms (Anthonisen
criteria), at least one of which is a major symptom (dyspnoea;
sputum purulence; sputum volume).
Results Sixty-nine paired baseline and exacerbation sputum samples
were obtained from 56 patients: mean (6SD) age 71.0 years (68.4);
predicted FEV1 46.4% (617.0); male gender 60.4%; current smoker
30.2%. Bacteria were detected at signiﬁcantly higher rate at exac-
erbation, being seen in 36/69 (52.2%) exacerbations, and 19/69
(27.5%) baseline samples (c2-test; p¼0.003). Mean bacterial load
was signiﬁcantly higher at exacerbation, with mean load of 8.3
(61.1) log10 cfu/ml, compared with mean of 7.3 (61.8) log10 cfu/ml
at baseline (paired-samples t test; p<0.001), indicating a 10-fold
overall-load increase at exacerbation. MC frequency increased
signiﬁcantly from 4.3% (3/69) at baseline to 17.4% (12/69) at
exacerbation (p¼0.014). Prevalence of HI (17.4% vs 26.1%) and SP
(8.7% vs 20.3%) showed non-signiﬁcant increases. Mean loads of SP
and MC increased signiﬁcantly from baseline to exacerbation
(p¼0.048; p¼0.008, respectively).
Conclusion Prevalence and load of airway bacteria in COPD
increases from baseline to exacerbation. This conﬁrms that bacteria
play an important role in exacerbation aetiology, implicating
increasing bacterial load as a key underlying mechanism, and
emphasises the importance of prompt antibiotic therapy at COPD
exacerbation.
Abstract S18 Figure 1 Bacterial load at baseline and exacerbation of
COPD as determined by quantitative PCR.
S19 MOLECULAR FINGERPRINTING AND METAGENOMIC
ANALYSIS REVEALS A POLYMICROBIAL ELEMENT IN
PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY
DISEASE
doi:10.1136/thoraxjnl-2011-201054b.19
1P J Purcell, 1A Nelson, 1A Fisher, 2J D Perry, 3A De-Soyza, 1S P Cummings.
1Northumbria University, Newcastle upon Tyne, England; 2Freeman Hospital,
Newcastle upon Tyne, England; 3Newcastle University, Newcastle upon Tyne, England
Introduction and objectives Chronic obstructive pulmonary disease
(COPD) patients commonly exhibit a multi-factorial pathology
with neutrophilic inﬂammation and chronic obstructive bronchio-
litis. COPD patients suffer episodes of pulmonary exacerbations.
The role of bacteria in exacerbations has been investigated in COPD
using culture-dependent techniques. Unlike cystic ﬁbrosis (CF),
there are few molecular studies describing the possibility of a
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Association Between Airway Bacterial Load And Clinical Parameters In Stable COPD And At
Exacerbation
, S. J. Thurston , A. J. Mackay , A. R.C. Patel , J. J. Goldring , T. D. McHugh , G. C. Donaldson , J. A. Wedzicha ,D. S. Garcha1 1 1 1 1 2 1 3
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London, United Kingdom
Corresponding author's email: davinder.garcha.09@ucl.ac.uk
Introduction:
Airway bacteria are associated with COPD exacerbations, with the typical bacteria  (HI),  (MC)Haemophilus influenzae Moraxella catarrhalis
and  (SP) frequently cultured. Quantitative PCR provides an accurate measurement of bacterial prevalence andStreptococcus pneumoniae
load. We aimed to explore the relationship of bacterial load with FEV  status in stable COPD outpatients, and with sputum purulence at1
exacerbation.
Methods:
Real-time quantitative PCR was used to assess prevalence and load of HI, MC and SP. Spirometry was performed in clinic. Baseline was
defined as being at least six weeks following, and two weeks before, an exacerbation. Exacerbation was defined as two consecutive days
of two symptoms (Anthonisen criteria), on prospectively-collected diary cards, at least one of which is a major symptom (dyspnoea;
sputum purulence; sputum volume), with the other being either a major or minor symptom (wheeze, cold, sore throat and cough).
SP, HI and MC gene targets were Spn9082; Haemophilus influenzae P4 lipoprotein gene; and copB outer-membrane-protein gene,
respectively.
Results:
Characteristics for 134 COPD patients: mean (±SD) age 69.8 (±8.7) years; FEV  (L) 1.22 (±0.5), at 48.5% (±18.1) predicted FEV ; FEV /FVC1 1 1
0.46 (±0.1); male gender 64.2%; current smoker 28.4%. For stable-state and exacerbation, 242 and 131 samples were analysed,
respectively. Sixty-five paired stable and exacerbation sputum samples were obtained from 52 of these patients: stable sample taken
median (IQR) 100 (35-172) days prior to its reciprocal exacerbation.
In stable COPD, higher bacterial load (HI, MC, SP) was significantly related to an equivalent poorer FEV  status during stable state, shown1
in Figure 1 (r=-0.299; p=0.033). In patients colonised at both stable and exacerbation state, there was no significant correlation between
total increase in load and change in FEV  at exacerbation (r=0.236; p=0.210). However, HI presence at exacerbation suggested a more1
severe fall in FEV  (-17.4±15.8%) compared to exacerbations without HI (-4.1±24.7%) although this did not reach statistical significance1
(p=0.086). Bacterial load trended towards being significantly higher in samples with sputum purulence against non-purulent (8.4±1.1 vs
7.8±1.4 log  CFU/ml; p=0.071).10
Conclusion:
We have shown that higher bacterial load in stable COPD patients is associated with poorer lung function. In patients harbouring lower
airway bacteria during stable state, increase in load at exacerbation was not significantly associated with a fall in FEV . These findings1
implicate bacterial load at stable state as having a role in disease severity, and underscores the role of prompt antibiotic therapy.
Figure 1. Association of bacterial load with FEV1 status in stable colonised patients (n=51). Figure 1 illustrates the association of higher
sum bacterial load with poorer FEV1 status. Note that samples with FEV1% predicted >80% were from patients who had FEV1% predicted
<80% at recruitment
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Bacterial prevalence and load during COPD exacerbation and recovery 
D. Garcha, A. Patel, A. Mackay, R. Singh, T. McHugh, G. Donaldson, J. Wedzicha (London, United 
Kingdom) 
 
Bacteria are a common aetiological trigger of COPD exacerbations, with prevalence and load 
increasing from stable state (Garcha et al, Thorax 2011: 66;A11). We investigated prevalence 
and load of H. influenzae, S. pneumoniae and M. catarrhalis during exacerbation recovery 
using quantitative PCR (qPCR). 
 
We collected sputum from subjects in the London COPD cohort at exacerbation presentation 
(n=137), day 3 (n=41), 7 (n=53), 14 (n=56) and 35 post-exacerbation (n=35). All 
exacerbations were treated with ≥7 days of antibiotics (±oral steroids) and defined by our 
usual symptomatic criteria (Seemungal et al, AJRCCM, 1998). 
 
Characteristics of 102 COPD patients: mean(SD) age 68.7(8.2) years; FEV1 1.2(0.5)L, 
48.6(24.8)% predicted. Bacterial prevalence was higher at exacerbation than Day 3 (50.4 vs 
26.8%; p=0.008), Day 7 (28.3%; p=0.006) and Day 14 (30.4%; p=0.011) (Fig. 1). In recovery 
samples paired with bacteria-positive exacerbations (different patients at each time point), 
load [median (IQR) Log10 CFU/ml] was significantly higher at exacerbation compared with 
Day 3 (n=15): 10
8.1(5.9-8.7) 
vs 10
0(0-4.0)
, p=0.001; Day 7 (n=17): 10
8.2(6.3-8.8)
 vs 10
4.2(0-6.6)
, 
p=0.01; Day 14 (n=14): 10
8.0(6.3-8.7) 
vs 10
4.4(0-6.6)
, p=0.022; and Day 35 (n=15): 10
7.7(5.7-9.3)
 vs 
10
5.9(0-6.74)
, p=0.047. 
 
Bacterial prevalence and load detected by qPCR falls within 3 days of antibiotic therapy for 
COPD exacerbations, with load remaining low for at least 35 days post-onset. 
 
 
 
